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Abstract 
Schizophrenia represents one of the world’s most devastating illnesses due to its often 
life-long course and debilitating nature. The treatment of schizophrenia has vastly 
improved over recent decades with the discovery of several antipsychotic compounds; 
however these drugs are not without adverse effects that must be addressed to maximize 
their therapeutic value.  
Newer, atypical, antipsychotics are associated with a compilation of serious metabolic 
side effects including weight gain, insulin resistance, fat deposition, glucose dysregulation 
and ensuing co-morbidities such as type II diabetes mellitus. The mechanisms underlying 
these side effects remain to be fully elucidated and adequate interventions are lacking. 
Further understanding of the factors that contribute these side effects is therefore 
required in order to develop effective adjunctive therapies and to potentially design 
antipsychotic drugs in the future with reduced impact on the metabolic health of 
patients.  
We investigated if the gut microbiota represented a novel mechanism contributing to the 
metabolic dysfunction associated with atypical antipsychotics. The gut microbiota 
comprises the bacteria that exist symbiotically within the gastrointestinal tract, and has 
been shown in recent years to be involved in several aspects of energy balance and 
metabolism  
We have demonstrated that administration of certain antipsychotics in the rat results in 
an altered microbiota profile and, moreover, that the microbiota is required for the full 
scale of metabolic dysfunction to occur.  
xvi 
 
We have further shown that specific antibiotics can attenuate certain aspects of 
olanzapine and risperidone–induced metabolic dysfunction, in particular fat deposition 
and adipose tissue inflammation.  
Mechanisms underlying this novel link appear to involve energy utilization via expression 
of lipogenic genes as well as reduced inflammatory tone. 
Taken together, these data indicate that the gut microbiota is an important factor 
involved in the myriad of metabolic complications associated with antipsychotic therapy. 
Furthermore, these data support the future investigation of microbial-based therapeutics 
for not only antipsychotic-induced weight gain but also for tackling the global obesity 
epidemic. 
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Chapter 1 
General Introduction 
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1.1 Schizophrenia  
Schizophrenia is a devastating disease which impacts drastically on an individual’s mental 
and physical well being. Attempts to define and understand schizophrenia began in the 
mid-late 19th century with the emerging definitions of dementia praecox. These early 
characterisations of the mental disorder based on ‘mental weakness’ were further 
developed by Bleuler, who in the early 20th century replaced the term dementia praecox 
with schizophrenia and defined schizophrenia as a group of psychoses characterised by 
alterations in thinking, feeling and relations with the external world. Bleuler also 
conceived the diagnostic concept of the four A’s: loosening of associations, inappropriate 
affect, ambivalence, and autism. This construct was extensively used for the diagnosis of 
schizophrenia until being widely replaced by Schneider’s first-rank symptoms: audible 
thoughts, voices arguing, voices discussing, voices commenting, thought withdrawal, 
experiences of influenced thought, thought broadcasting, delusional perceptions and 
other experiences involving made volition or impulse (Schneider 1957). The current 
nosological status of schizophrenia is based on the Diagnostic and Statistical Manual 
(DSM-IV) of the American Psychiatry Association and does not rely on either of the 
aforementioned criteria, though the major themes are retained, with an emphasis on the 
presence of both positive and negative symptoms (Table 1.1). 
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Positive Negative 
Delusions Affective flattening 
Hallucinations Alogia 
Disorganised speech Avoltion 
Disorganised or catatonic behaviour  
Table 1.1 Symptoms of schizophrenia. The positive and negative symptoms of 
schizophrenia currently included in the DSM-IV diagnostic criteria. 
Schizophrenia is a disabling group of brain disorders and has been described as the worst 
disease affecting mankind (Editorial 1988; Saha et al. 2005). This view point is based on 
the onset age (young adulthood), pervasiveness of the associated deficits and the often 
life-long duration of the disease (Tandon et al. 2008b). The incidence of schizophrenia is 
relatively low in the context of all disease, with annual incidence rates of 8-40/100,000 
people and a lifetime risk of approximately 0.7% (McGrath et al. 2004; Saha et al. 2005; 
Saha et al. 2006). Despite this relatively low incidence, schizophrenia remains one of the 
major contributors to the global health burden and is a leading cause of disease-related 
disability worldwide (Lopez and Murray 1998). 
Thus, there is a clear impetus for the development and advancement of 
pharmacotherapies used in the treatment of schizophrenia. This involves both the 
generation of newer, more efficacious drugs based on increased understanding of the 
neurobiology of schizophrenia, as well as the better use of already available therapies. 
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1.1.1 Neurochemistry of schizophrenia 
Dopamine brain circuitry has long been viewed as the key factor in the pathogenesis of 
schizophrenia. This is based largely on the observation that compounds blocking 
dopamine receptors are useful in the treatment of psychosis (van Rossum, 1966), first 
recognized in the 1950’s following the discovery of chlorpromazine (see section 1.2).  
In the 1970s and 1980’s, the development of receptor binding assays and the 
identification of receptor subtypes built on earlier evidence implicating dopamine in the 
mechanism of action of available antipsychotics (Carlsson and Lindqvist 1963). Indeed, 
this work led to the confirmation that antipsychotics block dopamine receptors (Creese et 
al. 1975; Creese et al. 1976) and the establishment of the dopamine hypothesis of 
schizophrenia (Snyder 1976). Later, positron emission tomography confirmed that 60-80% 
blockade of the dopamine D2 receptor produces an optimal therapeutic antipsychotic 
effect and indeed seemed essential for antipsychotic activity (Creese et al. 1996; Kapur 
1998).  
Dopamine neurotransmission in the brain comprises four pathways. The mesolimbic 
pathway arises from the ventral tegmental area and projects to the nucleus accumbens as 
well as the amygdala and hippocampus. Hyperactivity of this pathway is believed to be 
the primary cause of the positive symptoms of schizophrenia (delusions, hallucinations) 
(Davis et al. 1991; Remington et al. 2011).  
The mesocortical pathway also arises from the ventral tegmental area but projects to the 
frontal lobe of the pre-frontal cortex.  
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Hypoactivity of this pathway is believed to propagate the negative symptoms of 
schizophrenia (Davis et al. 1991; Remington et al. 2011).  
The nigrostriatal pathway projects from the substantia nigra to the dorsal striatum and 
disruption of this pathway results in extrapyramidal symptoms (EPS) associated with 
antipsychotics (Dayalu and Chou 2008) (see section 1.2.2). 
A distinct tuberoinfundibular pathway projects from the hypothalamus to the pituitary 
gland and this pathway regulates prolactin secretion. Thus, effects of antipsychotics on 
this pathways are responsible for antipsychotic-associated hyper-prolactinemia (Riecher-
Rossler et al. 2009). 
Dopamine receptors consist of two families, D1 and D5 comprise the D1-like family which 
acts via Gs to activate adenylatecyclase and in turn increase cAMP (cyclic-adenosine 
monophosphate). D2, D3 and D4, comprise the D2-like family and act via Gi to inhibit 
adenylatecyclase and hence decrease cAMP. Thus, D2 antagonism, the common 
denominator of all antipsychotics, reduces the hyperactivity of the mesolimbic 
dopaminergic pathway ameliorating the positive symptoms of schizophrenia. 
The dopamine hypothesis of schizophrenia as an over-activity of dopamine neurons has 
been built upon and modified in recent times such that schizophrenia may be seen as a 
profound dysregulation of mesocorticolimbic dopamine circuitry with both hypo 
(mesocortical) and hyper (mesolimbic) functioning aspects in respective brain regions 
(Svensson, 2003).  
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Moreover, schizophrenia is highly heterogeneous disorder and the pathophysiology and 
neurobiology is far from fully understood. Neurotransmitter systems including serotonin, 
GABA (gamma-amino butyric acid) and glutamate have also been implicated and the role 
of these systems and their interactions is yet to be fully elucidated (Keshavan et al. 2008). 
1.2 Treatment of schizophrenia 
The earliest pharmacological treatments of schizophrenia involved cocaine or even castor 
oil. However, these treatments were ineffectual meaning the main stay of treatment 
from the 1930’s to 1950’s consisted of insulin-coma therapy (Ban 2004). 
In the 1950’s, serendipity provided the first widely accepted drug for the treatment of 
schizophrenia; chlorpromazine. Chlorpromazine was first synthesized in 1951 
(Charpentier et al. 1952) before being introduced into clinical practice in 1953 (Delay et 
al. 1952) where it revolutionised the treatment of psychotic disorders (Turner 2007). 
Phenothiazines such as chlorpromazine were originally developed for use in the German 
dye industry before being used in medicine as antiseptics, anti-malarials and later as 
antihistamines. Indeed, it was while being utilised as an anti-shock therapy that the 
broader psychiatric potential of chlorpromazine was realised (Sigwald and Bouttier 1953; 
Shen and Giesler 1998; Lopez-Munoz et al. 2005). 
1.2.1 Typical antipsychotics 
Following the discovery of chlorpromazine, other antipsychotic compounds quickly 
followed including reserpine and haloperidol (Muller et al. 1952; Divry et al. 1959). 
Haloperidol is one of the few early antipsychotics that remains in relatively common use 
today (Verdoux et al. 2010).  
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1.2.2 Side effects of typical antipsychotics 
The introduction of first-generation compounds revolutionised the treatment of 
psychiatric illness; however, it was quickly realised that they produce EPS, a range of 
motor related side effects (Ayd 1961; Shen and Giesler 1998; Arana 2000).  
As already mentioned, the efficacy of these antipsychotics was shown to be produced by 
antagonism of dopamine D2 receptors. Antagonism of this same receptor is also 
responsible for the development of EPS. Binding studies suggest that while D2 receptor 
occupancy of 65% seems to be required for antipsychotic activity, occupancy levels 
greater than 80% induce EPS (Kapur et al. 2000).  
EPS may be acute, occurring within hours or days, or tardive, occurring after prolonged 
exposure. Acute syndromes comprise primarily: dystonia, akathisia and parkinsonism. 
Dystonia results in sustained muscle contractions and is characterised by repetitive 
movements, twisting or abnormal posture (Fahn 1988). Akathisia is a syndrome 
characterised by a sensation of inner restlessness and often results in an inability to sit 
still or remain motionless with affected patients displaying multiple complex movements 
in an attempt to control their urge to move (Braude et al. 1983).  
Parkinsonism, or Parkinson’s syndrome, is a compilation of motor deficits resembling 
those seen in Parkinson’s disease, which may present together or individually; common 
components include rigidity, tremor and postural instability (Shin and Chung 2012).  
Tardive syndromes are those that appear only after sustained treatment, typically >3 
months (American Psychiatric 2000).  
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These may include tardive dyskinesia, tardive akathisia or tardive dystonia. Tardive 
dyskinesia is characterised by repetitive, involuntary movements, commonly of the face 
such as lip smacking, tongue protrusion or grimacing (Schooler and Kane 1982). Tardive 
dystonia, though less common, often presents in conjunction with tardive dyskinesia. 
Thus, EPS are a major reason for non-adherence to treatment by patients (Tandon and 
Jibson 2002). This is especially problematic with the treatment of schizophrenia which has 
an extremely high rate of non-adherence in general (Mitchell and Selmes 2007). 
Typical antipsychotics are also associated with other side effects including prolactinemia 
which results in endocrine dysfunction and can lead to sexual dysfunction or infertility 
(Riecher-Roessler et al. 2009; Roke et al. 2009). As mentioned, these effects are due to 
dopamine receptor antagonism in the tuberofundibular pathway. 
1.2.3 Atypical antipsychotics 
The occurrence of EPS in conjunction with an unsatisfactory treatment response rate 
experienced with typical antipsychotics meant there existed a need for the development 
of more efficacious and safer antipsychotics. Clozapine, discovered in 1958, was 
developed by Sandoz and following its introduction to clinical practice in the 1970’s was 
noted for its lower incidence of EPS (Hippius 1989; Hippius 1999).  
This finding caused much incredulity regarding the utility of clozapine, as the dogma of 
the day was that EPS reflected efficacy of antipsychotic drugs (Van Rossum et al. 1970; 
Hippius 1989; Hippius 1999).  
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Thus, clozapine represents the first atypical antipsychotic (see section 1.2.4). Clozapine’s 
initial success was short-lived as the drug was associated with the life-threatening side 
effect agranulocytosis, the suppression of white blood cell production (Gerson and 
Meltzer 1992). This serious consequence of clozapine was especially brought to light 
during an epidemic in Finland (Idanpaanheikkila et al. 1975).  
The clozapine programme was subsequently halted, though it remained available to a 
limited degree in some countries. Subsequently, with growing anecdotal evidence of 
clozapine’s efficacy, coupled with advancements in the management of agranulocytosis, 
the clozapine programme was restarted in 1982, and the drug was approved by the FDA 
in 1989. Clozapine re-entered the market in 1990, primarily for treatment-refractory 
patients and with stringent patient monitoring rules attached (Crilly 2007). In addition to 
a lack of EPS, clozapine is also noted for it superior efficacy in preventing suicide in 
schizophrenia patients (Meltzer and Okayli 1995; Meltzer et al. 2003a). 
With the realisation that clozapine’s efficacy – without a propensity toward EPS was 
genuine, several other atypical antipsychotics were eventually developed some 30 years 
after the discovery of clozapine (Meyer and Simpson 1997). The first of these was 
risperidone, followed by others such as: quetiapine, ziprasidone, risperidone and 
olanzapine. 
At the time of its discovery, clozapine was noted for a lack of effect on amphetamine-
induced psychomotor agitation in rodents – the accepted model of the time for 
identifying potential antipsychotics that was known to depend on potent D2 antagonism 
(Meyer and Simpson 1997).  
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This had important connotations, as researchers searched for alternative models to 
discover antipsychotic compounds. LSD (lysergic acid diethylamide), a compound known 
to produce certain schizophrenia-like effects in humans (Lake et al. 1981) had not been 
used in experimental models as it did not produce any measurable behaviour in rodents 
that could be translated to humans.  
However, Janssen developed a drug-discriminating tool that allowed for screening of 
drugs with LSD-antagonising properties and hence potentially antipsychotic properties 
(Colpaert 2003).  
This led Janssen to developing risperidone in the 1980’s (Colpaert 2003). Crucially, LSD 
was known to produce its effect via both dopamine and serotonin receptors, and 
risperidone was found be a potent 5-HT2 antagonist. Thus, the way was paved for the 
mixed pharmacology of subsequent atypical antipsychotics that now dominate the 
psychopharmacology landscape of schizophrenia therapy (Table 1.2). 
Generic name Brand names 
Typical antipsychotics 
Chlorpromazine Largactil, Thorazine 
Thioridazine Mellaril, Melleril, Novoridazine, Thioril 
Mesoridazine Serentil 
Levomepromazine Nosinan, Nozinan, Levoprome 
Loxapine Loxapac, Loxitane 
Molindone Moban 
Perphenazine Trilafon 
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Thiothixene Navane 
Trifluoperazine Stelazine 
Haloperidol Haldol 
Fluphenazine Prolixin 
Droperidol Droleptan, Dridol, Inapsine, Xomolix, 
Innovar 
Zuclopenthixol Clopixol 
Prochlorperazine Compazine, Stemzine, Buccastem, 
Stemetil, Phenotil 
Atypical antipsychotics 
Amisulpride Solian 
Asenapine Saphris 
Blonanserin Lonasen 
Clotiapine Entumine 
Clozapine Clozaril 
Iloperidone Fanapt 
Lurasidone Latuda 
Olanzapine Zyprexa, Ozace 
Paliperidone Invega 
Perospirone Lullan 
Quetiapine Seroquel 
Remoxipride Roxiam 
Risperidone Risperdal, Zepidone 
Sertindole Serdolect 
Sulpiride Sulpirid, Eglonyl 
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Ziprasidone Geodon, Zeldox 
Zotepine Nipolept 
Third generation antipsychotics 
Aripiprazole Abilify 
In Phase II/Phase III trials 
Bifeprunox DU-127,090 
Pimavanserin ACP-103 
Vabicaserin SCA-136 
Zicronapine LLU 31-130 
ITI-007 - 
LY 2140023 - 
RP 5063 - 
AZD 2624 - 
OPC-34712  
Table 1.2 Drugs used in the treatment of schizophrenia. Currently used drugs are 
classified as typical (first generation), second generation (atypical) and third generation. 
Several compounds are also currently in development 1(Tandon et al. 2008a; 
http://www.clinicaltrials.gov/ 2013). 
1.2.4 Typicality versus atypicality 
The distinction between the first generation typical antipsychotics and second generation 
atypical was established based on their liability to induce EPS. Of note, early 
antipsychotics were only termed typical, or first-generation, following the introduction of 
the newer, atypical or second-generation drugs. 
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It must also be noted that both classes of antipsychotic are extremely heterogeneous in 
terms of pharmacology. A number of prevailing theories exist to explain what indeed is 
atypicality and separates the newer compounds from the older ones. This is an important 
point, as understanding why the two classes differ in EPS liability will allow for the better 
design of future antipsychotics, minimising or eliminating the occurrence of EPS. Indeed, 
the heterogeneity of both groups have led some to question whether atypicality really 
exists at all (Tyrer and Kendall 2009). Although, differences in potency, as well as efficacy 
in treating certain symptoms, suggests that the newer drugs are worthy of differentiation 
from older compounds(Meltzer 2009)  
One prominent theory of atypicality relates to the ratio of serotonergic to dopaminergic 
receptor blockade (Meltzer et al. 1989). Atypical antipsychotics have a more diverse 
pharmacological profile than typical antipsychotics that act almost exclusively as 
dopamine antagonists. In particular, atypical antipsychotics are noted for their high 
affinity for serotonin receptors, especially the 5-HT2A receptor (Miyamoto et al. 2004).  
As serotonin can inhibit dopamine transmission (Kapur and Remington 1996), the 
blocking of serotonin receptor may augment dopamine release thereby lessening the 
effects of the antipsychotic and preventing EPS.  
However, the 5-HT2A:D2 ratio of atypical antipsychotics does not predict their EPS liability 
(or lack thereof) (Kapur and Mamo 2003). Moreover, as already mentioned, the 
identification of a ‘therapeutic window’ whereby greater than 65% D2 receptor occupancy 
confers therapeutic benefit while greater than 80% leads to EPS (Kapur et al. 2000) 
indicates that 5-HT2A antagonism may be unnecessary for atypicality. 
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The second major hypothesis to explain the mechanism of reduced EPS with the atypical 
antipsychotics is commonly referred to as the ‘fast-off’ theory. This theory suggests that 
the faster dissociation rates of atypical compounds (i.e. lower affinity) compared to the 
typical drugs leads to adequate occupancy for therapeutic response but prevents 
occupancy levels reaching those required for EPS (Kapur and Seeman 2001). 
It must also be noted that atypical antipsychotics do cause EPS, further greying the area 
between typical and atypical drugs. However, EPS as a side-effect of atypical compounds 
occurs much more rarely in clinical practice due mainly to the fact that they achieve a 
therapeutic response at lower doses, as increasing doses lead to increased incidence of 
EPS with atypical antipsychotics such as risperidone and olanzapine (Kapur et al. 1999; 
Tarsy et al. 2002). 
1.3 Body weight regulation 
The regulation of energy homeostasis is a critical biological process. Through evolution, 
humans have developed several physiological strategies in order to maintain both short 
and long-term energy balance. In the simplest terms, energy balance is a paradigm 
controlled under the first law of thermodynamics (energy can neither be created nor 
destroyed) and as such consists of energy intake, energy expenditure and stored energy 
(Goran 2000; Hall 2012) (Fig 1.1). However, the control of energy balance and body 
weight is a highly complex and multifactorial process and numerous factors contribute to 
the regulation of energy intake, energy storage and energy expenditure (Galgani and 
Ravussin 2008). 
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Fig. 1.1 The energy balance equation. 
It is clear therefore, that differences between each side of this equation results in a net 
energy balance which may be: positive; associated with weight gain, negative; associated 
with weight loss, or neutral; associated with weight maintenance (Fig 1.2). The goal of the 
regulatory system is to drive energy balance in the direction necessary to maintain 
adequate adiposity and body weight to ensure survival and several mechanisms are in 
place that can affect both sides of the equation in order to achieve this goal (Galgani and 
Ravussin 2008; Williams and Elmquist 2012) 
Physical Activity
Energy Expenditure
Basal Metabolic Rate
Energy Intake
FOOD WEIGHT GAIN
Physical Activity
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Energy Intake
FOOD
WEIGHT LOSS
 
Fig. 1.2 Body weight regulation. The main contributors to both sides of the energy 
balance equation and the effect of shifting the energy balance on body weight. 
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To ensure an adequate energy balance, a central neural regulatory system receives 
information regarding the nutritional status and energy stores of the body, and 
subsequently generates appropriate signals to drive food intake, energy storage and 
energy expenditure in the direction necessary to maintain a steady state of adiposity and 
body weight. As we will see below however, this system consists of numerous inter-
related factors, and moreover, the mechanisms of body weight regulation are complex 
and not yet fully understood (Gale et al. 2004).  
This adaptable regulatory system is also a vulnerable one. As such, numerous 
physiological and psychological factors can exert influences on the system, which, in the 
context of the modern world, may not ultimately be beneficial to the individual.  
Thus, understanding the various components which act both centrally and peripherally to 
affect either side of the energy balance equation is critical to both understanding body 
weight regulation as well as tackling associated medical problems. 
1.3.1 Energy intake  
Our entire energy intake comes from one source - the food we eat. Thus, one might think 
controlling this side of energy balance is a relatively simple task. However, food intake is 
one of the most complex human behaviours and regulating it is a considerable 
physiological challenge. The complexity and importance of regulating energy balance and 
food intake is highlighted by the fact they are controlled by the intricate interaction 
between neural systems, hormonal and nutrient signals involving thousands of genes.  
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Appetite is regulated by a complex network of central and peripheral hormones, peptides 
and receptors (Stanley et al. 2005). Interactions between these components help 
maintain the homeostatic balance between energy intake and expenditure. Food intake 
and ingested nutrients modulate the peripheral release of a plethora of hormones and 
gut peptides, which all act through the brain to co-ordinate appetite and subsequent food 
intake. This bidirectional communication between the gut and the brain represents the 
brain gut axis and is important in body weight and obesity as well as potentially many 
other disorders (Konturek et al. 2004). 
1.3.1.1 Hypothalamic regulation of food intake 
The hypothalamus, situated at the base of the brain, is the major regulator of food intake. 
Studies carried out as long as seventy years ago demonstrated the critical role played by 
the hypothalamus in food intake (Hetherington and Ranson 1940; Elmquist et al. 1999). 
Lesions of the ventromedial hypothalamus led to hyperphagia and obesity while lesions 
of the lateral hypothalamus caused reduced food intake and leanness. Furthermore, 
electrical stimulation (i.e. activation) of the respective areas produced the opposite 
effects (Hetherington and Ranson 1940; Anand and Brobeck 1951; Delgado and Anand 
1953; Stellar 1954). Subsequent work has revealed that the role hypothalamus plays in 
food intake is complex, and involves connections with other brain regions. Moreover, the 
role of the mediobasal hypothalamus and in particular the arcuate nucleus (ARC) has 
come to the fore.  
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The ARC, as the name suggests, is an arc-shaped collection of neuronal cell bodies. It is 
ideally located to sample the peripheral circulation through semi-permeable capillaries in 
the underlying median eminence, allowing it to integrate the peripheral signals with 
central regulation (Neary et al. 2004). The ARC contains two distinct neuron populations 
which exert potent and opposite effects on food intake. Agouti-related peptide (AgRP)/ 
Neuropepetide Y (NPY) co-expressing neurons are orexigenic, promoting food intake (and 
inhibiting energy expenditure) (Hahn et al. 1998) while pro-opiomelanocortin (POMC) and 
cocaine-amphetamine regulated transcript (CART) co-expressing neurons are 
anorexigenic, reducing food intake (and increasing energy expenditure) (Elias et al. 1998; 
Elias et al. 2001).  
1.3.1.2 Neuropeptide Y 
NPY is potently orexigenic and acts primarily via its Y1 and Y5 receptors in exerting this 
function (Stanley et al. 1986; Stanley et al. 1992; Zarjevski et al. 1993; Gerald et al. 1996; 
Michel et al. 1998).  
It is unsurprising therefore, that NPY expression is increased in genetically obese, leptin 
deficient, (ob/ob) mice (Wilding et al. 1993) and that secretion of NPY in the 
hypothalamus is increased when fat stores are depleted, but levels are decreased by 
expanding fat mass (White and Kershaw 1990; Kalra et al. 1991; Wilding et al. 1993). 
1.3.1.3 Agouti-related peptide 
AgRP is also a potent orexigenic peptide (Rossi et al. 1998). Like NPY, AgRP expression is 
localised to the ARC (Shutter et al. 1997) and is up-regulated by fasting (Hahn et al. 1998). 
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AgRP acts as a competitive antagonist of the melanocortin MC3 and MC4 receptors 
(Ollmann et al. 1997; Haskell-Luevano and Monck 2001) and though less potent than NPY, 
AgRP appears to have longer lasting effects on food intake (Seeley et al. 2000).  
The MC3 and MC4 receptors are highly unusual in human physiology as they have an 
endogenous agonist (melanocortins) and endogenous antagonist (AgRP). The 
melanocortins are anorexigenic and act by binding primarily to the MC3 MC4 receptors 
(Mountjoy et al. 1992; Huszar et al. 1997; Irani et al. 2011). AgRP therefore inhibits this 
anorexic effect, indirectly promoting feeding.  
1.3.1.4 Pro-opiomelanocortin 
POMC is a precursor of several biologically active peptides and is cleaved in a site-specific 
manner to produce a number of products including α- melanocyte stimulating hormone 
(α-MSH) and β-MSH. These melanocortins act on the melanocortin receptors MC3 and in 
particular MC4 to illicit anorexic responses (Cone et al. 1996; Cone 2005). AgRP neurons 
can also release GABA, the main inhibitory neurotransmitter in the CNS, and thus can also 
inhibit nearby POMC neurons via this GABA release (Cowley et al. 2001).  
The transduction of neuronal signals to increase/decrease food intake is far from fully 
understood, however a number of integrated pathways which are involved have been 
identified (Valassi et al. 2008; Harrold et al. 2012). Neurons from the ARC signal to other 
discrete hypothalamic nuclei including the paraventricular nucleus (PVN), lateral 
hypothalamus (LHA) and perifornical area (PFA) (Sainsbury and Zhang 2010; Rediger et al. 
2012)(Fig 1.3). Secondary neurons from the ARC innervate these regions and cause the 
release of further catabolic/anabolic neuropeptides. 
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1.3.1.5 Hypothalamus-pituitary-adrenal axis 
Neuropepetides synthesised in the PVN include coritcotropin-releasing hormone and 
thyrotropin-releasing hormone, both of which are anorectic (Kow and Pfaff 1991; Grill et 
al. 2000). These hormones are also crucially involved in regulating the hypothalamus-
pituitary-adrenal (HPA) and hypothalamus-pituitary-thyroid (HPT) axes.  
Both these axes can affect peripheral energy regulation through the release of hormones 
such as glucocorticoids in the case of the HPA (Dallman et al. 1993; Dallman et al. 1995), 
and oxytocin by the thyroid gland (Olson et al. 1991). Thus, the PVN plays a crucial role in 
regulating energy intake and energy balance by integrating signals from the ARC with 
these hormone systems (Schwartz et al. 2000). 
1.3.1.6 Melanocyte-concentrating hormone  
Melanocyte-concentrating hormone (MCH) is an orexigenic hormone synthesised in the 
LHA/PFA hypothalamic regions and is important for stimulating a feeding response (Qu et 
al. 1996; Shimada et al. 1998). Other hormones in this region, orexin A and orexin B, as 
their name suggests, are also orexigenic (Sakurai et al. 1998).  
1.3.1.7 Orexins 
The orexins are involved in the regulation of sleep (Chemelli et al. 1999; Lin et al. 1999) 
and thus may play an integrative function within the hypothalamus, helping to coordinate 
its various homeostatic functions including feeding, sleep, arousal and stress responses 
(Yamanaka et al. 2003; Spinazzi et al. 2006)  
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The bidirectional contact between these various nuclei and other brain regions remains to 
be fully elucidated, but it is clear that the complex interaction between them is central to 
the proper regulation of energy balance. 
1.3.1.8 Dopamine 
Dopamine also plays an important role in the hypothalamic control of food intake 
(Schwartz et al. 2000).  
There is evidence that decreased dopaminergic tone in hypothalamic nuclei contributes 
to the obesity/insulin resistant phenotype as seen in seasonally obese (hibernating) 
animals in which dopaminergic neuronal activities change profoundly with the changing 
seasons (Luo et al. 1999). Antagonism of hypothalamic D2 receptors has been shown to 
affect food intake, inducing hyperphagia in rats (Parada et al. 1988). 
However, dopamine’s role in feeding behaviour is highly complex and far from fully 
understood. Indeed, projections of the nigrostriatal pathway have recently been 
implicated in feeding behaviour and evidence suggests the dorsal striatum may be 
particularly important to this function of dopamine (Palmiter 2007; Narayanan et al. 
2010). 
1.3.1.9 Serotonin 
Serotonin (5-HT) is potently anorexigenic and is keenly involved in the regulation of 
appetite and energy balance. The 5-HT2C receptor is particularly implicated in this role 
(Lam et al. 2008) though several other 5-HT receptors including 5-HT1A, 5-HT1B, 5-HT2A and 
5-HT7 seem to be involved in possibly complementary mechanisms (Nonogaki, 2008).  
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Serotonin’s satiety effects are mainly hypothalamic driven, though the wide expression of 
receptors suggests its influence on eating behavior may not be restricted to the 
hypothalamus (Leibowitz and Alexander 1998; Lucki 1998).  
The 5-HT2C receptor shares a high degree of homology with 5-HT2A and 5-HT2B receptors 
and all three are coupled to Gαq. Their activation typically invokes activation of 
phospholipase C, the generation of the second messenger inositol triphosphate (IP3) and 
influx of extracellular calcium resulting in activation of protein kinase C (Leysen 2004).  
These receptors are found in several brain regions including the hypothalamus, striatum, 
frontal cortex and several others where they modulate both excitatory and inhibitory 
neurons allowing for normal functioning of feeding, locomotor and anxiogenic processes. 
5-HT2c knockout mice have been shown to be hyperphagic and obese (Tecott et al. 1995). 
Furthermore, 5-HT2c receptors have been shown to be co-expressed with POMC neurons 
(Xu et al. 2008) and re-expression of 5-HT2c receptors on POMC neurons was shown to 
rescue the obese phenotype in 5-HT2c null mice (Xu et al. 2008). Thus, 5-HT2C blockade or 
deletion can result in decreased POMC expression and subsequent hyperphagia 
(Nonogaki et al. 2008).  
5-HT2c agonist have been shown to reduce weight in humans (Sargent et al. 1997) and 
some agonists such as the sibutramine and fenfluramine have been used clinically to treat 
obesity (though these are no longer used due to adverse effects).  
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1.3.1.10 Histamine 
Histamine is also anorexigenic and central histamine originates in the tuberomammilary 
body of the posterior hypothalamus and arising histaminergic neurons project to several 
brain areas with the highest density found in the hypothalamus (JÃ¸rgensen et al. 2007). 
Histamine’s hypothalamic effects are mediated by the H1 receptor which is a post-
synaptic Gα protein coupled receptor and activation results in increase mobilisation of 
intracellular calcium and thus activation of phospholipase C as well other intracellular 
mechanisms. H1 receptor knockout mice have increased food intake and body weight gain 
(Masaki et al. 2004) and histamine H1 antagonists dose dependently increase feeding in 
rats (Sakata et al. 1988). 
Histamine may not only have a direct effect on appetite but also plays an important role 
in the regulation of leptin’s central effects. Leptin administration has no effect in H1 
knockout mice (Morimoto et al. 1999) and ob/ob mice show decreased levels of 
histamine in the hypothalamus. This demonstrates the important role played by 
histamine in the mechanisms of action of leptin (Machidori et al. 1992). Hence, histamine 
H1 receptor antagonism seems to disrupt the action of leptin (Masaki et al. 2001) 
preventing leptin from exerting its satiety effects, causing or at least exacerbating leptin 
resistance (Starrenburg and Bogers 2009). Histamine can also effect peripheral 
metabolism by activating the sympathetic nervous system promoting energy expenditure 
by accelerating lipolysis in white adipose tissue and hence reduce fat deposition in 
adipose tissue (Tsuda et al. 2002). 
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1.3.1.11 Noradrenaline 
Noradrenaline can affect food intake with α1 and α2-adrenoceptor agonists having 
opposing effects on food intake (McCabe et al. 1984; Wellman and Davies 1992). 
The incorporation of these many monoamine systems in to an already complex regulatory 
system that controls food intake highlights the incredibly multi faceted nature of energy 
regulation, and the scale of the task in trying to understand and combat metabolic 
disorders such as obesity.  
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Fig. 1.3 Hypothalamic regulation of energy intake. The major nuclei of the hypothalamus: 
VMN; ventromedial nucleus, PVN; paraventricual nucleus, DMN; dorsomedial nucleus, 
LHA; lateral hypothalamus, and ARC; arcuate nucleus. The ARC contains both orexigenic 
neurons coexpressing NPY/AgRP and anorexigenic POMC/CART neurons which receive 
peripheral signals including ghrelin, leptin, insulin, GLP-1 and PYY as well as central signals 
such as monoamines.. The ARC (arcuate nucleus) communicates with other hypothalamic 
regions via melanocortin (MC3-R and MC4-R) and neuropeptide Y (NPY) receptors. (Figure 
courtesy of H. Schellekens). 
1.3.2 Peripheral signals in the regulation of energy balance 
The communication to stimulate feeding is dependent on energy stores, i.e. adiposity. 
Hormones termed adiposity signals relate information regarding the body’s energy status 
to the hypothalamus allowing for an appropriate neuronal and endocrine response. 
Arguably the most important of these signals is the hormone leptin. Leptin is released 
directly from adipocytes, and plasma leptin levels correlate to adipose mass (Friedman 
and Halaas 1998). Moreover, brain leptin levels are proportional to plasma levels and 
hence adiposity (Schwartz et al. 1996). 
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Over forty peripheral hormones are known to affect food intake. Many of these signals 
are released from peripheral tissues and act centrally as feedback signals in order to 
influence appetitive drive. These include adiponectin, resistin, PYY, leptin, ghrelin and 
insulin which all also have important peripheral metabolic effects (Fig 1.4). 
Cholecystokinin, amylin and pancreatic glucagons are peptides released rapidly from the 
intestine and pancreas with the onset of feeding and have short durations of action. 
These peptides all act to propagate meal termination. The postprandially released 
cholecystokinin was the first gut hormone demonstrated to have an effect on food intake 
(Gibbs et al. 1973). Amylin, secreted from the pancreatic α cell secretory vesicles in 
response to food, has a glucose-regulatory and an anorexigenic action, reducing food 
intake via actions on the hindbrain area postrema and central nucleus of the amygdala 
(Lutz 2006).  
PYY, glucagon-like peptide 1 (GLP-1) and oxyntomodulin are peptides for which longer-
term feeding inhibitory actions have been identified (Stanley et al. 1985; Cohen et al. 
2003; Dakin et al. 2004; Baggio and Drucker 2007). These are released from intestinal L 
cells in the distal intestine and levels rise slowly during a meal, peaking after meal 
termination and remaining elevated for several hours. Pancreatic polypeptide is also 
released postprandially into the circulation in proportion to calories ingested to reduce 
food intake (Batterham et al. 2002).  
In addition, adipokines including leptin, adiponectin and resistin are secreted by the 
adipose tissue in proportion to fat mass.  
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These adipokines mediate their central effects via the hypothalamus to affect food intake 
as well as energy expenditure (Zhang et al. 1994; Tovar et al. 2005; Ahima and Lazar 2008; 
Kadowaki et al. 2008). Leptin counteracts the effect of NPY and promotes the synthesis of 
α-MSH. Leptin mediated inhibition of food intake is long-term, in contrast to the rapid 
inhibition by cholecystokinin and the slower suppression of hunger between meals 
mediated by PYY.  
Insulin is secreted by the pancreas upon increase in glucose load and, like leptin, has 
profound anorexigenic effects on appetite (Woods et al. 1979; Hallschmid et al. 2004). 
Insulin accesses the brain via receptor-mediated transport across the blood-brain barrier 
where it acts on insulin receptors that are highly expressed in the ARC and are also co-
expressed with POMC, CART and NPY, meaning insulin is in prime position to carry this 
weight-reducing function. Insulin also of course exerts crucial functions in peripheral 
tissues such as liver, muscle and adipose tissue to maintain glucose homeostasis. 
Ghrelin acts as a growth hormone-releasing peptide and is secreted from the stomach. 
Ghrelin is the only peripheral hormone identified as being orexigenic. Therefore, ghrelin 
has been aptly coined the ‘hunger hormone’ due to its strong appetite enhancing action 
(Tschop et al. 2000; Nakazato et al. 2001; Kojima et al. 2004). Moreover, ghrelin secretion 
is enhanced in between meals and under conditions of negative energy balance, such as 
starvation and anorexia (Wren et al. 2001; Lawrence et al. 2002; Sun et al. 2004). In 
contrast, food intake leads to a decrease in plasma ghrelin levels. Considerable evidence 
supports the role for the hormone ghrelin in mealtime hunger and meal initiation, 
increasing food intake and body weight (Tschop et al. 2000; Cummings et al. 2001a). 
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Ghrelin exerts its effect centrally via the growth hormone secretagogue receptor, a G-
protein coupled receptor. 
 
Fig. 1.4 Bi-directional regulation of energy balance. Signal from the periphery including 
the gut, adipocytes, stomach and pancreas are integrated centrally producing outputs 
that in turn signal to these organs in order to ensure proper energy balance is maintained 
(Figure courtesy of H. Schellekens). 
1.3.3 Energy storage 
The body is able to store excess energy if intake exceeds the body’s energy needs (i.e. 
expenditure). This is an extremely valuable asset in terms of long term survival and short-
term homeostasis as it ensures that the body has access to required energy stores even in 
times when energy intake is severely reduced.  
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This is an obvious advantage in times such as famine of course but also perhaps more 
relevantly today in circumstances such as strenuous exercise.  
Short-term energy requirements can be met by the storage of energy as carbohydrate, 
i.e. glycogen, in the liver and muscle tissue. In the fed-state (postprandial) carbohydrates 
(mainly glucose) are assimilated into the hepatic portal blood stream and transported to 
tissues for use as an energy source. The remainder of the absorbed glucose is transported 
directly to the liver where some of the excess glucose is converted to glycogen by the 
process of glycogenesis and stored. As the option for glycogen stores is relatively limited, 
further glucose is converted to fat, also within the liver, via the process of lipogenesis 
(Fig.1.5). 
 
Fig.1.5 Biochemical process of lipogenesis. Carbohydrate is converted to acetyl-CoA via 
glycolysis and acetyl-CoA is converted to malonyl-CoA catalysed by acetyl-CoA carboxylase 
(Acc) which is in turn catalysed by fatty acid synthase (FAS) to form fatty acids.     
The storage of large amounts of energy is achieved by storing it as fat. Fat is energy 
dense, 1g containing 9 kilocalories (kcal), twice as much as carbohydrate or protein. 
Dietary fat is absorbed primarily as triglycerides in the form of chylomicrons. 
Chylomicrons bypass the liver as they reach the venous circulation by way of the 
lymphatic system. Lipoprotein lipase (LPL) is the key enzyme involved in the uptake of 
triglycerides into adipocytes (Wang and Eckel 2012). LPL is bound to capillary 
endothelium and converts circulating triglycerides to free fatty acids and monoglycerides. 
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These molecules can then diffuse into the cell where they are reassembled into 
triglycerides and stored, mainly as triacylglycerol. 
Fatty acids produced in the liver via de novo lipogenesis are packaged as triglycerides, 
typically as very low density lipoprotein (VLDL), and released into the bloodstream before 
being transported to adipose tissue and stored as outlined above. 
1.3.3 Energy expenditure 
Three processes account for energy expenditure, namely: resting metabolic rate, diet-
induced thermogenesis and physical activity. Resting metabolic rate is the energy 
expended to survive i.e. maintain heat rate, breathing etc. and is the main contributor to 
an individuals daily energy expenditure (Donahoo et al. 2004). Basal metabolic rate is 
metabolic rate during sleep and is generally around 3% lower than resting metabolic rate 
due to the energy required for arousal (Donahoo et al. 2004). These terms are therefore 
commonly used interchangeably. Inter-individual variations in daily resting metabolic rate 
can reach 20-25% though an individuals’ tends to be stable. The typical adult resting 
metabolic rate is approximately 1 kcal/min (Goran 2000).  
Diet-induced thermogenesis constitutes the energy cost of digesting, metabolising and 
storing nutrients. Also known as the thermic effect of food, diet-induced thermogenesis is 
approximately proportional to the caloric density of the meal, with the energy cost of a 
meal being roughly 10% of the energy intake (Schutz 2004). 
Physical activity or exercise is the most variable aspect of energy expenditure (van Baak 
1999) and comprises all movement carried out during a day.  
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An Individual’s occupation, environment, age and gender all have a significant impact on 
one’s daily activity and thus on energy expenditure (Goran 2000). 
Thus, energy expenditure coupled with food intake is clearly an important factor in the 
regulation of energy homeostasis and for the development of related disorders such as 
obesity. Moreover, due to the voluntary nature of energy expenditure (i.e. exercise), 
energy expenditure is also an important target in tackling obesity and related diseases 
(Poehlman et al. 1991) (see section 1.4.3.). 
1.4 Obesity 
The prevalence of obesity is rapidly increasing in both developed and developing 
countries and is a considerable burden upon health care systems worldwide (Bloom et al. 
2008; Swinburn et al. 2011). In the U.S., the prevalence of obesity now exceeds 30% 
(Flegal et al. 2010) with European figures trending towards the same astonishing rate 
(Berghoefer et al. 2008). Perhaps even more worrying is the increasingly high rates of 
childhood and adolescent obesity  Worldwide, the prevalence of childhood overweight 
now stands at approximately 60% with 43 million pre-school children were overweight in 
2010 (de Onis et al. 2010). Thus, with obesity now accepted as a global epidemic, there 
has never been a greater need for research into the aetiology of the disease and ways to 
combat it. 
The development of this obesity epidemic largely stems from alterations in gene x 
environment interactions. Genetic predisposition within individuals increases the 
likelihood of the development of obesity (Loos and Bouchard 2003; Dahlman and Arner 
2007; Bouchard 2008).  
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These include variants of the fat mass and obesity associated gene (FTO) and the MC4 
receptor (Li and Loos 2008; Loos et al. 2008; Willer et al. 2009). However, the alarming 
rate at which obesity rates have increased in recent times indicates that lifestyle and 
environmental changes represent the major cause for a shift toward an obese society 
rather than genetic changes (Marti et al. 2004).  
As can be seen from the energy balance equation earlier (Fig. 1.1), the root cause of 
obesity is energy imbalance i.e. more calories consumed than expended (Chakrabarti 
2009). However, genetic and environmental interaction acts in concert with physiological 
processes to make obesity a highly complex disease. For obese individuals therefore, 
eating less and exercising more is not as straightforward a remedy as it may seem. From 
an evolutionary point of view our bodies have a primal nature that drives eating and 
storage of body fat (Wells, 2009). Moreover, in obese individuals, the homeostatic set 
point is changed and the obese state is perceived as the normal state (Harris 1990) 
meaning all the ‘good intentions’ of diets, can be undermined by the body’s physiological 
adjustments in chronic obesity. Losing excess weight, it seems, is a very unnatural thing to 
do in non-hibernating mammals, making efforts to tackle the obesity epidemic extremely 
complex.  
1.4.1 Obesity and energy intake 
The recent boom in the prevalence of obesity worldwide clearly indicates that lifestyle 
factors are the major contributor to this epidemic. An increase in the availability of cheap, 
energy-dense foods has undoubtedly resulted in increases in caloric intake.  
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A reliance on processed foods, ready meals and fast food which all contain a high 
carbohydrate and fat content means that people are chronically over consuming these 
macro-nutrients leading to a prevalence of weight gain and obesity (Hill and Peters 1998; 
Hill 2006; Heitmann et al. 2012). 
1.4.2 Obesity and energy storage  
As discussed above, excess energy is primarily stored as triglyceride within adipocytes. 
However, a chronic state of positive energy balance brought about by sustained intake of 
calorie rich foods results in an accumulation of triglyceride and ultimately adipocyte 
dysfunction. 
Excessive delivery of triglycerides to adipocytes leads to adipocyte hypertrophy and 
hyperplasia (Ferre 2003; de Ferranti and Mozaffarian 2008). Evidence suggests that the 
adipose tissue reaches a critical mass after which hypertrophy and hyperplasia result in 
cell dysfunction, leading to pro-inflammatory responses which contribute to the 
metabolic dysfunction associated with obesity (Langin 2006).  
1.4.3 Obesity and energy expenditure 
As with energy intake, lifestyle changes have contributed in a significant way to decreases 
in energy expenditure. Advances in transport and technology have led to a more 
sedentary lifestyle. A reduction in exercise and general physical activity levels combined 
with increased food intake are thought to be the major forces driving the ever growing 
numbers of overweight and obese individuals (Goran 2000; Heitmann et al. 2012).  
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The high rate of obesity has led to increases in complications associated with obesity, 
notably the metabolic Syndrome (MetS) (also known as Reaven’s syndrome X and the 
insulin resistance syndrome). Metabolic syndrome describes a constellation of 
cardiovascular risk factors, specifically: insulin resistance (type 2 diabetes), glucose 
intolerance, dyslipidemia and hypertension (see section 1.5). 
1.5 Metabolic syndrome 
The metabolic syndrome is a constellation of obesity-related abnormalities (Eckel et al. 
2005; Alberti et al. 2009; Bruce and Byrne 2009; Bruce and Hanson 2010). Definitions of 
the metabolic syndrome are varied and differ based on epidemiological parameters such 
as race and gender. However, general guidelines on what constitutes the metabolic 
syndrome have been compiled (Table 1.3). The main metabolic complications associated 
with the syndrome include: glucose dysregulation, increased adiposity, dyslipidemia and 
raised blood pressure.  
Measurement Diagnostic cut-off point 
Waist Circumference ≥ 102 cm (men); ≥88 cm (women) 
Triglycerides ≥ 150 mg/dl 
On medication for elevated triglycerides HDL < 40 mg/dl (men); < 50 mg/dl (women) 
Blood Pressure ≥ 130 mm Hg (systolic); ≥ 85 mm Hg 
(diastolic) 
On antihypertensive medication 
Fasting Glucose ≥ 100 mg/dl 
On medication for el vat  glucose 
Table 1.3 Components and diagnostic criteria for the metabolic syndrome. HDL; high 
density lipoprotein (adapted from (Grundy et al. 2005). 
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Importantly, obesity per se is not a prerequisite of the metabolic syndrome. This can be 
an important distinction as ‘healthy-obese’ individuals may not be at risk of serious co-
morbidities and equally, non-obese, metabolically-unhealthy individuals may be. This 
difference is particularly relevant in the context of visceral fat, as increased central 
adiposity (i.e. visceral fat) is a component of the metabolic syndrome and, as will be 
discussed below, plays a considerable role in the milieu of metabolic complications 
ensuing from the syndrome. Indeed, the co-occurrence of adiposity within the metabolic 
syndrome increases the relative morbidity risk for an individual (Cheng and Leiter 2006; 
Mikhail 2009). 
Unsurprisingly given its close links to obesity, the prevalence of the metabolic syndrome 
is at an all time high with some 31% of Americans fulfilling the above diagnostic criteria in 
2002 (Ford et al. 2002). Furthermore, as a major risk factor for the development of Type II 
diabetes, this increase in the prevalence of the metabolic syndrome undoubtedly 
contributes to the current and future predicted rise in cases Type II diabetes (Wild et al. 
2004; Shaw et al. 2010).  
1.5.1 Visceral adiposity 
Visceral fat comprises the adipose tissue found in the abdominal cavity, where is acts to 
insulate and support several organs. Hence, adipose tissue is found in discrete locations 
associated with particular organs. These depots include mesenteric fat (associated with 
the intestines), perirenal fat (associated with the kidneys) and gonadal fat associated with 
uterus and ovaries in females and the epididymis and testes in males).  
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Adipose tissue, a common type of connective tissue, is comprised of circa 80% adipocytes 
with the remainder being made up by macrophages, fibroblasts and endothelial cells. 
Visceral adiposity may be measured in humans directly by tomography or magnetic 
resonance imaging (MRI), or as a function of central obesity i.e. waist to hip ratio. The 
accurate assessment of visceral adiposity is becoming increasingly important clinically for 
proper assessment of patient metabolic disease risk (Shuster et al. 2012). Increased 
visceral fat is associated with increased risk of developing the metabolic syndrome 
(Nieves et al. '03). Some definitions of the metabolic syndrome do not distinguish 
between visceral fat and subcutaneous fat while some do, as the debate over the 
significance of such differences continues.  
Visceral adiposity correlates with other metabolic derangements (Wisse '04) and recent 
imaging studies support a correlation between visceral abdominal adiposity and the 
metabolic syndrome versus abdominal subcutaneous adipose tissue (Demerath et al. '08). 
As discussed earlier, adipose tissue plays a critical role in energy storage. However, the 
adipose tissue is no longer viewed as a simple storage depot but rather as an active 
endocrine organ (Fantuzzi 2005). The adipose tissue has the capacity to release a number 
of factors including adipokines and cytokines which can act in an autocrine, paracrine or 
endocrine fashion to modulate metabolic processes (Maury and Brichard 2010). 
Adipose tissue secretes several immune-modulating factors such as cytokines; tumor 
necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-1β and hormones such as leptin. 
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The release of these molecules is triggered by macrophages which infiltrate the adipose 
tissue in obese individuals and together with adipocytes release these proteins. 
As mentioned in section 1.3.2, leptin is a hormone which acts both centrally and 
peripherally to regulate energy balance by decreasing food intake and restricting 
triglyceride deposition (Gade et al. 2010). Leptin levels increase proportionally with 
increasing adiposity (Galic et al. 2010) and increasing leptin exerts a strong negative 
feedback on insulin sensitivity thereby enhancing insulin resistance. 
TNF-α can directly evoke insulin resistance within adipose tissue as well as systemically 
via interruption of insulin signaling pathways (Bastard et al. 2006b). This involves the 
serine phosphorylation of both the insulin receptor and the insulin receptor substrate 
resulting in diminished activation of second messengers responsible for insulin’s 
metabolic effects (Wisse 2004). 
Adipose tissue also secretes adiponectin, an anti-inflammatory adipokine. Reduced 
circulating levels of adiponectin have been linked to development of the metabolic 
syndrome (Kadowaki et al. 2006) as well as sub-clinical coronary heart disease (Maahs et 
al. 2005). 
Hence, these inflammatory-related molecules play a key role in the development of the 
metabolic syndrome and as such in the cardiovascular risk of the individual 
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1.5.2 Inflammation 
Obesity is now recognised as a chronic low grade inflammatory state (Das 2001; Bastard 
et al. 2006a; Bastard et al. 2006b) The inflammation associated with this disease is tightly-
linked to abnormalities that together constitute the metabolic syndrome. The link 
between inflammation and obesity was first made by Hotamisligil, who showed increased 
TNF-α release from white adipose tissue was associated with obesity, and that nullifying 
TNF-α improved insulin sensitivity (Hotamisligil et al. 1993). 
The underlying cause of obesity-related inflammation is not altogether understood. 
Endoplasmic reticulum (ER) stress is one mechanism however that contributes to the 
induction of an inflammatory state observed in obesity (Zeyda and Stulnig 2009). ER 
stress in the liver and adipose tissue occurs in obesity due to excess lipid accumulation 
and disturbed energy metabolism brought about by over-nutrition (Ozcan et al. 2004). 
This activates a stress response known as the unfolded protein response which activates a 
number of inflammatory cascades via activation of Nf-ΚB and/or JNK pathways 
(Hummasti and Hotamisligil 2010).  
The crucial step in obesity-induced inflammation is macrophage infiltration of adipose 
tissue (Weisberg et al. 2003; Xu et al. 2003). Though not fully elucidated, this appears to 
occur in response to a number of factors including monocyte chemotactic protein-1,IL-8 
or leptin (Cancello and Clement 2006; Yu et al. 2006; Surmi and Hasty 2008).  
These macrophages, in conjunction with adipocytes, produce and release a number of 
pro-inflammatory cytokines such as TNF-α and IL-6, promoting local and systemic 
inflammation.  
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As discussed in the previous section, the pro-inflammatory cytokines released by adipose 
tissue/macrophages can contribute to insulin resistance by impairing insulin sensitivity. In 
addition to the aforementioned effects of leptin and TNF-α, IL-1 can prevent insulin 
signalling via serine phosphorylation of IRS-1 following the activation of ERK (Jager et al. 
2007). Also, IL-6 blocks IRS-mediated signalling in the liver via induction of SOCS-3 protein 
expression and in muscle via activation of protein kinase C-delta (Weigert et al. 2006).  
Obesity leads to adipocyte hypertrophy and resulting cell death (Cinti et al. 2005; Murano 
et al. 2008). In obesity, adipose-tissue macrophages are found surrounding the necrotic 
cells in what are known as crown-like structures (Apovian et al. 2008). It is thought these 
dying cells, along with other factors such as the extracellular matrix protein osteopontin, 
attract the macrophages to adipose tissue adding to macrophage accumulation (Cinti et 
al. 2005; Nomiyama et al. 2007). 
Thus, the inter-relationship between obesity, insulin resistance and inflammation is a 
complex and over-lapping one (Dandona et al. 2004). Inflammation is a key marker of 
metabolic disease and acts as a central player in a vicious spiral of metabolic 
derangements in association with obesity and/or insulin resistance which can ultimately 
lead to type 2 diabetes and/or cardiovascular disease (Xu et al. 2003; Dandona et al. 
2004; Shoelson et al. 2006; Apovian et al. 2008). 
1.5.3 Insulin resistance 
The metabolic syndrome has also been known as the insulin syndrome, highlighting the 
pivotal role this hormone plays in energy regulation (Reaven 2005). Insulin is a hormone 
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secreted by the pancreas and plays a key role in glucose homeostasis as well as several 
other functions important for energy homeostasis.  
Insulin acts primarily on muscle, liver and adipose tissue causing the uptake of glucose 
and reducing the plasma glucose concentration. Insulin resistance is the key factor in the 
pathogenesis of type II diabetes mellitus.  
Obesity has long been recognised to be associated with increased risk of insulin 
resistance. The link between obesity and insulin resistance is not fully elucidated but 
seems to be mediated mainly through increased adiposity and the development of a pro-
inflammatory state as outlined above (Everson et al. 1998; Dandona et al. 2004; Kahn et 
al. 2006).  
1.5.4 Dyslipidemia 
Abnormal lipid profile is a major factor in the metabolic syndrome and is both a cause and 
effect of insulin resistance. Moreover, obesity is highly co-morbid with dyslipidemia 
(Fabbrini et al. 2010). Dyslipidemia commonly presents as the atherogenic triad, namely, 
elevated plasma triglycerides, decreased high-density lipoprotein (HDL)-cholesterol and 
the presence of small dense low-density lipoproteins (LDLs) (Czyzewska et al. 2010). The 
ratio of HDL-cholesterol to LDL-cholesterol is a marker of a person’s chance of developing 
atherosclerosis, with HDL the “good” cholesterol and LDL the “bad” cholesterol. This 
distinction is based on the fact that HDL delivers cholesterol to the liver to be metabolised 
or excreted while LDL delivers cholesterol to cells which can lead to atherosclerosis. 
Dyslipidemia resulting from the metabolic syndrome is therefore a major link between 
obesity, atherosclerosis and ultimately cardiovascular disease. 
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Fig 1.6 Overlapping factors that contribute to obesity and associated morbidities. 
Numerous integrated physiological processes contribute to the development of obesity. 
Increased food intake leads to increased delivery of nutrients to the liver, subsequent 
increases in lipogenesis leads to increased energy storage and expansion of adipose tissue. 
Increased adipose mass leads to tissue inflammation and eventual release of 
proinflammatory factors as well as free-fatty acids leading to dyslipidemia and insulin 
resistance which further propagates metabolic dysfunction leading to a vicious cycle.  
1.6 Side effects of atypical antipsychotics  
The emergence of atypical antipsychotic drugs and the subsequent reduction in the 
prevalence of EPS was a substantial step forward in improving patient outcomes and 
increasing adherence to treatment. However, these newer compounds brought with 
them their own constellation of side effects including weight gain and a number of 
associated metabolic abnormalities including; visceral fat deposition, glucose 
dysregulation, dyslipidemia and low grade inflammation.  
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These side effects are a considerable clinical problem as they too contribute to the huge 
problem of patient non-adherence to antipsychotic treatment (Baptista et al. 2004; 
Weiden et al. 2004). Thus, reduced compliance due to metabolic side effects can lead to 
patient relapse and poor patient outcomes (Nasrallah 2003).  
As outlined earlier, obesity and metabolic disorders represent a major problem in modern 
healthcare due to their association with a number of serious co-morbidities including type 
II diabetes mellitus and cardiovascular disease. As such, the metabolic side effects of 
antipsychotics are of considerable concern as they too can lead to these detrimental 
diseases (Stahl et al. 2009; Starrenburg and Bogers 2009).  
The primary metabolic side effect observed in patients is that of body weight gain. 
However, as one might expect given the aforementioned heterogeneity of this drug class, 
the various atypical antipsychotics show widely differing weight gain liabilities. Clozapine, 
the original atypical, is the worst offender in terms of inducing weight gain in patients, 
closely followed by the structurally similar olanzapine (Allison et al. 1999; Schwartz et al. 
2004). 
1.6.1 Antipsychotic-induced weight gain 
There are currently several atypical antipsychotic drugs (AAPDs) in use or in development 
(Table 1.2) including: clozapine, olanzapine, quetiapine, risperidone, ziprasidone, 
ariprazole, paliperidone, lurasidone and amisulpride. In terms of weight gain liability, 
clozapine and olanzapine have long been recognised as having the highest incidence 
(Allison et al. 1999; Schwartz et al. 2004; Newcomer 2005).  
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Moreover, evidence suggests that olanzapine and clozapine are also the main culprits in 
causing metabolic dysregulation (Newcomer 2007).  
Clozapine is the oldest of the atypical compounds and its clinical use is indicated only for 
treatment-resistant schizophrenia and requires weekly monitoring of patients. 
Olanzapine is also widely used with reported sales of $8b in 2008, making its propensity 
to induce metabolic changes of particular concern. 
Quetiapine and risperidone have also been associated with weight gain and metabolic 
disturbances, albeit to a lesser degree (Lee et al. 2004; Brecher et al. 2007). In particular, 
a retrospective study found low dose quetiapine was associated with significant weight 
gain in patients (Williams et al. 2010).  
Paliperidone is the active metabolite of risperidone and though information is limited, 
indications are it has a similar efficacy and side effect profile to its parent drug (Marino 
and Caballero 2008) with reported incidences of weight gain in patients of 6-8% 
(Harrington and English 2010; Gopal et al. 2011).   
Ziprasidone and aripiprazole seem to be weight neutral and show little or no adverse 
metabolic effects, and have even been shown to attenuate some of olanzapine’s negative 
effects (Snigdha et al. 2008). Amisulpride is an atypical drug used in Europe but is not 
licensed by the Food and Drug Administration (FDA) for use in the U.S.; it is associated 
with a low risk of both weight gain and metabolic symptoms in comparison to other 
atypical antipsychotics.  
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1.6.2 Antipsychotic-induced metabolic dysfunction 
AAPD treatment has been associated with all aspects of the metabolic syndrome (Tables 
1.4 and 1.5). The aetiology of these adverse effects however is not yet known. It is clear 
however that a number of central and peripheral mechanisms overlap to induce weight 
gain and increased fat mass which ultimately leads to insulin resistance and dyslipidemia 
culminating in the development of co-morbidities such as cardiovascular disease and/or 
diabetes mellitus.  
1.6.2.1 Antipsychotic-induced visceral adiposity 
Weight gain associated with AAPD use consistently involves increased visceral adiposity 
(Cheng et al. 2005; Coccurello et al. 2006; Raskind et al. 2007; Ferno et al. 2009). 
Mechanisms of AAPD induced visceral fat accumulation include not only hyperphagia-
driven weight gain but also direct disruption of lipid handling.  
A number of preclinical studies have demonstrated increased adipose mass independent 
of weight gain (Victoriano et al. 2009; Albaugh et al. 2010). Alterations in adipocyte size 
as well as number have been observed demonstrating that AAPDs alter adipose 
physiology in addition to merely increasing weight. Mechanisms underlying these effects 
may involve genetic pathways as evidence suggests that antipsychotics, especially 
olanzapine and clozapine, can directly impact on key genes involved in lipid storage 
including FAS and SREBP (Ferno et al. 2006; Ferno et al. 2009; Ferno et al. 2011). 
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1.6.2.2 Antipsychotic-induced insulin resistance 
Decreased insulin sensitivity and disruption to glucose handling is commonly found in 
patients receiving AAPDs, particularly olanzapine and clozapine, (Dolder and Jeste 2003; 
Haupt et al. 2007; Newcomer et al. 2009; Smith et al. 2009). Importantly, AAPD treatment 
can cause the development of new onset diabetes (Farwell et al. 2004; Holt and Peveler 
2006; Lambert et al. 2006) and in rare cases, even ketoacidosis (excess metabolism of 
fatty acids in the liver leading to excess ketone bodies) (Cohen and Correll 2009). 
Therefore, as an antipsychotic side effect, insulin resistance is a prime concern and 
accordingly all AAPDs now carry a black label warning for diabetes mellitus, indicating the 
scale of this problem.  
Intriguingly, there is evidence that the progression to diabetes in cases of AAPD-induced 
diabetes is much quicker than is typically seen in non-psychiatric obese patients. This 
suggests mechanisms beyond weight gain are involved in AAPD–induced diabetes (Scheen 
and De Hert 2007). One hypothesis is that insulin resistance caused by AAPD-induced 
weight gain is compounded by inadequate compensation by β-cells due to direct AAPD 
effects, resulting in quicker progression to diabetes in some patients (Bergman and Ader 
2000; Scheen and De Hert 2007). These direct effects of AAPD on insulin secretion are 
thought to involve antagonism of muscarinic (M) receptors with the M2 (Johnson et al. 
2005) and M3 receptors (Stahl et al. 2009) implicated. 
Furthermore, AAPD-induced insulin resistance has been found in patients independent of 
effects on weight, and the degree of insulin resistance was found to be above and beyond 
that normally found in association with obesity alone (Kim et al. 2010).  
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This supports the idea that AAPDs have specific actions resulting in insulin resistance as 
opposed to simply being a consequence of obesity. This is somewhat corroborated by 
findings of the FDA that 25% of new-onset Type II Diabetes were not associated with 
substantial weight gain or obesity (Newcomer 2004).  
AAPDs may also directly induce insulin resistance via a number of potential mechanisms 
including a direct effect on β-cell function (which produce and secrete insulin) thereby 
impairing insulin secretion (Bergman and Ader 2005; Johnson et al. 2005). Preclinical 
models have shown that a single injection of olanzapine or clozapine can alter hepatic 
metabolism, supporting this hypothesis (Houseknecht et al. 2007; Chintoh et al. 2008a). 
As discussed above, evidence also suggests that AAPDs can cause increases in visceral fat 
mass without causing overt weight gain. Thus, AAPD induced dysfunction in adipose 
tissue physiology could indirectly lead to the development of insulin resistance via the 
release of pro-inflammaotry mediators (see section 1.5) independent of effects on body 
weight.  
1.6.2.3 Antipsychotic-induced inflammation  
Antipsychotic therapy has been associated with both local and systemic inflammation. 
Increased levels of circulating cytokines, including TNF, soluble TNF and IL-2 receptors 
have been observed in response to antipsychotics, in particular clozapine in (Schuld et al. 
2000; Kluge et al. 2009). These increases in cytokines are likely secondary to other 
metabolic effects of these drugs, however they are still an important consequence and 
are important consideration when assessing the side effects of atypical antipsychotics 
(Baptista and Beaulieu 2002).  
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Moreover, the development of a pro-inflammatory state in adipose tissue was found 
following antipsychotic administration in rats (Victoriano et al. 2010). 
1.6.2.4 Antipsychotic-induced dyslipidemia 
Antipsychotic treatment, both clinical and pre-clinical, has been shown to result in at least 
some of form of lipid abnormality (Graham et al. 2005; Coccurello et al. 2008; Perez-
Iglesias et al. 2009). Hence, dyslipidemia may in many cases be caused by antipsychotic 
treatment as a result of weight gain and spiraling metabolic dysfunction (Meyer and Koro 
2004). However, a direct influence cannot be ruled out due to evidence of acute effects of 
some AAPDs on cholesterol and triglycerol levels in animal models, for example, clozapine 
increased circulating levels of triglycerides, phospholipids and cholesterol in rats (Ferno et 
al. 2009), though the mechanism underlying such a direct effect is not yet understood.  
Furthermore, some clinical studies have not found a correlation between weight gain and 
observed dyslipidemia suggesting an alternative mechanism for AAPD induced 
dyslipidemia (Meyer and Koro '04).  
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DRUG N  PERIOD STUDY 
PARAMETERS 
WEIGHT MAIN FINDINGS REF 
Olanzapine 133  Patients with 
early psychosis 
80% > 7% increase 22/133 patients developed MetS (Patel et al. 2009) 
Quetiapine 134 52w  50% > 7% increase 18/134 patients  developed MetS  
Risperidone 133   57.6%> 7% increase 11/133 patients developed MetS  
       
Olanzapine 3    Average gain of 3 BMI points  (Oriot et al. 2008)  
Quetiapine 12  Drug-naïve; lean  Insulin Resistance indicated by HOMA scores  
Risperidone 10 36w patients with no 
MetS 
↑body weight (all 
groups) 
(for all groups)  
Ariprazole 11      
       
Olanzapine 573  open study 6.26 kg mean gain statistically significant but sub-clinically 
relevant 
(Kinon et al. 
2001)  
Haloperidol 103 58w  0.69 kg mean gain increase in cholesterol.(olanzapine)  
       
Olanzapine 10 104w open study ↑body weight ↑body fat ↑fasting glucose ↑fasting insulin 
↑insulin resistance (HOMA) 
(Ebenbichler et 
al. 2003)  
       
Olanzapine 10 8w consecutive 
inpatients 
3.3 kg mean gain ↑body fat    9/10 ↑Leptin (Eder et al. 2001)  
       
Olanzapine 30 8w First-episode 
schizophrenia 
patients 
6 kg mean gain 60% > 7% increase in body weight (Poyurovsky et al. 
2002)  
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DRUG N  PERIOD 
STUDY 
PARAMETERS WEIGHT MAIN FINDINGS REF 
Olanzapine 438 52w Retrospective 
(1st yr of 
treatment) 
40% > 7% increase 8% developed new onset diabetes (Farwell et al. 
2004)  
Risperidone 482  Retrospective 
(1st yr of 
treatment) 
37% > 7% increase 3.5% developed new onset diabetes  
       Olanzapine 54    ↑Triglycerides ↑Cholesterol (Perez-Iglesias et 
al. 2009) 
Risperidone 58 52w Drug-naive 
patients 
10.5 kg mean gain  ↑Insulin   
Haloperidol 52      
       
Olanzapine 43  Drug naive, first 7.5 kg mean gain ↑Cholesterol   ↑Triglycerides (Perez-Iglesias et 
al. 2007)  
Risperidone 44 12w episode 
patients 
5.6 kg mean gain ↑Cholesterol  
Haloperidol 41   3.8 kg mean gain ↑Cholesterol  
       
Olanzapine 54  Drug naive, first 7.16 kg mean gain weight gain rapid onset and the plateaued (Perez-Iglesias et 
al. 2008) 
Risperidone 58 52w episode 
patients 
5.85 kg mean gain steady weight gain   
Haloperidol 52   4.28 kg mean gain very gradual weight gain  
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DRUG N  PERIOD 
STUDY 
PARAMETERS WEIGHT MAIN FINDINGS REF 
Olanzapine 228   4.6 kg mean gain 45.7% >7% increase (Bobes et al. 
2003b) 
Risperidone 232 App. 52w Retrospective 3.1 kg mean gain 30.6%>7% increase   
Haloperidol 130  outpatient 
study 
2.9 kg mean gain 22.4%>7% increase (Bobes et al. 
2003b) 
Quetiapine 43   no significant gain 0%>7% increase  
       
Olanzapine 30 12w newly 
diagnosed 
 ↑body weight and 
BMI 
↑Blood sugar (Ingole et al. 
2009)  
Risperidone 30  Schizophrenia 
pts. 
 ↑body weight and 
BMI 
  
Olanzapine 7 1w Healthy, normal 
weight men 
 blunted insulin effects on glucose disposal; 
FFA reduced 
(Vidarsdottir et 
al. 2010)  
       
Olanzapine 146  open-label 4.6 kg mean gain ↑glucose↑insulin ↓insulin sensitivity ↑T.G (Newcomer et al. 
2009)  
Risperidone 134 24w randomized trial 3.6 kg mean gain ↑glucose ↓insulin sensitivity  
Quetiapine 115   3.7 kg mean gain   
       
Olanzapine 24  non-diabetic  Waist circumference and BMI predicted 
presence of insulin resistance 
(Haupt et al. 
2007) 
Risperidone 16 > 12w  patients N/A   
Ziprasidone 11      
       
Olanzapine 23 21w treatment 
comparison 
↑BMI all groups ↑prolactin ↑insulin resistance↓insulin 
sensitivity 
(Smith et al. 
2009)  
Risperidone 23    ↓prolactin   
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DRUG N  PERIOD 
STUDY 
PARAMETERS WEIGHT MAIN FINDINGS REF 
Olanzapine 12 taking 
medication 
non-obese 
patients 
N/A ↑insulin resistance ↓glucose effectiveness (Henderson et al. 
2005)  
Clozapine 12    ↑insulin resistance ↓glucose effectiveness  
Risperidone 12    no significant changes  
       
Olanzapine 8 104w  non-obese 
patients 
 ↑insulin resistance↓glucose effectiveness 
↑basal glucose 
(Henderson et al. 
2006) 
Quetiapine 7    no change vs. Control  
       
Olanzapine 31 24w Randomized ↑ weight ↑ adiposity @6w & 24w ↑visceral adiposity (Ader et al. 2008)  
Risperidone 28  prospective 
study 
↑ weight ↑adiposity @ 24w ↑visceral adiposity  
       
Olanzapine 9 12w Drug naive 
or<7w 
treatment 
4.7 kg mean gain 
(↑ 7.3%) 
↑waist:hip ratio  ↑%body fat  ↑fasting 
insulin  ↑C-peptide ↑fasting triglyverides. 
No changes found in leptin/prolactin or HDL 
(Graham et al. 
2005) 
       
Olanzapine 7 3d Healthy men & 
women 
 ↑fasting plasma ↑triglycerides (Albaugh et al. 
2011b) 
       
Quetapine 17 8w Drug naïve 
patients 
11.8% > 7% increase ↑insulin resistance ands secretion (Chen et al. 2011) 
       
Risperidone 30 28d Healthy men 50% > 7% increase 
Avg. 4.23 kg 
Weight gain attenuated by a glucocorticoid 
receptor antagonist 
(Gross et al. 
2010) 
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DRUG N  PERIOD 
STUDY 
PARAMETERS WEIGHT MAIN FINDINGS REF 
Olanzapine 22 28d Healthy men Avg ↑ 3.2 kg ↑ waist circumference (Gross et al. 
2009) 
       
Olanzapine 59 12w Drug-free pts Significant ↑ ↓ adiponectin ↑prevalence of MetS (Wampers et al. 
2012) 
Risperidone 54 12w  Significant ↑ ↑adiponectin  
       
Olanzapine 30 16w Newly 
diagnosed 
patients 
Significant ↑ BMI ↑fasting glucose ↑cholesterol 
↑triglycerides 
(Fernandez-Egea 
et al. 2011) 
 
Table 1.4 Clinical studies investigating the metabolic effects of antipsychotics. ↑; significant increase unless otherwise stated, MetS; 
metabolic syndrome, BMI; body mass index, HOMA; homeostasis mode assessment, FFA; free fatty acids, HHL; high density lipoprotein
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DRUG DOSE SPECIES/
STRAIN 
Sex N Duration Weight Adiposity Lipid 
Profile 
Insulin Glucose OTHER REF 
Olanzapine 3mg/kg Rat/ 
Sprague-
Dawley 
M 8 Acute                  
- 
              -                 - ↓Production 
(To glucose 
Challenge) 
↑H.G.P 
↓Utilisation 
↓G.I.R 
↓C-Pepitide 
Levels 
(Chintoh 
et al. 
2009b) 
Clozapine 3mg/kg Rat/ 
Sprague-
Dawley 
M 8 Acute                  
- 
              -                - ↓Production 
(To glucose 
Challenge) 
↑H.G.P 
↓Utilisation 
↓G.I.R 
↓C-Pepitide 
Levels 
 
             
Clozapine 25/50 
mg/kg 
Rat/ 
Sprague 
Dawley 
F/
M 
6 Acute                 -              - ↑TG 
↑Phospho
lipids 
  ↑Cholesterol (Ferno et 
al. 2009) 
             
Olanzapine 2/7.5 
mg/kg 
Rat/ 
Sprague 
Dawley 
F  Chronic 
28d 
non-
significan
t ↑ 
↑Visc 
Fat 
              -                    - ↑H.G.P 
↓Utilisation 
↓Locomotor   
Activity 
(Chintoh 
et al. 
2008b) 
    20         
Olanzapine 1.75 
mg/kg 
Rat/Sprag
ue-
Dawley 
F 10 Chronic 
28d 
Avg ↑ 
3kg 
day 4 on 
↑Visc 
Fat 
              -                    - Hyperglycemia ↑Cholesterol 
↑Food Intake 
(Lykkegaa
rd et al. 
2008) 
             
Olanzapine 4-12 
mg/kg  
Rat/ 
Sprague-
Dawley 
M 10 Chronic 
35d 
no 
change 
↑ % fat 
from 
week 1 
 ↓ Insulin 
Sensitivity 
↑Plasma 
Levels 
↓ Leptin 
(acutely) 
(Albaugh 
et al. 
2010) 
             
Olanzapine 2 mg/kg Rat/Hood
ed Lister 
F 10 Chronic 
28d 
Initial ↑ 
overall ↓ 
no 
change  
              -                         -                -  (Fell et al. 
2008) 
             
Clozapine 4 mg/ 
kg 
Rat/ 
Wistar 
F 16 Chronic 
21d 
no 
change  
↑Visc 
Fat 
↑Adipone
-ctin 
 
 
no change  no change   (Cooper 
et al. 
2008a) 
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DRUG DOSE SPECIES/
STRAIN 
Sex N Duration Weight Adiposity Lipid 
Profile 
Insulin Glucose OTHER REF 
Clozapine 7.5 mg/ 
kg 
Rat/ 
Sprague-
Dawley 
F 8 Sub-
Chronic 
14d 
non-
significan
t ↑ 
 ↑Triglycer
ides 
↑Serum Levels ↑Serum Levels ↑Leptin Levels (Tulipano 
et al. 
2007) 
Olanzapine 1/2 
mg/kg 
Rat/Hans
-Wistar  
M 14 Chronic 
20d 
↓overall ↑VisC 
Fat 
↑Adipon
ectin 
                      -               - ↑Prolactin 
↓Testosterone 
(Cooper 
et al. 
2007) 
             
Olanzapine 1/2 
mg/kg 
Rat/Hans
-Wistar  
F 6 Chronic 
20d 
↑ ↑renal 
fat  
 ↑Plasma Levels no change 
found 
↑Prolactin (Cooper 
et al. 
2005) 
             
Olanzapine 3.2 
mg/kg 
Rat/Han-
Wistar 
F 6 Acute                -               -  Resistance 
Indicated 
↑H.G.P 
↓G.I.R 
 (Housekn
echt et al. 
2007) 
             
Risperidon
e 
0.4 
mg/kg 
Rat/Sprag
ue-
Dawley 
M 12 Chronic 
28d 
no 
change  
no 
change  
                - non-significant ↑ no change   ↑Glucagon (Lin et al. 
2006) 
             
Olanzapine 1 mg/kg Rat/Sprag
ue-
Dawley 
M 10 Chronic 
42d 
↑              - ↑TG 
↑HDL 
no change  no change  ↑Leptin Levels (Minet-
Ringuet et 
al. 2006) 
             
Olanzapine 4-20 
mg/kg 
Rat/Sprag
ue-
Dawley 
F/
M 
10 Chronic 
33d 
↑(F 
Only) 
↑ 
Paramet
rial Fat 
              - ↑Plasma Levels 
↓Insulin Sensitvity 
↑Plasma 
Levels 
 (Albaugh 
et al. 
2006) 
            
Olanzapine 2 mg/kg Rat/Sprag
ue-Dawley 
M 6 Chronic 
46d 
non-sig. 
↑ 
no 
change 
             - no change  ↑Fasting 
Levels 
↑Meal 
Frequency 
(Victorian
o et al. 
2009) 
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DRUG DOSE SPECIES/
STRAIN 
Sex N Duration Weight Adiposity Lipid 
Profile 
Insulin Glucose OTHER REF 
Olanzapine 2 
mg/kg 
Rat/Spragu
e-Dawley 
F 11 Chronic 
56d 
↑10% vs 
controls 
↑Visceral Fat    (Raskind et al. 
2007) 
            
Olanzapine 2 
mg/kg 
Rat/Hoode
d-Lister 
F 10 Chronic 
21d 
↑ from 
day 1 
non-sig. 
↑ 
no 
change 
  -  (Fell et al. 
2007) 
            
Olanzapine 1 
mg/kg 
Rat/Spragu
e-Dawley 
F 8 Sub-
Chronic 
↑                 -                    
- 
   -  (Davoodi et 
al. 2009) 
            
Olanzapine 2 
mg/kg 
Rat/Spragu
e-Dawley 
M 6 Chronic 
42d 
↑ ↑Subcutaneous 
fat 
                   
- 
     -  (Minet-Ringuet 
et al. 2006) 
                 
Olanzapine 6/12 
mg/kg 
Mice/c57B
L/6 
F 12 Chronic
28d 
  ↑ ↑     (Cope et al. 
2005) 
             
Olanzapine 3 
mg/kg 
Mice CD-1 F 10 Chronic 
36d 
    ↑ d32 on ↑TG  ↑Serum Levels ↑Serum 
Levels 
 (Coccurello 
et al. 2006) 
             
Olanzapine 3 
mg/kg 
Mice/CD-1 F 10 Chronic 
50d 
↑ from d10 
on 
↑ 
uterine 
fat 
↑Triglycerides 
↑NEFA 
Hyper-
insulinemia 
↑Serum 
Levels 
↑Cholesterol 
nocturnal 
hypomotility 
(Coccurello 
et al. 2008) 
             
Olanzapine 2 
mg/kg 
Rat/Hanov
er-Wistar 
F 8 Sub-
chronic 
↑d4 on ↑    ↑energy 
expenditure 
(Liebig et 
al. 2010) 
Olanzapine 0.25-2 
mg/kg 
Rat/Spragu
e-Dawley 
F 12 Sub-
chronic 
14d 
↑d4 on ↑ all  
deposits 
 ↓fasting 
plasma levels 
 ↑ghrelin 
↑CCK 
(Weston-
Green et 
al. 2011a) 
Table 1.5 Preclinical studies of antipsychotics’ metabolic effects. ↑; significant increase unless otherwise stated, HGP; hepatic glucose 
production, GIR; glucose infusion rate, SREBP; sterol regulatory-binding protein, CCK; cholecystokinin; TG, triglycerides 
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1.7 Pharmacology of atypical antipsychotics: metabolic side effects 
The major receptors that are targeted by AAPD are not only dopamine but also 5-HT, 
histamine, adrenergic and muscarinic receptor subtypes (Table 1.5). Centrally, 
antagonism of these receptors induces alterations in eating behavior, leading to increased 
body weight as discussed above.  
DRUG 
Association with 
weight gain/MetS 
Receptor Affinity 
 
  D2 5-HT1A 5-HT2B 5-HT2C H1 M3 α1 α2 
Olanzapine High M N H M H M M L 
Clozapine High L N H M H M H L 
Risperidone Moderate H N H M N N H M 
Quetiapine Moderate L N H M M L H N 
Ziprasidone Low H H H H N N M N 
Aripiprazole Low H M H L L L M L 
Table 1.6 Major receptor affinities of certain atypical antisychotics N=none, L=low, 
M=moderate,H=high (adapted from Miyamoto et al 2005 and Horacek et al,2006)  
1.7.1 Dopamine receptors  
As already discussed in section 1.3.1, monoamines, including dopamine, play an 
important role in central energy regulation. However, as outlined, typical antipsychotics 
are noted for their higher potency at dopamine receptors, and yet it is atypical drugs 
which are associated with metabolic effects to a much greater degree. Hence, this 
undermines any dopamine-led hypothesis of AAPD induced weight gain. However, that is 
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not to say that dopamine circuitry is not still an import factor in AAPD-induced metabolic 
side-effects.  
Evidence suggests that atypical compounds such as olanzapine may have discrete effects 
on the dopamine pathways. This selectivity could perceivably play a role in the side effect 
profile of these drugs and offer a potential mechanism of antipsychotic-induced increases 
in feeding and weight gain. This is due to the fact that dopamine transmission in the 
mesocorticolimbic region is crucial for motivation or “wanting” rewards (Wise 2004; Toh 
and Williams 2011). Thus, it has been postulated that increased burst firing of 
dopaminergic neurons in the nucleus accumbens and prefrontal cortex may promote 
feeding, and that low dopamine levels in the brain may therefore promote excessive 
behaviours such as eating to restore dopamine levels (Palmiter 2007). This hypothesis is 
supported by a study showing that obesity-prone rats have reduced extracellular 
midbrain dopamine levels as well as reduced dopamine release following electrical 
stimulation in the nucleus accumbens, prefrontal cortex and dorsal striatum (Geiger et al. 
2008).  
Atypical antipsychotics such as olanzapine and clozapine could therefore, by normalising 
dopamine transmission in mesocorticolimbic areas, invoke increased motivation towards 
eating, ultimately leading to weight gain. In line with this theory, a recent study 
investigating the eating behaviours of 153 schizophrenic patients found that those taking 
atypical antipsychotics were more responsive to external eating cues than those treated 
with typical antipsychotics (Sentissi et al. 2009). This is intriguing as reaction to contextual 
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cues in animal feeding paradigms has been particularly associated with the mesolimbic 
dopamine pathway (Narayanan et al. 2010).  
It has also been suggested recently that chronic blockade of D2 receptor in β cells of the 
pancreas may contribute to insufficient compensation by the pancreas in the setting of 
hyperglycemia (Hahn et al. 2012) 
1.7.2 Serotonin Receptors  
Several AAPDs, including clozapine and olanzapine, are high affinity antagonists for 
numerous 5-HTreceptors (Table 1.5). Thus, antagonism of 5-HT neurotransmission by 
these drugs could conceivably disrupt normal regulation of appetite, food preference and 
energy balance. However, the association between 5-HT2c and AAPD induced weight gain 
is not cut and dry and is challenged by the fact that ziprasidone, also an AAPD with high 
affinity for 5-HT2c receptors, is not associated with increased weight gain (Citrome 2009). 
It has been demonstrated however, that ziprasidone also acts at the 5-HT1A receptor as a 
partial agonist (Ohlsen and Pilowsky 2005) which may confer protection against weight 
gain (Kirk et al. 2004).  
A number of AAPDs have a higher affinity for 5-HT2A than for D2 receptors (which Meltzer 
and colleagues have proposed as a criteria for atypicality) (Meltzer et al. 1989). This may 
indirectly play a role in increased feeding and weight gain. This is due to the fact that 5-
HT2A antagonism in the prefrontal cortex results in increased dopamine output (Horacek 
et al. 2006) and may also lead to increased motivation and reward associated with eating, 
as mentioned above.    
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Pharmacogenetic evidence for the role of 5-HTreceptors in AAPD-induced weight 
gain/metabolic disturbance is beginning to emerge (Lencz and Malhotra 2009).  
Three single nucleotide polymorphisms (SNP) in the promoter region of the 5-HT2c 
receptor gene have been identified (Yuan et al. 2000) with one of the polymorphisms 
being associated with AAPD induced weight gain in drug-naive patients (Reynolds et al. 
2002). However, the validity of these findings has been challenged by some on the 
grounds of lack of subject variance and lack of complete explanation for weight gain 
(Martyn 2005). A further polymorphism in the 5-HT2C receptor gene has been identified, 
as patients with the 5-HTR2c-759 C-allele showed a significantly higher risk of weight gain 
(Laika et al. 2010).  
Further genetic components for AAPD-induced weight gain have been reported including 
variants of alleles for the 5-HT2A receptor as well as for the adrenergic β-3 receptor and 
these genetic variants seem to have an additive effect (Basson et al. 2001a).  
Hence, serotonin antagonism, independent of and in conjunction with dopamine 
antagonism, may cause increased feeding/altered feeding patterns in patients receiving 
atypical antipsychotics, contributing to increased body weight.  
1.7.3 Histamine Receptors  
Some AAPDs, especially clozapine and olanzapine, exhibit strong antagonistic effects at 
the H1 receptor supporting the view of this receptor as a key player in AAPD metabolic 
side effects. Indeed, two meta-analyses have implicated the histamine H1 receptor as the 
primary receptor in AAPD-induced obesity (Kroeze et al. 2003; Matsui-Sakata et al. 2005).  
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As well as effects on appetite antagonism of H1 receptors by AAPDs may also prevent 
histamine driven lipolysis, leading to a disproportionate accumulation of triglycerides and 
increased adipose mass as seen in AAPD treated patients (Tsuda et al. 2002; Masaki et al. 
2004; Deng et al. 2010). 
Further evidence for a histamine-driven mechanism in AAPD adverse side effects is the 
reduction in hypothalamic histamine H1 receptor mRNA expression seen in olanzapine 
treated rats (Han et al. 2008).  
There is also an implication that the histamine H3 receptor contributes to AAPD side 
effects as antagonism of this pre-synaptic, inhibitory auto-receptor could slow the 
production and secretion of histamine, therefore compounding the enhancement on 
feeding behavior and energy storage of H1 antagonism (Deng et al. 2010). 
1.7.4 Muscarinic Receptors  
Muscarinic acetylcholine receptors comprise five subtypes, M1-M5 with M1, M3 and M5 
being Gq/11 protein coupled receptors. M2 and M4 are Gi/o protein coupled receptors 
which when activated inhibit adenylatecyclase decreasing cAMP. In the CNS, the M1 is the 
most abundant receptor expressed primarily in the forebrain where it plays an important 
role in cognition (Bymaster and Felder 2002).  
Hence, central muscarinic effects of AAPDs seems to related more to their effects on 
cognitive symptoms of schizophrenia rather than weight gain and this is supported by the 
work of Matsui-Sakata and colleagues who found that muscarinic receptor affinity was 
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correlated with H1 receptor binding such that H1 was the key receptor involved in weight 
gain in this study (Matsui-Sakata et al. 2005).  
However, in the periphery, M3 receptors are involved in the regulation of insulin release 
from the pancreas and glucose metabolism (Gautam et al. 2006) making them a potential 
target for direct metabolic effects of certain AAPDs.  
Indeed, it has been suggested that M3 affinity may be the best predictor of antipsychotic-
induced diabetes (Silvestre and Prous 2005). This is supported by the fact olanzapine and 
clozapine have the highest affinities for the M3 receptor (Roth et al. 2004). 
As already mentioned, the M2 and M3 receptors have been implicated in the direct 
metabolic effects of AAPDs. Antagonism of these sites on pancreatic β-cells may diminish 
insulin secretion contributing to disrupted glucose homeostasis ultimately leading to 
diabetes mellitus (Johnson et al. 2005; Stahl et al. 2009). 
1.7.5 Adrenergic Receptors  
A recent study showed that the α2 receptor antagonist, yohimbine, prevented clozapine-
induced hyperglycemia (Savoy et al. 2010). This suggests that AAPD adrenocepter 
antagonism could potentiate activation of the sympathetic nervous system disrupting 
glucose handling in the periphery. However, the contribution of α1/α2 receptors to AAPD 
metabolic effects is likely to be a minor one as evidence of a prominent role for 
adrenoceptors in AAPD-induced weight gain or metabolic disturbances is lacking. The 
effect of AAPD on adrenoceptors is more strongly implicated in sexual dysfunction side 
effects of antipsychotics such as priapism (Andersohn et al. 2010). 
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The disruption of these systems may also contribute to metabolic disturbances 
independent of weight changes, in particular altered glucose homeostasis by impacting 
on sympathetic outflow.  
This is due to the fact that sphlanic sympathetic nerves directly innervate the liver and 
adipose tissue where they impact on glucose and free-fatty acid metabolism by increasing 
gluconeogenesis and increasing lipolysis respectively (Nonogaki 2000).  
In line with this, an acute intravenous administration of olanzapine to rats induced 
hepatic insulin resistance and increased glucose production suggesting a direct central 
mechanism of AAPD induced effects on glucose regulation (Martins et al. 2010).  
1.8 Predisposition to antipsychotic side effects 
A number of potential factors have been proposed as predisposing a patient to adverse 
side affects of antipsychotics including sex, baseline weight and therapeutic response.  
That weight gain is a predictor of drug efficacy (or vice-versa), has been suggested by a 
number of studies with leptin implicated as a mechanistic link (Meltzer et al. 2003b; 
Venkatasubramanian et al. 2010). However, such a correlation has not been observed in a 
number of studies (Citrome et al. 2009b; Hermes et al. 2011). Thus, it remains to be 
determined but it seems a correlation between weight gain and therapeutic outcome is at 
best weak. 
Another factor commonly suggested as predictive of weight gain is a low baseline weight 
or BMI. This correlation has been found in some settings (Basson et al. 2001a; Gebhardt 
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et al. 2009; Verma et al. 2009). A number of studies, however, have not found any such 
connection and the validity of such correlations has subsequently been challenged 
(Allison et al. 2009).  
Another reported difference in the epidemiology of antipsychotic side effects is sex. As 
with other variables, no clear cut distinction exists here. A review by Aichhorn et al, found 
the incidence of weight gain and the metabolic syndrome to be more frequent in females 
and that this correlated to higher drug plasma levels in women (Aichhorn et al. 2007). 
This strongly indicates a sex difference, although another study of olanzapine found that 
males had a higher frequency of weight gain (Basson et al. 2001a). While a number of 
clinical studies have found sex differences in the propensity to incur weight gain when 
taking antipsychotics, these have so far not been conclusive (Haack et al. 2009).  
1.9. Schizophrenia and obesity  
It is important to note that schizophrenia has been associated with obesity related 
abnormalities since before even the first antipsychotic was used.  
Patients with schizophrenia have a higher prevalence of obesity and diabetes than the 
general public (Brown 1997; Bobes 2007). The reasons for this are multifactorial but stem 
mainly from socioeconomic reasons. Patients with schizophrenia tend to live a sedentary 
lifestyle, have poor diets and are more likely to smoke (Pack 2009). 
Furthermore, schizophrenia itself is associated with a proinflammatory phenotype as well 
dysfunction in stress responses leading to high levels of cortisol (Thakore et al. 2002; Fan 
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et al. 2007; Richard and Brahm 2012). Hence, it is likely disease pathogenesis also 
contributes to poor metabolic health of patients with schizophrenia (Leonard et al. 2012). 
It is therefore important that epidemiological data assessing the metabolic side effects of 
AAPDs is carefully scrutinized in order to ensure separation of drug from non-drug related 
events.  
1.10 Animal models of metabolic side effects of antipsychotics 
In order to investigate the mechanisms behind antipsychotic induced weight gain, rodents 
have typically been used to reproduce the clinically observed side effects. However, a 
number of confounding factors have been realised that means the task of developing 
reliable and valid animal models for antipsychotic induced weight gain has not been easy 
in this area of research. 
Firstly, mice appear to be largely resistant to the metabolic effects of these drugs and a 
number of studies have failed in producing significant weight gain in treated mice 
following a number of different protocols (Arjona et al. 2004). However, some groups 
have reported weight gain in mice and other aspects of the metabolic syndrome following 
antipsychotic treatment (Cheng et al. 2005; Coccurello et al. 2008). However these 
required extended periods of treatment and in the case of clozapine actually caused 
weight loss, neither of which are the case in clinical practice. 
Rats have proven much more reliable than mice for incurring weight gain in response to 
antipsychotic treatment. However, this is the case only for female rats as demonstrated in 
several reports (Kinon et al. 2001; Arjona et al. 2004; Fell et al. 2007; Cooper et al. 2008a; 
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Fell et al. 2008; Kirk et al. 2009) (see table 1.4). The reason for this discrepancy remains 
unknown, however the steep growth curve seen in male rats may be one reason why the 
effects of these drugs are not apparent in male rats.  
In humans, a sex-dependent effect of these drugs in causing weight gain is debatable, 
with some reports suggesting it is more likely to occur in females (Aichhorn et al. 2007) 
and other suggesting it is more likely in males (Kinon et al. 2001).  
However, data on patients is typically hard to interpret due to differences in age, lifestyle 
and treatment, and a recent meta-analysis reported that there is no conclusive 
correlation between sex and antipsychotic side effects (Haack et al. 2009). 
Animal models of any drug effect present challenges as is inevitable when dealing with a 
different species. Antipsychotics are no different, and overcoming these challenges is key 
to developing valid animal paradigms of antipsychotic side effects.  
Overall, though not ideal, rodent models of antipsychotic-induced weight gain and 
metabolic syndrome do reflect the situation observed in human patients (Weston-Green 
et al. 2011a; Weston-Green et al. 2011b). Therefore, these models are useful in the 
continued effort to understand the cause of these side effects and to investigate ways to 
prevent them (Boyda et al. 2010; Weston-Green et al. 2011b). Going forward, efforts 
should be made to produce models that reflect as close as possible the clinical situation 
while still producing the relevant side effects. 
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1.11 Gut microbiota 
The gut microbiota comprises the approximate 100 trillion bacteria that reside within the 
gastrointestinal tract (Lupp and Finlay 2005). Thus the human gut likely represents the 
most densely populated ecosystem on earth (Molloy 2006). These microorganisms consist 
mainly of bacteria, though archaea, fungi and viruses are also present (Eckburg et al. 
2005). The microbiota has co-evolved with their hosts over the millennia to occupy this 
environmental niche in a mutually beneficial manner (Ley et al. 2008a).  
The role of bacteria in human and health and disease has been noted for many decades 
(Gibbons and Houte 1975).  
However, more recently, there has been a bloom in interest in the microbiota as evidence 
for a role of the microbiota in numerous physiological and pathophysiological processes 
mounts. This interest culminated in the establishment of the human microbiome project 
(HMP), a 5-year project which began its work in 2007 (Peterson et al. 2009).  
The HMP is an international initiative of the NIH common fund, set-up to characterise the 
microbiota of individuals across a range of anatomical sites and to determine if specific 
changes in the microbiota are associated with disease states (Peterson et al. 2009). To 
date, the HMP has resulted in several new and enlightening findings linking the 
microbiota to diseases such as colon cancer, cystic fibrosis and Crohn’s disease (Hu et al. 
2011; Filkins et al. 2012; Zhang et al. 2012). Furthermore, the HMP has generated a freely 
available reference database of over 1600 bacterial genomes, a number set to reach 3000 
before completion of the HMP.  
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1.11.1 Establishment of the gut microbiota 
The foetus is sterile until birth when colonisation begins. As the progeny moves through 
the birthing canal, initial colonisation occurs by bacteria originating primarily from the 
mother’s vaginal and then faecal microbiota (Dominguez-Bello et al. 2010). The 
microbiota continues to establish itself during early post-natal years and by 
approximately two years of age a relatively stable microbiota resembling that of an adult 
is established (Palmer et al. 2007). However, differences between infants, adolescents 
and adults can still observed (Hopkins et al. 2001; Agans et al. 2011).  
In addition to age, several other factors apply selective pressures on the development of 
the gut microbiota (Rawls et al. 2006). These include a number of host factors such as the 
presence of specific glycolipids on the epithelium or glycans in the mucus which allow 
specific bacteria to adhere (Backhed 2011).  
Similarly, diet has a considerable impact on shaping the gut flora (Tannock and Savage 
1974; Hildebrandt et al. 2009). Host immunity also plays a role in determining ones 
microbiota by killing specific bacterial groups as evidenced by the altered microbial profile 
observed in mice lacking toll-like receptors (TLRs) or nucleotide–binding oliogomerisation 
domains (NODs), both of which acts as microbial signatures (Petnicki-Ocwieja et al. 2009; 
Vijay-Kumar et al. 2010).  
1.11.2 Microbiota taxonomy and composition 
In taxonomy, bacteria represent one of the three domains of life (along with Eukaryotes 
and Archea). Bacteria subsequently follow the same ranks as these other domains 
(though the rank of kingdom is generally disused). Thus, bacteria are ranked; Phylum-
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Class-Order-Family-Genus. Additional classification of species and strain follow. Phylum 
represents the main evolutionary lineage of the bacteria and at present there are 29 
phyla, and 23 candidate-phyla characterised. No single classification exists for subsequent 
assignment, though Bergey’s manual of systematic bacteriology is widely considered the 
authorative guide (Anonymous 2001). Although no definitive classification system exists, 
the nomenclature of bacteria is regulated under the International Code of Nomenclature 
of Bacteria (Lapage 1992) 
The human microbiota is known to comprise circa 35 000 bacterial species, with an 
individual typically harbouring 500-1000 of these species. In general, 150-200 species 
dominate an individual’s microbiota, with the remainder consisting of less common 
species (Eckburg et al. 2005).  
Despite this variety at species level, at the phylum level, the adult microbiota is highly 
conserved across mammals, highlighting the ancient evolutionary pressures and 
important functional role played by this microbial organ (Backhed et al. 2005a). Indeed, 
approximately 90% of the gut microbiota is made up of the Gram negative Bacteriodetes 
and the Gram positive Firmicutes (Table 1.7). 
Phylum % Representation Major Genera 
Firmicutes ~60-65 Ruminococcus, Clostridium, Lactobacillus, 
Enterocccus, Peptostreptococcus, 
Bacteriodetes ~30-35 Bacteriodes, Prevotellae 
Actinobacteria ~5-15 Bifidobacteria 
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Proteobacteria ~1-5 Escherichia, Desulfovibrio, Heliocobacter 
Cyanobacteria/ 
Verrucomicrobia/ 
Fusobacteria) 
<1 N/A 
Table 1.7 Bacterial phyla and genera present in the gut microbiota. The main phyla 
found in the mammalian gut microbiota, their proportional representation and the main 
associated genera. Adapted from (DiBaise et al. 2008; Sekirov et al. 2010; Cho and Blaser 
2012). 
The concentration and content of microbiota varies widely throughout the 
gastrointestinal tract based on the differing environmental conditions with strict 
anaerobes in the vast majority followed by facultative anaerobes and aerobes (Gordon 
and Dubos 1970; Sekirov et al. 2010) (Fig.1.7).  
 
Fig. 1.7 Distribution of bacteria in the gastrointestinal tract. Concentration of bacteria 
increases along the gastrointestinal tract (adapted from (DiBaise et al. 2008). 
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1.11.3 Gut microbiota and energy regulation 
A number of elegant studies have highlighted the extensive role the gut flora can exert on 
host metabolism and energy regulation. In particular, animal models such as germ-free 
mice and genetically obese (ob/ob) mice have been utilised to demonstrate the various 
important effects of the microbiota on body weight.  
Germ-free, or axenic, animals lack any microbiota as they are born and raised under 
sterile conditions. Germ-free mice have up to 40% less body fat than conventionally 
raised (full compliment of microbiota) mice despite increased food intake (Backhed et al. 
2004).  
Moreover, colonisation of germ-free mice with the microbiota from ob/ob mice resulted 
in greater weight gain compared to mice colonised with microbiota from lean mice 
(Turnbaugh et al. 2006).  
In perhaps the most direct and best understood way, the gut flora contributes to energy 
balance through the fermentation of otherwise indigestible complex polysaccharides 
(fibres) to simpler, digestible monosaccharides, typically short chained fatty acids (scfa) 
(Hooper et al. 2002; Macfarlane and Macfarlane 2003).  
It is estimated that approximately 10% of our daily caloric intake is produced in this 
fashion (Flint et al. 2008). The main scfa produced are butyrate, propionate and acetate. 
These may be used locally or absorbed into the hepatic circulation and subsequently 
delivered to the liver where they stimulate gluconeogenesis and lipogenesis (Jenkins et al. 
1997). This direct symbiosis whereby the gut microbiota are provided with a rich energy 
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source and subsequently provide the host with energy substrates likely represents the 
evolutionary underpinning of microbial-host symbiosis. 
The microbiota can hence affect a number of hepatic gene pathways intimately involved 
in lipogenesis and energy storage. These changes appear to result from increased delivery 
of scfa as well from other indirect mechanisms. 
Sterol-regulatory element binding protein 1c (SREBP-1c) and carbohydrate regulatory 
element binding protein (ChREBP) are two master transcription factors expressed in the 
liver as well as other tissues including adipose tissue (Uyeda et al. 2002; Ferre and 
Foufelle 2007).  
These genes control the expression of a number of enzymes in response to nutrient 
signals that subsequently drive metabolism in one direction (usage) or another (storage) 
by promoting or inhibiting both gluconeogenesis and lipogenesis (see section 1.3). 
Investigations into the impact of the microbiota on body weight have shown that the 
microbiota can influence both SREBP-1c and ChREBP as well as their downstream targets, 
fatty acid synthase (FAS) and acetyl-CoA carboxylase (AAC) (Backhed et al. 2007). As 
already discussed, these enzymes are crucial for the regulation of lipogenesis and the 
resultant release of triglycerides into circulation that ultimately are stored in adipocytes 
contributing to fat deposition and subsequent weight gain.  
1.11.3.1 Microbiota and adiposity 
As mentioned, germ-free mice have less body fat than their conventional littermates and 
are resistant to diet-induced obesity (Backhed et al. 2004). The mechanisms underlying 
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the gut flora’s influence on adiposity and thus weight gain involve in part adenosine 
monophosphate activated kinase (AMPK).  
AMPK is highly conserved, highly sensitive cellular fuel gauge, activated when the ratio of 
ATP to AMP is reduced (such as during exercise) (Hardie and Sakamoto 2006). AMPK 
activation leads to glucose uptake, lipid metabolism and an increase in the availability of 
energy substrates to the cell while at the same time shutting off anabolic pathways (Kahn 
et al. 2005; Steinberg and Kemp 2009).  
The microbiota was found to suppress AMPK phosphorylation which is required for 
AMPK-activation.  
Germ-free mice on the other hand had increased levels of phosphorylated AMPK and 
were subsequently protected from diet-induced obesity (Backhed et al. 2007). 
Furthermore, the microbiota can also influence the intestinal expression of fasting-
induced adipose factor (Fiaf) (Backhed et al. 2007). Fiaf inhibits lipoprotein lipase (LPL) 
which is required for the hydrolysis of triglycerides allowing for their storage in 
adipocytes (Bensadoun and Kompiang 1979; Preiss-Landl et al. 2002). Germ free mice 
were found to have increased levels of Fiaf and moreover germ-free Fiaf-/- mice were no 
longer protected from diet-induced obesity (Backhed et al. 2007). 
Thus, the microflora can regulate fat storage and as such influence body weight (Fig. 1.8). 
As already discussed, the adipose tissue is now recognised as an endocrine organ that can 
release a plethora of adipokines and cytokines to influence both local and systemic 
inflammation and metabolism. Thus, given the microbiota’s established links to adiposity, 
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it is of little surprise that the gut flora has been found to influence several other aspects 
of metabolic dysfunction such as inflammation and insulin resistance, as discussed below. 
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Fig.1.8 Mechanisms linking the microbiota and metabolism Microbe-produced short 
chain fatty acids (scfa) are ligands for the G-protein receptor (GPR) 41 which can stimulate 
the release of hormones peptide-YY (PYY) and glucagon-like peptide (GLP) -1. Microbial 
suppression of Fiaf (fasting-induced adipose factor) expression in the gut increases 
lipoprotein lipase (LPL)-mediated triglyceride storage in adipose tissue as well as reduces 
fatty acid oxidation in skeletal muscle by a yet unidentified mechanism. Furthermore, 
lipopolysaccharide (LPS) derived from the gut may augment adipose inflammation and 
reduce insulin sensitivity. Adapted from (Backhed 2011). 
1.11.4 Microbiota and metabolic Disease 
Several studies have identified a number of links between the gut flora and aspects of 
metabolic disease. These include both preclinical and clinical investigations. In addition to 
effects on adiposity as outlined above, studies have also found that microbiota alterations 
associated with insulin resistance and inflammation (Bienenstock and Collins 2010; Caesar 
et al. 2010; Membrez et al. 2010).  
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Thus, the microbiota’s role in the progression and development of metabolic diseases 
such as Type II diabetes mellitus has received increasing levels of attention. 
Understanding the mechanisms by which the microbiota influences these metabolic-
related processes under both normal and pathological states is an extremely difficult but 
important challenge in elucidating the full scale of the involvement of the microbiota in 
human physiology. 
1.11.4.1 Microbiota and inflammation 
Obesity is now regarded by many as a chronic low-grade inflammatory disease (Das 2001; 
Bastard et al. 2006a). Inflammation and metabolism are tightly connected and the innate 
immune system can contribute to obesity and metabolic disease (Pickup 2004; Olefsky 
and Glass 2010). The microbiota can directly contribute to metabolic inflammation 
through lipopolysaccharide (LPS) a component of the cell wall of Gram negative bacteria. 
LPS is a potently inflammatory endotoxin and may enter the circulation via uptake with 
chylomicrons or via increased intestinal permeability (Caesar et al. 2010). LPS is a ligand 
for the toll-like receptor 4 (TLR4) receptor which is expressed on macrophages and 
elsewhere. Activation of TLR4 promotes inflammation and hence contributes to insulin 
resistance.  
Increased plasma levels of LPS, coined metabolic endotoxemia, has been linked to 
metabolic disorders in both animal models and clinical studies (Cani et al. 2007a; Amar et 
al. 2008). Moreover, antibiotic treatment attenuated endotoxemia as well as insulin 
resistance in experimental models (Cani et al. 2008). 
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It is well established that the microbiota plays a critical role in intestinal inflammation 
through its effects on several cells including macrophages, CD3+ T cells and CD45+ 
leukocytes (Abt and Artis 2009; Duerkop et al. 2009). These cells have the capacity to 
release proinflammatory cytokines into enterohepatic circulation and thus can contribute 
to systemic low grade inflammation and associated metabolic effects. Indeed, a recent 
study found changes in intestinal inflammation coincided with the earliest detectable 
increases in fat mass in mice fed a high-fat diet (Ding et al. 2010).  
As mentioned, the microbiota is responsible for the production of the majority of scfa 
absorbed from the diet. In addition to the already discussed effects on metabolism, scfa 
can act as direct ligands for a number of G-protein coupled receptors (GPCRs) present on 
immune cells and thus may directly promote release of proinflammatory factors. These 
include GPR43, a chemoattractant receptor found on neutrophils (Sina et al. 2009) which 
has been shown to be regulated by the gut microbiota (Maslowski et al. 2009).  
Moreover, GPR43-/- mice were found to be resistant to resistant to diet-induced obesity 
(Bjursell et al. 2011) further highlighting the complex interaction between the microbiota, 
inflammation and metabolism. In addition, GPR41, expressed on enteroendocrine cells, is 
also modulated by short chain fatty acids (s.c.f.a.) and thus may be regulated by the gut 
microbiota linking both inflammation and adiposity (Samuel et al. 2008).  
1.11.4.2 Microbiota and insulin resistance 
Germ-free mice have reproducibly been shown to have improved glucose tolerance and 
insulin sensitivity (Backhed et al. 2004; Rabot et al. 2010).  
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Moreover, evidence suggests that the gut flora can directly impact on the development of 
insulin resistance, at least in animal models (Ding et al. 2010; Membrez et al. 2010). 
Furthermore, antibiotic treatment was shown to attenuate insulin resistance in mice fed a 
high fat diet (Cani et al. 2008). 
1.11.5 Microbiota composition and obesity 
Several studies have been focused on identifying links between the composition of the 
microflora and disease phenotype, in particular, obesity. A surge in the number of such 
studies has been facilitated by the development of sophisticated, molecular based 
techniques for analysing the flora (Fraher et al. 2012). Indeed, the number of publications 
on the gut microbiota rose from approximately 100 per annum in 1998 to over 500 per 
annum in 2009 (Sekirov et al. 2010).  
In their seminal studies, Gordon and colleagues identified an “obese microbiome” in 
mice, that promotes fat storage and weight gain, and a lean microbiome, that does not 
(Turnbaugh et al. 2008). The primary difference between these two microbial phenotypes 
was observed to be a phylum level shift in the ratio between the two dominant phyla, 
Firmicutes and Bacteriodetes (Turnbaugh et al. 2008), with an increase in the proportional 
representation of Firmicutes and a concomitant reduction in Bacteriodetes found to be 
associated with the development of obesity in recolonised mice. However, while evidence 
for the same shift was observed in diet-induced mice, it was found to be temporal and 
age-related as opposed to directly correlating to obesity (Murphy et al. 2010). 
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In humans, evidence for such a shift associated with obesity has been somewhat 
contentious. A study by Turnbaugh et al., found a similar alteration in the major phyla in 
obese versus lean twins (Turnbaugh et al. 2009). A reduction in Bacteriodetes was also 
observed in obese individuals in a study by Armougom and colleagues (Armougom et al. 
2009). Furthermore, Ley et al., observed reduced levels of Bacteriodetes in obese subjects 
and found weight loss correlated with increased levels of same (Ley et al. 2006).  
However, other studies have not observed this finding (Duncan et al. 2008) or indeed 
observed the opposite (Schwiertz et al. 2010). These discrepancies may be due to a 
number of factors including analysis method and the sequencing power of the different 
methods employed or dietary factors. It is important note however that these studies did 
indeed find alterations to the gut flora in association with obesity. These involved changes 
observed at the genera level, including reduced levels of Eubacteriumrectale (Duncan et 
al. 2008), and decreases in the proportion of Bifidobacteria (Schwiertz et al. 2010). This 
latter finding was recently supported by a study of overweight pregnant women in which 
a similar reduction in Bifidobacterium was observed (Santacruz et al. 2010).  
We are only beginning to routinely see the inclusion of in-depth microbiota sequencing in 
studies of obesity, and given the massive diversity beyond phylum level of the microbiota 
coupled with environmental linked variations means we are yet to uncover the true 
significance and reproducibility of any shift seen in specific phyla, genera or species. 
Another major issue yet to be addressed in assessing the microbiota composition in 
disease versus healthy states is establishing the causal nature of any observed 
differences.  
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Diet has long been recognised as a rapid modifier of the gut microbiota (Tannock and 
Savage 1974). In particular high-fat diets are known to affect the gut flora, thus in human 
studies of obese subjects, individuals are likely to consume a diet higher in fat than lean 
counterparts which could account for differences in the flora. This is not to say that these 
diet-induced alterations to the microbiota are not important, indeed the impact of diet on 
the gut flora represents a crucial factor in both understanding as well as targeting 
microbiota-host interactions.  
In particular, arguably the most robust finding to date in human obesity is reductions in 
the levels of Bacteriodetes species (Angelakis et al. 2012). Levels of Bateriodetes were 
found to correlate with energy intake rather than obesity (Furet et al. 2010). Intriguingly, 
the numbers of Bacteriodetes were found to dramatically decrease when obese subjects 
consumed a low-fat or low-carbohydrate diet (Ley et al. 2006). Thus, while diet may be 
responsible for observed changes in microbial populations of obese individuals, these 
diet-induced changes may still be involved in the pathogenesis of ensuing disease. This 
opens up intriguing avenues of potential therapeutic intervention using both dietary and 
microbial targeted approaches. 
In further support of a causative role of the microbiota in the pathogenesis of obesity, 
Kalliomaki et al. found that alterations in the gut flora of infants predicted their risk of 
being over weight at seven years of age (Kalliomaki et al. 2008). Moreover, it must be 
remembered than in animal models which do not have confounders such as diet, 
microbiota transplantation led to the development of obesity showing a direct link 
between the composition of the microbiota and weight gain (Turnbaugh et al. 2006). 
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As we now move in to the metagenomic era, studies have emerged investigating the 
obesogenic profile of the microbiota. As already mentioned, the microbiota possesses 
approximately 100 times the number of genes of the human genome. This massive 
genetic resource accounts for the diverse functions of the gut microbiota emphasises the 
need to focus on alterations in the genetic potential of the microbiota between obese 
and lean individuals as well differences in bacterial composition.  
Recently, attempts have been made to classify people by their microbiota profile. One 
such investigation identified three microbial profiles in faecal samples which they coined 
enterotypes (Arumugam et al. 2011). These enterotypes were identified by their 
enrichment in Bacteroides spp. (enterotype 1), Prevotella spp. (enterotype 2) and 
Ruminococcus spp. (enterotype 3). These enterotypes have been shown to be affected by 
diet, and the Bacteroides enterotype is associated with a western diet (Wu et al. 2011). 
However, direct evidence for a link between this or another enterotype and obesity is 
currently lacking (Zupancic et al. 2012). Moreover, some have questioned whether the 
model of enterotypes represents an over-simplistic model, especially given the dynamic 
nature of the gut microbiota (Jeffery et al. 2012).  
Thus, it appears that the microbiota and the host’s energy balance affect one another and 
indeed that the microbiota may act to drive the energy balance equation in either 
direction (Musso et al. 2010a). Further studies will hopefully elucidate the direct 
associations between specific bacterial populations and disease pathogenesis allowing for 
therapeutic targeting of the microbial organ (Jia et al. 2008; Burcelin et al. 2011). 
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1.11.6 Brain-gut-microbiota axis 
The brain gut axis is a bidirectional, integrative link between the CNS and the enteric 
nervous system (ENS) involving various neural, immune and endocrine mechanisms 
(Tougas 2000). This communication between the gut and the brain is involved in 
numerous physiological processes including energy regulation, abdominal pain, bone 
metabolism and nociception and hence contributes to a persons overall physiological 
state (Aziz and Thompson 1998; Blackshaw et al. 2007; Romijn et al. 2008; Mayer and 
Tillisch 2011).  
A relationship between emotional state and gut function has long been recognised 
(Cannon 1909). Stress has been implicated in a range of gastrointestinal disorders 
including functional dyspepsia, peptic ulcer disease and irritable bowel syndrome (Bhatia 
and Tandon ’05). The tangible link between gut and brain extends beyond stress, as there 
is up to 60% co-morbidity between functional gastrointestinal disorders and psychiatric 
disorders such as depression and mania (Mikocka-Walus et al. 2008). This emphasises the 
importance of understanding the link between the gastrointestinal tract and the CNS that 
is the brain-gut axis. 
The brain’s limbic system comprises the amygdala, thalamus, hypothalamus and anterior 
cingulated cortex. This complex neural circuitry receives and integrates external 
environmental and psychosocial stressors and accordingly activates physiological 
responses with the ultimate goal of ensuring survival of the individual.  
Given the intricate relationship of the intestinal microbiota and the gastrointestinal tract 
it is almost inevitable that one influences the other and vice-versa.  
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However, the role the microbiota plays within the brain-gut axis has only recently begun 
to be investigated and the mechanisms and effects of the CNS on the gut flora remain, as 
yet, mostly elusive. In turn, the possible influences of the microbiota on central systems 
i.e. the brain are now becoming the focus of much research and will no doubt become 
clearer in the near future (Cryan and O'Mahony 2011; Cryan and Dinan 2012).  
Hence, the gut microbiota is now integrated into the brain-gut axis (Fig 1.9) The 
bidirectional relationship between the gut microbiota and the brain is currently of great 
interest and while the “bottom-up” effects of the gut microbiota remain some-what 
unclear a number of works have begin to reveal the importance of this connection. 
Fig.1.9 Brain-Gut-Microbiota Axis The proposed bidirectional communication between 
the brain, the gastrointestinal system and the gut microbiota (Grenham et al. 2011) 
1.11.6.1 Microbiota and the CNS 
Initial evidence for a link between microbes and the brain comes from the long 
recognised fact that administration of oral antibiotics improves brain function in patients 
with hepatic failure who have cognitive impairments or even dementia secondary to the 
hepatic encephalitis(Cash et al. 2010).  
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Furthermore, one only has to consider syphilis for a clear example of an infectious 
bacterium resulting in serious mental impairment (Simon 1985). Thus, work has begun in 
recent years to investigate the potential impact of the gut flora on central systems.  
One area that has yielded interesting findings is studies of the microbiota regarding the 
hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a neuroendocrine system 
intimately involved in regulating the body’s response to stress as well as being involved in 
other diverse processes such as immune function and digestion (Tsigos and Chrousos 
2002).  
A number of animal studies have demonstrated an effect of stress on the composition of 
the microbiota. O’Mahony et al., showed that maternal separation in rats induced 
changes to the gut flora of the offspring and this was associated with an altered immune 
profile (O'Mahony et al. 2009).  
Intriguingly, Sudo et al. (2006), showed that germ-free mice had a hyper-responsivity to 
stress, as seen by increased adreno-corticotropin hormone (ACTH) and corticosterone, 
demonstrating an effect of microbiota on the stress response (Sudo et al. 2004). This 
response could be subsequently normalised by the commensal bacteria Bifidobacterium 
infantis but only if administered before six weeks of age, implicating the microbiota in the 
early development of the HPA axis. This group also went onto show that germ-free mice 
had lower levels of brain-derived neurotrophic factor (BDNF), noradrenaline and 
serotonin in certain brain regions which are all key modulators of neurotransmission 
within the CNS (Sudo 2006).       
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As already discussed, the gut flora is crucial for the proper development and function of 
the immune system and hence can impact on the inflammatory state of the host. 
Inflammation is rapidly becoming recognised as a central feature of numerous 
pathological states including diabetes (Wellen and Hotamisligil 2005), depression (Raison 
et al. 2006) and even schizophrenia (Potvin et al. 2008). As such, the role of the gut flora 
in the production of pro- or indeed anti-inflammatory molecules is of keen interest to the 
study of several diverse disease states. 
1.11.7 Measuring the gut microbiota 
In order to identify the members of the intestinal microbiota at any one time a number of 
techniques may be employed. For many years, the main stay for microbiota analysis was 
via culture methods. This involves plating of fresh faecal or intestinal material onto 
chosen media, incubation for a period of time, and then quantitative analysis by 
microscopy and qualitative analysis by a number of classic biochemical tests. However, 
estimates put the number of culturable bacteria from the human microbiota at between 
10 and 50% (Zoetendal et al. 2004). Thus, while culture techniques were invaluable in 
times past, procedures with greater capacity for indentifying different bacterial species 
were sought.  
In the last decade the development of molecular techniques have provided this resource, 
meaning the challenge of characterising this diverse ecosystem is more achievable than 
ever (O'Sullivan 2000; Fraher et al. 2012). This advancement in technology represents one 
of the main factors that has led to the recent surge in work carried out in the field and the 
resultant vast increase in knowledge pertaining to host-microbiota interactions. 
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Common techniques that are used include fingerprinting techniques such as denaturing 
gradient gel electrophoresis and temperature gradient gel electrophoresis. These 
techniques are pcr-based and can be useful for monitoring microbial shifts over time as 
they relatively quick and inexpensive (Zoetendal et al. 2004). However, such methods lack 
the depth of sequencing provided by modern platforms. 
More recently, the field of metagenomics has come to the fore. Metagenomics may be 
defined as culture-independent studies of the collective set of genomes of mixed 
microbial communities present in environmental niches, in plants, or in animal hosts 
(Petrosino et al. 2009). The Sanger-sequencing method (Sanger et al. 1977) provided a 
relatively fast method of DNA sequencing and was a key technological development for 
the progression of biological sciences. Indeed, it is still essentially used in many guises 
today (e.g. Taq) and was the corner-stone of metagenomic techniques until recently.  
The newer pyrosequencing technique was invented in the 1990’s based on the detection 
of a chemoilluminescent pyrophosphate released on nucleotide incorporation (Ronaghi et 
al. 1998). The technology utilises a “sequencing by synthesis” whereby the template 
strand is synthesised one base at a time through the use of picotiter plates. This 
technique is made applicable to microbial metagenomics via knowledge of the 16s rRNA 
gene and the compilation of large-scale gene banks of identified bacteria.  
The 16S rRNA gene is comprised of highly conserved regions interspersed with more 
variable regions. This allows PCR primers to be designed that are complementary to 
universally conserved regions.  
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Amplification, sequencing, and comparison to databases allow for the identification of 
bacterial species and to asses their respective proportions in a sample. (Wu et al. 2010) 
The Roche-454 pyrosequencer is a commercial high-throughput pyrosequencer that uses 
modern adaptations of pyrosequencing chemistry to provide relatively unambiguous and 
in-depth metagenomic data of a given sample (Petrosino et al. 2009).  
1.12 Linking the gut microbiota and antipsychotic side effects 
It is clear from the previous sections that the gut microbiota must be a consideration 
when attempting to assess and understand global metabolic processes related to obesity 
and metabolic disease. This is widely seen in animal studies of several immune and 
metabolic disease models (O'Mahony et al. 2009; Murphy et al. 2010). This integration of 
the microbiota into systemic physiology may potentially also need to be considered 
therefore when attempting to understand the aetiology of antipsychotic-induced 
metabolic effects (Fig. 1.10).  
Research into these metabolic effects of antipsychotics, such as olanzapine, have 
revealed that weight gain alone is not the primary issue when considering patients long 
term health, and that the peripheral mechanisms involved in developing cardiovascular 
risk and diabetes must be addressed. 
Further understanding of the potential contribution of the gut flora to the multiple 
metabolic mechanisms involved in the myriad of antipsychotic-associated metabolic 
effects may allow for preventative or interventive adjunctive therapies targeting the 
microbiota ultimately improving patient outcomes. 
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Fig 1.10 Potential links between the functions of the gut microbiota and the 
pathophysiology of antipsychotic-induced metabolic dysfunction. The gut microbiota 
has been independently associated with several metabolic processes involved in 
antipsychotic-induced dysfunction including energy storage, fat deposition and 
inflammation. 
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1.13 Aims of thesis 
This thesis aims to investigate the potential novel contribution of the gut microbiota to 
the adverse effects of certain antipsychotic compounds and to further elucidate the 
involvement of the gut microbiota in physiological mechanisms governing body weight, 
adiposity and diseases thereof.  
1.13.1 Can a mouse-based model of antipsychotic weight gain be established? 
Germ-free mice offer an unparalleled opportunity to assess the role of the gut microbiota 
within any particular paradigm. We therefore wanted to establish a murine model of 
antipsychotic-induced weight gain that could feasibly be replicated in gnotobiotic mice 
(Chapter 2).  
1.13.2 Do rats incur weight gain and metabolic dysfunction in response to 
olanzapine? 
We set out to establish if we could replicate previous findings showing that rats do incur 
weight gain in response to olanzapine and risperidone, and to establish a suitable 
protocol within our laboratory (chapter 3/6). We also aimed to investigate previously 
observed differences between male and female rats in their propensity to incur such 
effects (chapter 3). 
Moreover, we aimed to investigate whether the gut flora was altered in response to 
atypical antipsychotics in conjunction with other metabolic dysfunction observed. We 
therefore analysed the microbial composition of faecal or caecal flora of rats chronically 
treated with olanzapine (chapters 3,4,5) or risperidone (chapter 6). 
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1.13.3 Does the microbiota potentially represent a therapeutic target for 
antipsychotic-induced metabolic dysfunction? 
To establish if the gut flora plays a functional role in antipsychotic induced weight gain 
and metabolic side effects, we co-administered a broad-spectrum antibiotic cocktail along 
with olanzapine, chronically, to assess if obliteration of the gut flora in female rats could 
negate any of the previously observed negative effects of olanzapine (chapter 4). 
To further investigate if the gut microbiota potentially represents a therapeutic target for 
antipsychotic-induced metabolic dysfunction, we assessed if specific, non-absorbable 
antibiotics could attenuate any of olanzapine’s (chapter 5) or risperidone’s (chapter 6) 
metabolic effects.  
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Abstract 
Background: Atypical antipsychotics are associated with increases in body weight which 
can lead to serious co-morbidities such as type II diabetes and cardiovascular disease. 
Recent reports suggest peripheral mechanisms may play an important role in such side 
effects including increases in visceral fat. Moreover, sex differences in the liability of 
antipsychotic-induced weight gain has been reported though whether this difference 
extends to other aspects of antipsychotic-induced dysfunction is only beginning to be 
examined.  
Methods: Male and female C57Bl/6 mice were administered one of vehicle, olanzapine (2 
mg/kg/d) or olanzapine (4 mg/kg/d) for 21 days, I.P. and body weight and food intake 
were recorded daily. Body composition was measured by magnetic resonance prior to 
sacrifice and specific visceral fat deposits were dissected to assess effects of olanzapine 
on fat deposition in both male and female mice. 
Results: Olanzapine treatment in male mice was associated with a reduction in body 
weight and body fat mass despite temporal increases in food intake. In female mice, 
olanzapine increased not only total body fat but also visceral and subcutaneous fat 
despite reductions in overall body weight.  
Conclusions: Contrary to the clinical effect, olanzapine caused decreases in body weight in 
this study. However, olanzapine increased fat deposition in a region and sex-specific 
manner. Thus, this report, demonstrates the importance of gender in developing models 
of antipsychotic induced weight gain, and highlights the need to evaluate metabolic side 
effects beyond overt weight gain, especially increased fat mass.  
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2.1 Introduction 
The discovery of chlorpromazine and the subsequent development of typical 
antipsychotics in the 1950’s and 1960’s revolutionized the treatment of psychiatric 
disorders (Turner 2007). However, these drugs are associated with extra pyramidal side 
effects (EPS), a debilitating collection of motor disorders including akathisia and tardive 
dyskinesia (Dayalu and Chou 2008). In the late 1950’s, clozapine was developed and was 
found to carry a greatly reduced risk of EPS and thus was termed atypical. Since then, 
many more atypical antipsychotics have been developed, all with a lower propensity to 
cause EPS.  
While atypical antipsychotics were a breakthrough in terms of EPS liability, they brought 
with them their own constellation of serious metabolic side effects. Significant body 
weight gain (>7% from baseline) occurs in as many as 50% of patients receiving an 
atypical antipsychotic (Citrome et al. 2011b). Furthermore, complications such as glucose 
dysregulation and dyslipidemia commonly occur and can be seen with or without overt 
weight gain (Eder et al. 2001; Oriot et al. 2008; Patel et al. 2009; Perez-Iglesias et al. 
2009)(for review see (Newcomer 2005). 
The mechanisms underlying these metabolic side effects are not well understood, though 
in recent years it has become apparent that both central and peripheral mechanisms are 
involved. The various pathways affected by antipsychotics appear to play an integrated 
role in causing the myriad of metabolic complications which ultimately lead to co-
morbidities such as type II diabetes mellitus (Newcomer 2004; Chintoh et al. 2008a; 
Sacher et al. 2008; Chintoh et al. 2009a). 
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In particular, much focus has been placed on expansion of visceral fat mass as a major 
contributor to the development and progression of metabolic disease in general 
(Demerath et al. 2008). This is due to the realisation that the adipose tissue is an active 
endocrine organ rather than simply an energy repository (Trayhurn and Wood 2004; 
Wisse 2004).  
Moreover, evidence for effects of antipsychotics on visceral fat suggests that the adipose 
tissue may be an important source of antipsychotic-induced metabolic defects (Victoriano 
et al. 2010). 
One factor recently found to be involved in fat deposition and the aetiology of obesity, in 
mice at least, is the gut microbiota (Backhed et al. 2004). The gut microbiota represents 
the approximate 100 trillion bacteria that live symbiotically within the gastrointestinal 
tract. This microbial organ contains 100 times the number of genes in the human genome 
and hence has a huge capacity to influence human physiology via a number of 
mechanisms (Turnbaugh et al. 2007; Ley et al. 2008b; Bienenstock and Collins 2010; 
Backhed 2011; Burcelin et al. 2011). Whether the gut microbiota contributes to the 
metabolic effects of any or all antipsychotic drugs is thus far unexplored. 
Mice offer a unique opportunity to investigate the role of the gut microbiota in a given 
model due to the availability of germ-free mice (mice lacking any microbiota), first 
developed in the early 1960’s (Trexler 1961).  
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However, in order to investigate if the gut microbiota plays a significant role in 
antipsychotic induced metabolic dysfunction using a tool such as germ-free mice, we first 
needed to establish a reproducible and clinically relevant mouse-model of antipsychotic 
induced metabolic effects. 
An additional unresolved question in relation to antipsychotic-induced metabolic effects 
is that of sex. Several reports have suggested that females have an increased liability for 
such adverse effects compared to males (Hakko et al. 2006; Verma et al. 2009). Clear 
differences in body weight between males and females in animal models have been 
demonstrated (Albaugh et al. 2006), however, direct comparisons between male and 
females in other aspects of metabolic dysfunction induced by atypical antipsychotics have 
been lacking. 
Thus, we investigated the effects of olanzapine on body weight and body composition in 
male and female C57Bl/6 mice. 
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2.2 Methods 
Animals 
Male and female C57Bl/6 mice were used (Harlan, UK). Mice receiving the same drug 
treatment were housed in pairs. Animals were maintained on a 12 hour light/dark cycle 
with lights on at 7:30 am. Animals had access to standard chow and water ad libitum. All 
experiments were approved by the Animal Experimentation Ethics Committee (AEEC) of 
University College Cork and carried out in accordance with the Cruelty to Animals Act 
1876 and European Directive 86/609/EEC on the protection of animals used for 
experimental and other scientific purposes. 
Drug administration 
Olanzapine (Discovery Fine Chemicals, Ireland) was prepared fresh daily and was 
dissolved in a minimal amount of glacial acetic acid (approx 0.1 ml) and then made to 
volume and pH adjusted to approximately 6 with 1M NaOH. Vehicle consisted of distilled 
water acidified with glacial acetic acid and pH adjusted to 6 with 1M NaOH. Drug and 
vehicle were administered at an injection volume of 10 ml/kg. 
Treatment groups 
Mice (n=8) received vehicle, olanzapine (2 mg/kg/d) or olanzapine (4 mg/kg/d) via twice-
daily (B.I.D) intra-peritoneal injection for 21 days. Injections took place between 9:00 am 
and 10:00 am and 4:00pm and 5:00pm. 
Daily measurement 
Body weight and food intake were measured daily to the nearest 0.01g using an 
electronic balance. 
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Body composition  
Body composition was analysed in conscious animals using a minispec nuclear magnetic 
resonance body composition analyser (Bruker Optics, MA, U.S.). Briefly, mice were placed 
carefully into a clear plastic tube which was then inserted horizontally into the minispec 
machine.  
The analysis takes 20-30 seconds before the mouse was removed from the tube, the tube 
cleaned and the next animal placed inside.  
Body composition was further assessed by careful dissection of subcutaneous, 
mesenteric, peri-uterine and peri-renal fat deposits which were excised and weighed to 
the nearest 0.0001g on an electronic balance. 
Statistical analysis 
Body weight and food intake were analysed using repeated measures ANOVA. Where 
sphericity was violated, Greenhouse-geisser correction was applied. Body composition 
was analysed using one way ANOVA, with LSD post hoc test used for further analysis 
where appropriate. LSD was selected as an appropriate post-hoc test due the relatively 
small N numbers and expected effect sizes. 
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2.3 Results 
Body weight 
Time had a significant effect on body weight, (F(3.63,149.06) = 81.641, p < 0.001). Drug 
treatment also had a significant overall effect (F(2,41) = 9.66, p < 0.001) and there was a 
significant time x drug interaction (F(7.27,149.06) = 2.803, p < 0.01). Gender did not have a 
significant overall effect (F(1,41) = 0.846, p = 0.363). 
In male animals, post-hoc analysis revealed that mice treated with olanzapine (2 mg/kg) 
or olanzapine (4mg/kg) had significantly reduced weight gain on days 2-10 (inclusive) (p < 
0.001 to p < 0.05) (Fig. 2.1A). Female mice receiving olanzapine (2 mg/kg) displayed 
reduced body weight gain compared to vehicle treated mice on days 2-5 and days 9-22 
(inclusive) (p < 0.01 to p < 0.05) while those receiving olanzapine (4 mg/kg) displayed 
reduced body weight gain compared to vehicle treated mice on days 2-22 inclusive (p < 
0.001 to p < 0.05) (Fig. 2.1B). 
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Fig. 2.1 Effect of olanzapine on body weight in C57Bl/6 mice. Percent body weight 
change following 21 days vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or olanzapine (4 
mg/kg) administration in (A) Male C57Bl/6 mice and (B) Female C57Bl/6 mice. Data 
expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p <0.001 compared to vehicle treated 
group. 
Food Intake 
Food intake was not significantly affected by time (F(2,372) = 2.618, p = 0.08). Gender did 
significantly affect food intake (F(2,36) = 23.547, p < 0.001) and there was a significant time 
x gender interaction, (F(2,72) = 4.74, p < 0.05). Drug treatment did not have an overall 
effect (F(2,36) = 2.443, p = 0.101).  
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Further analysis revealed that in male mice receiving OLZ (2 mg/kg) there was evidence of 
increased food intake which was significantly increased compared to mice receiving OLZ 
(4 mg/kg) in week 3 (p < 0.5) (Fig. 2.2A). In the females, mice receiving olanzapine (2 
mg/kg) had increased food intake in week 2 compared to both the vehicle treated animals 
and those receiving olanzapine (4 mg/kg) (p < 0.05) (Fig. 2.2B). 
 
Fig. 2.2 Effect of olanzapine on food intake in C57Bl/6 mice. Average weekly food intake 
following administration of vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or olanzapine (4 
mg/kg) in (A) Male C57Bl/6 mice and (B) Female C57Bl/6 mice. Data expressed as mean ± 
S.E.M. *p < 0.05 versus vehicle treated group, #p < 0.05 versus olanzapine (4 mg/kg) 
treated group. 
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Body Composition 
Body fat percentage was significantly affected by gender (F(1,42) = 88.64, p < 0.001) but not 
drug treatment, (F(2,42) = 1.893, p = 0.163). There was however a significant gender x drug 
interaction (F(2,42) = 5.561, p < 05).  
In the male mice, both olanzapine (2 mg/kg) and olanzapine (4 mg/kg) resulted in a 
significant reduction in body fat percentage compared to vehicle treated mice (p < 0.05) 
(Fig. 2.3A). In the female mice, the opposite was seen with mice treated with olanzapine 
(2 mg/kg) displaying significantly increased body fat compared to both vehicle treated 
mice (p < 0.01) and mice receiving olanzapine (4 mg/kg) (p < 0.05) (Fig 2.3B). 
Total body lean mass was not affected by drug treatment (F(2,42) = 1.401, p = 0.258) while 
gender did have a significant effect (F(1,42) = 62.929, p < 0.001). There were no significant 
differences in lean mass observed between treatment groups in the male (Fig. 2.4C) or 
female mice (Fig. 2.4D). 
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Fig. 2.3 Effect of olanzapine on body composition in C57Bl/6 mice. Effect of vehicle, 
olanzapine (2 mg/kg) or olanzapine (4 mg/kg) administration for 21 days on percent body 
fat percentage in (A) Male and (B) Female C57Bl/6 mice and on lean mass percentage 
in(C) Male and (D) Female C57Bl/6 mice. Data expressed as mean ± SEM. *p < 0.05 versus 
vehicle treated mice, #p < 0.05 versus olanzapine (4 mg/kg) treated mice. 
Fat distribution 
Olanzapine treatment was found to have a significant effect on visceral fat mass (F(2,42) = 
4.827, p < 0.05) as did gender (F(1,42) = 73.865, p < 0.001). No differences in visceral fat 
were seen for male mice in visceral (Fig 2.4A ) however female mice treated with 
olanzapine (2 mg/kg) or olanzapine (4 mg/kg) had increased visceral fat compared to 
vehicle treated mice (p < 0.05) (Fig.2.4B). 
Subcutaneous fat was also affected by drug treatment (F(2,42) = 3.109, p < 0.05) and 
gender, (F(1,42) = 43.555, p < 0.001).  
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Male mice did not show any difference in subcutaneous fat (Fig 2.4C) but the female mice 
receiving olanzapine (2mg/kg) had increased subcutaneous fat compared to the vehicle 
and olanzapine (4 mg/kg) treated mice (p < 0.05) (Fig. 2.4D). 
 
Fig. 2.4 Effect of olanzapine on fat deposition in C57Bl/6 mice. Effect of vehicle (veh), 
olanzapine (OLZ) (2 mg/kg) or olanzapine (4 mg/kg) administration for 21 days on visceral 
fat in (A) Male and (B) Female C57Bl/6 mice and on subcutaneous fat mass in (C) Male 
and (D) Female C57Bl/6 mice. Data expressed as mean ± SEM. *p < 0.05 versus vehicle 
treated group, #p < 0.05 versus olanzapine (4 mg/kg) treated mice.  
To further assess fat distribution, the individual deposits were dissected and weighed. 
Gender had a significant effect on fat mass in all of the areas measured: gonadal (F(1,42) = 
68.947, p < 0.001); mesenteric (F(1,42) = 16.381, p < 0.001) and renal (F(1,42) = 41.914, p < 
0.001). In the case of gonadal fat there was also a significant gender x drug interaction 
(F(2,42) = 5.587, p < 0.01). 
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Further analysis revealed that in the male mice, treatment with olanzapine (2 mg/kg) led 
to increased levels of peri-renal fat compared to vehicle treated mice (p < 0.05) (Fig. 2.6A) 
while the other fat deposits were unaltered (Fig. 2.6 B-C).  
In the female mice, peri-renal fat was not altered following olanzapine treatment (Fig. 
2.5B). However, female mice receiving olanzapine (2 mg/kg) or olanzapine (4 mg/kg) had 
increased gonadal fat mass compared to vehicle treated mice (Fig. 2.6D). No change in 
mesenteric fat was observed in female mice (Fig. 2.6F). 
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Figure 2.5 Effect of olanzapine on regional fat deposition in C57Bl/6 mice. Effect of 
vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or olanzapine (4 mg/kg) on peri-renal (A-B), 
gonadal (C-D) and mesenteric (E-F) fat deposits in male and female C57Bl/6 mice. Data 
expressed as mean ± S.E.M. *p < 0.05 versus vehicle treated mice, #p < 0.05 versus 
olanzapine (4 mg/kg) treated mice. 
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2.4 Discussion 
In the present study, we set out to establish a murine model of antipsychotic-induced 
weight gain and metabolic dysfunction. This has proven to be difficult in the past, as a 
number of studies have reported a failure of mice to gain excessive weight when 
administered antipsychotics (Albaugh et al. 2006; Shertzer et al. 2010). Studies which 
have produced weight gain in murine models have relied on high doses and long 
treatment protocols which arguably do not represent the clinical setting in a relevant 
fashion (Cope et al. 2005; Coccurello et al. 2008).  
Herein, the atypical antipsychotic olanzapine did not induce weight gain in mice. Indeed, 
somewhat surprisingly, olanzapine was associated with decreased body weight. This is 
however not without precedent, as clozapine, an atypical antipsychotic associated with 
severe weight gain in patients (Allison et al. 1999) has repeatedly been found to induce 
reduced weight gain in rodents (Cheng et al. 2005; Yuan et al. 2008).  
Furthermore, the initial injection of olanzapine was associated with acute hypophagia 
leading to reductions in body weight. This peculiar finding was seen in a previous study 
(Yoon et al. 2010), suggesting that a species-specific hypophagic effect of acute 
olanzapine may exist and this may have precluded weight gain. 
The possible role of the gut microbiota in antipsychotic-induced weight gain thus remains 
to be explored. This study suggests that future studies investigating if the gut microbiota 
contributes to the metabolic liabilities of antipsychotics will likely have to employ 
different species other than mice as they do not reflect the clinical setting in a 
reproducible fashion.  
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However, given the complex and multifactorial nature of the mechanisms underlying the 
side effects of antipsychotics, the study described herein is not without potential 
implications. 
Increased food intake is the primary factor behind initial weight gain observed in patients 
and animals receiving atypical antipsychotics such as olanzapine (Kluge et al. 2007; 
Davoodi et al. 2009; Fountaine et al. 2010). This hyperphagia is caused by antagonism of 
numerous receptors which are intimately involved in the regulation of food intake, 
including dopamine D2, serotonin 5-HT2C and histamine H1 receptors (Nasrallah 2008). 
Both male and female olanzapine treated mice displayed evidence of increased food 
intake at the lower, 2 mg/kg, dose. These increases, while not sufficient to produce 
overall body weight gains, suggest olanzapine was exerting a central effect reminiscent of 
that seen in patients. 
Crucially, research into the mechanisms underlying antipsychotic association with co-
morbidities such as type II diabetes mellitus has revealed that several overlapping factors 
are involved, both central and peripheral (Basson et al. 2001a; Houseknecht et al. 2007; 
Jassim et al. 2011). Furthermore, it is important to note that weight gain per se is not 
necessary for metabolic abnormalities to develop in patients or animals receiving 
antipsychotics (Zhang et al. 2004; Minet-Ringuet et al. 2006) or indeed in the general 
population (Alberti et al. 2009). 
Recently, emphasis has been placed on the expansion of visceral fat as a critical factor in 
metabolic disease (Demerath et al. 2008). Visceral, or abdominal, fat is no longer thought 
of as a simple storage depot, but rather as an endocrine organ (Galic et al. 2010).  
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There are several converging mechanisms that make increased visceral adiposity 
particularly dangerous, including the release of pro-inflammatory mediators such as 
cytokines: TNF, IL-6, IL-1β, and hormones such as leptin. Together with the release of free 
fatty acids into circulation, these factors all contribute to a vicious cycle of metabolic 
dysfunction instigating insulin resistance which leads to further fat expansion and 
exacerbating metabolic dysregulation. 
Intriguingly, the female mice receiving olanzapine (2 mg/kg) displayed significantly 
greater body fat percentage than vehicle treated mice. Furthermore, female mice 
receiving either dose of olanzapine displayed increased levels of visceral fat. In addition, 
female mice receiving olanzapine (2 mg/kg) displayed increased levels of subcutaneous 
fat. Thus, this increase in subcutaneous fat at only the lower dose of olanzapine likely 
explains why an overall increase in body fat percentage was observed only at this dose.  
We further investigated potential effects of olanzapine on visceral fat by dissecting three 
discrete visceral regions, namely; gonadal, renal and mesenteric fat deposits. We found 
both doses of olanzapine increased gonadal (peri-uterine) fat in female mice. 
Interestingly, in the male mice, increases in peri-renal fat were observed in response to 
olanzapine suggesting that despite limited effects on body weight and fat mass, the male 
mice were susceptible to certain effects of olanzapine. 
These increases in visceral fat without increased body weight are not too surprising as 
normal weight individuals can have increases in visceral fat mass and this has also been 
seen in rodents receiving antipsychotics (Minet-Ringuet et al. 2006).  
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Moreover, a number of studies have observed increases in adipose mass and adipose 
dysfunction in male rodents in response to antipsychotics in the absence of effects on 
body weight (Albaugh et al. 2010; Victoriano et al. 2010).  
As already mentioned, increased visceral fat is a key step in the development of metabolic 
disease, and is not necessarily associated with body weight gain. Hence, these findings 
suggest that while not sufficient to replicate the weight gain observed in humans, 
olanzapine’s effects on fat mass in this study are potentially highly clinically relevant.  
In particular, the sex-specific nature of the alterations may be of importance when 
assessing the metabolic effects of olanzapine in both animal and clinical studies. 
The observed sex differences in the effects of olanzapine on fat deposition are extremely 
interesting as many, if not all, studies in patients have found a gender bias, with females 
exhibiting a greater propensity towards the weight gain liabilities of antipsychotics (Hakko 
et al. 2006; Aichhorn et al. 2007; Haack et al. 2009).  
This difference may be due to gender differences in drug pharmacokinetics (Harris et al. 
1995; Beierle et al. 1999) as females exhibit higher plasma levels of olanzapine for a given 
dose compared to males (Callaghan et al. 1999; Kelly et al. 1999; Seeman 2004). Sex 
differences in metabolic enzyme systems such as cytochrome enzymes CYP3A4 and 
CYP1A2 (Parkinson et al. 2004) also exist. CYP1A2 is the main metabolising enzyme for 
olanzapine, and is less active in women than men (Kelly et al. 1999; Gex-Fabry et al. 2003) 
and polymorphisms in CYP1A2 are associated with reduced liability for metabolic side 
effects of antipsychotics (Laika et al. 2010). 
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Moreover, sex-differences in hepatic drug metabolism are more robust in rodents than 
humans (Waxman and Celenza 2003). Thus, the sex-specific differences in drug 
pharmacokinetics and pharmacodynamics may impact on side effect susceptibility in 
humans, and this may be exaggerated in experimental models. 
Thus, we have shown that while this model was not sufficient to investigate the effects 
olanzapine on body weight, a number of potentially relevant observations were made. A 
potentially important sex-difference in the nature of olanzapine-induced alterations in 
visceral fat deposition was revealed. Critically, this occurred in the absence of weight 
gain, drawing attention to the importance of considering potential metabolic 
complications without evidence of overt weight gain in patients. 
An unanswered question from this study is the impact of the gut microbiota in 
antipsychotic-induced alterations in body weight and fat mass. This study suggests that 
other species, such as the rat, may represent a better choice for attempting to unravel 
such a question. 
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Abstract  
Background: Atypical antipsychotic drugs (AAPDs) such as olanzapine have a serious side 
effect profile including weight gain and metabolic dysfunction and a number of studies 
have suggested a role for gender in the susceptibility to these effects. In recent times, the 
gut microbiota has been recognised as a major contributor to the regulation of body 
weight and metabolism. Thus, we investigated the effects of olanzapine on body weight, 
behaviour, gut microbiota and inflammatory and metabolic markers in both male and 
female rats.  
Methods: Male and female rats received olanzapine (2 mg/kg/d or 4 mg/kg/d) or vehicle 
for 3 weeks. Body weight, food and water intake were monitored daily. The faecal 
microbial content was assessed by 454 pyrosequencing. Plasma cytokines, as well as 
expression of genes including sterol-regulatory element binding protein-1c (SREBP-1C) 
and CD68 were analysed.  
Results: Olanzapine induced significant body weight gain in the female rats only. Only 
female rats treated with olanzapine (2 mg/kg) had elevated plasma levels of IL-8 and IL-1β 
while both males and females had olanzapine-induced increases in adiposity and 
evidence of macrophage infiltration into adipose tissue. Furthermore, an altered 
microbiota profile was observed following olanzapine treatment in both genders.  
Conclusions: This study furthers the theory that gender may impact on the nature of, and 
susceptibility to, certain side effects of antipsychotics. In addition, we demonstrate, what 
is to our knowledge the first time, an altered microbiota associated with chronic 
olanzapine treatment. 
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3.1 Introduction 
Atypical antipsychotics (AAPDs) such as olanzapine represent the mainstay of treatment 
for schizophrenia and bipolar disorder. AAPDs are a diverse drug class grouped together 
based on their lack of extra-pyramidal symptoms (EPS) associated with typical 
antipsychotics (De Oliveira and Juruena 2006). AAPDs however are associated with their 
own side effects, most notably weight gain and metabolic dysfunction (Birkenaes et al. 
2008; Chintoh et al. 2008b; Oriot et al. 2008; Perez-Iglesias et al. 2009; Albaugh et al. 
2010). Clinically significant weight gain (> 7%) often occurs in greater than 50% of patients 
receiving an atypical antipsychotic (Ahmer et al. 2008; Patel et al. 2009; Citrome et al. 
2011a; Citrome et al. 2011b). This has ramifications for the patient in terms of metabolic 
and cardiovascular disease co-morbidity as well treatment compliance (Nasrallah 2003; 
Farwell et al. 2004; Cohen and Correll 2009; Correll et al. 2009; Starrenburg and Bogers 
2009).  
A number of factors such as base-line weight (Basson et al. 2001a; Gebhardt et al. 2009), 
therapeutic outcome (Basson et al. 2001a; Meltzer et al. 2003b) and gender (Aichhorn et 
al. 2007; Haack et al. 2009), have been proposed to confer susceptibility to the metabolic 
effects of antipsychotics. In the majority of cases, females have been found to have a 
higher prevalence of AAPD induced weight gain (Hakko et al. 2006; Aichhorn et al. 2007; 
Haack et al. 2009; Verma et al. 2009). However, exceptions exist, where men have 
increased weight gain (Basson et al. 2001a) or no gender bias has been apparent (Lee et 
al. 2004).  
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Intriguingly, in rat (and to a lesser extent mouse) models of antipsychotic-induced weight 
gain, there appears to exist gender-dependent effects with female rats showing more 
robust weight gain following treatment compared to males (Albaugh et al. 2006; Choi et 
al. 2007). This has led some to challenge the relevance of these models (Pouzet et al. 
2003). However, recent studies have demonstrated that male rats do incur a number of 
the detrimental metabolic effects in the absence of weight gain (Minet-Ringuet et al. 
2006; Victoriano et al. 2009; Albaugh et al. 2010) and can even incur weight gain with 
extended protocols (Shobo et al. 2011).  
Overall therefore, gender differences in animal models may be more relevant to the 
clinical setting than previously thought (Weston-Green et al. 2011b) and while current 
models are not perfect, they are extremely important in tackling the problems associated 
with AAPDs (Boyda et al. 2010). 
It is important to note that AAPDs such as olanzapine can lead to the development of 
Type II diabetes mellitus with or without the presence of overt weight gain (Newcomer 
2004; Kim et al. 2010). Therefore, direct and indirect metabolic actions of these drugs are 
important considerations when assessing their overall metabolic impact. Inflammation, 
for instance, is an important factor in the development of obesity and the metabolic 
syndrome (Das 2001; Bastard et al. 2006a) and a correlation between increased cytokine 
production and AAPD-induced weight gain has been observed (Kluge et al. 2009). 
The gut microbiota comprises the approximate 1013-1014bacteria which reside within the 
gastrointestinal tract and exist in a symbiotic relationship with the host.  
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Recently, a role for the gut microbiota in body weight, metabolism and systemic 
inflammation has begun to be elucidated (Backhed et al. 2004; Ley et al. 2005; Turnbaugh 
et al. 2006; Backhed et al. 2007; Clarke et al. 2010; Murphy et al. 2010; Bailey et al. 2011). 
Furthermore, as with many other systems, a definitive gender divide exists in the 
composition of the gut microbiota in both humans and animals (Mueller et al. 2006; 
Fushuku and Fukuda 2008). Moreover, the microbiota can have marked effects on the 
brain-gut axis (Cryan and O’Mahony, 2011; Bravo et al., 2011). It is currently unclear 
whether chronic AAPD treatment can affect microbiota composition in addition to 
affecting body weight, metabolism and systemic inflammation. 
Thus, we investigated the impact of chronic olanzapine treatment on metabolic, 
inflammatory and microbiome parameters and assessed whether there was a sexually 
dimorphic response. 
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3.2 Methods 
Animals 
Male and female Sprague-Dawley rats, initially weighing approximately 200g, were used 
(Harlan, UK). Animals were habituated to the animal facility for one week. They were 
housed four per cage (56x38x17 cm), allowed access to standard chow and water ad 
libitum and kept on a 12 hour light-dark cycle with lights on at 7.30am. All experiments 
were approved by the Ethical Committee of University College Cork (#2010/013) and 
carried out in accordance with the Cruelty to Animals Act 1876. 
Drug administration  
Olanzapine (Discovery Fine Chemicals, UK) was dissolved in a minimal amount of glacial 
acetic acid (approx 0.1ml) and then made to volume with deionised water and pH 
adjusted to approximately 6.0 with 0.1M NaOH. Vehicle consisted of distilled water 
acidified with glacial acetic acid and pH adjusted with 0.1M NaOH. All solutions were 
prepared fresh daily. The treatments were administered via intra-peritoneal injection 
B.I.D. with the first injection between 9.00am and 10.00am and the second injection 
between 4.00pm and 5.00pm. 
Treatment groups 
Rats (n=8) received vehicle, olanzapine 2 mg/kg/day or olanzapine 4 mg/kg/day for 21 
days. All groups were weight matched prior to treatment commencing. Doses were 
selected on the basis they reflect therapeutic concentrations and have been shown to 
induce weight-gain and metabolic side-effects previously (Kapur et al. 2003; Cooper et al. 
2005; Fell et al. 2005). 
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Daily measurements 
Body weight, food intake and water intake were measured each morning to the nearest 
0.01g using an electronic balance. This was carried out prior to the first injection. 
Locomotor activity 
On day 22, animals were allowed one hour to habituate to the testing room (13.00-14.00) 
before being placed into the centre of a rectangular plastic box (60x50x40 cm). The 
behaviour was recorded via an overhead camera for 30 minutes (14.00-14.30) and 
locomotor activity was analysed using a tracking software system (Ethovision, Noldus, The 
Netherlands). 
Sample collection 
Animals were sacrificed by decapitation and trunk blood was collected in EDTA coated 
tubes and centrifuged for fifteen minutes at 6000 rpm. The plasma supernatant was 
aliquoted and stored on dry ice. The brain was quickly excised and dissected and each 
brain region was initially stored in RNALater for 24 hours. The gonadal, mesenteric and 
subcutaneous fat deposits were carefully excised and weighed to the nearest 0.0001g. 
The gonadal and mesenteric deposits were added together as a measure of visceral fat. 
The frontal lobe of the liver was snap-frozen in isopentane and stored on dry ice. All 
samples were frozen at -800C for later analysis. Faecal pellets were collected directly from 
the animals on day 22 on dry ice and quickly stored at -800C. 
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Plasma analysis  
Concentrations of the cytokines tumour necrosis factor alpha (TNF-α), interleukin-8, (IL-
8), interleukin-6 (IL-6) and interleukin-1 beta (IL-1β) were analysed using a commercially 
available electrochemiluminescence multiplex system (MSD, Gaithersburg, MD, USA). The 
highly sensitive assay has a range of 9.8-40,000 pg/ml. The plates were analysed on a 
SECTOR Imager 2400 from Mesoscale Discovery. 25μl of plasma was used for each well 
and all samples were analysed in duplicate. Plasma leptin was analysed using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit (Millipore, 
Billerica, MA, USA). The assay range of this assay is 0.2 ng/ml to 30 ng/ml. 10 μl of plasma 
was used for each well and all samples were analysed in duplicate. 
Plasma ghrelin was measured using a mouse/rat total ghrelin multi-array assay from 
Mesoscale discovery (MSD, Gaithersburg, MD, USA). The assay has a sensitivity of 11-
5000 pg/ml. All samples were measured in duplicate and analysed on a SECTOR Imager 
2400 from Mesoscale Discovery. 
Gene expression analysis 
RNA from brain and liver samples was extracted for gene analysis using a commercially 
available kit (Agilent Technologies, CA, USA). Qiagen RNeasy Lipid Mini Kit was used for 
adipose tissue (QIAGEN, Valencia, CA, USA). mRNA was reverse transcribed using High 
capacity cDNA reverse transcription Kit (Applied Biosystems) in a G-storm thermocycler 
(G-storm, Surrey , UK). Gene expression was analysed using TaqMan Gene Expression 
Assays and the AB7300 system (Applied Biosystems). The expression value of each gene 
was normalised to that of β-actin. All samples were analysed in triplicate. 
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Microbial community composition: pyrosequencing  
For analysis of the microbial community composition, total DNA was extracted from the 
faecal pellets of two rats per cage using the QIAamp DNA stool mini kit according to the 
manufacturer’s instructions (Qiagen, West Sussex, UK) coupled with an initial bead-
beating step. Universal 16s rRNA primers, designed to amplify from highly conserved 
regions corresponding to those flanking the V4 region, i.e. the forward primer F1 (5’-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1 (5’-
TACCRGGGTHTCTAATCC), R2 (5’-TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing 
Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp) were used for Taq-based PCR 
amplification. Sequencing was performed on a Roche 454 GS-FLX using Titanium 
chemistry by the Teagasc454SequencingPlatform. Resulting raw sequences reads were 
quality trimmed as previously described (Claesson et al., 2009) Trimmed FASTA sequences 
were then BLASTed (Altschul et al. 1997) against a previously published 16s rRNA-specific 
database (Urich et al. 2008) using default parameters. The resulting BLAST output was 
parsed using MEGAN (Huson et al. 2007a; Huson et al. 2007b). MEGAN assigns reads to 
NCBI taxonomies by employing the Lowest Common Ancestor algorithm. Bit scores were 
used from within MEGAN for filtering the results prior to tree construction and 
summarization. A bit-score of 86 was selected as previously used for 16s ribosomal 
sequence data (Urich et al. 2008). Phylum and family counts for each subject were 
extracted from MEGAN. Clustering and alpha diversities were generated with the 
MOTHUR software package (Schloss et al., 2009).  
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Statistical analysis 
Two-way repeated measures analysis of variance (ANOVA) was used to analyse body 
weight change, food intake and water intake and locomotion, with gender, treatment as 
factors. Two-way ANOVA was used for gene and cytokine analysis with gender and 
treatment as factors. As a possible effect gender was the central hypothesis of this study, 
males and females were analysed separately, regardless of whether there was an overall 
effect of gender. Due to the increased number of groups, further analysis was carried out 
using Tukey’s post-hoc test in order to protect against Type I errors caused by increased 
comparisons. p< 0.05 was considered statistically significant. 
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3.3 Results 
Body weight gain  
The effect of olanzapine on body weight gain was significantly affected by gender (F(1,42) = 
26.906, p < 0.001) and time (F(2.85,119.56)= 271.878, p < 0.001). There was a significant 
interaction between gender and treatment (F(2,42) = 4.883 p = 0.01) as well as between 
gender and time (F(2.85,119.56) = 34.425, p < 0.001) and a gender X treatment X time 
interaction (F(5.69,119.56) = 15.101 p < 0.001).  
The increase in the weight in the female rats was evident within the first days of 
treatment, with significant increases observed in animals given olanzapine (2 mg/kg) on 
days 5 to 15 and days 19-23 inclusive (p < 0.05 to p < 0.001). Females treated with 
olanzapine (4 mg/kg) displayed significant weight gain on days 3 to 15 inclusive (p < 0.05 
to p < 0.001) but subsequently showed a reduction in body weight returning to normal 
levels such that the animals receiving olanzapine (2 mg/kg) were significantly increased 
compared to those receiving olanzapine (4 mg/kg) on days 21-23 inclusive (p < 0.05) (Fig. 
3.1a). In the male rats, no difference between treatment groups was observed (Fig. 3.1b). 
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Fig. 3.1 Effect of olanzapine on body weight in Sprague-Dawley rats. Effect of olanzapine 
(OLZ) (2 mg/kg and 4 mg/kg) on percentage body weight gain in (a) female rats and (b) 
male rats treated for 21 days B.I.D. First injection on day 1. Data shown represents mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001 OLZ (2 mg/kg) significantly different versus 
vehicle group. +p < 0.05, ++p < 0.01, +++p < 0.001 4 mg/kg significant versus vehicle group. 
#p < 0.05, OLZ (2 mg/kg) significant versus OLZ (4 mg/kg) group. 
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Food and Water intake  
Olanzapine treatment significantly affected food intake (F(2,90) = 21.212, p < 0.001). There 
was also a significant effect of gender (F(1,90) = 530.485, p < 0.001) and a significant time X 
gender X treatment interaction (F(3.34,150.66) = 4.28, p < 0.01). Hyperphagia was observed in 
the female rats in both treatment groups compared to vehicle in week one (2 mg/kg p < 
0.05, 4 mg/kg p < 0.001) and week 2 (2 mg/kg p < 0.05 4 mg/kg p < 0.01). The observed 
increases in the rats treated with olanzapine (4mg/kg) was significantly greater than 
those receiving olanzapine (2 mg/kg) group in week one (p < 0.05). In week 3, 
hyperphagia persisted in the animals treated with olanzapine (2 mg/kg) (p < 0.05) but was 
significantly reduced in those receiving olanzapine (4 mg/kg) compared to vehicle treated 
rats (p < 0.01) and the olanzapine (2 mg/kg) group (p < 0.01). In the male rats, the 
olanzapine (4 mg/kg) group displayed a significant increase in food intake compared to 
the vehicle group in week 1 (p < 0.05) but not in the subsequent weeks (Fig. 3.2a). 
Olanzapine treatment also induced significant increases in water intake (F(2,90) = 6.573, p < 
0.01) with a further significant effect of gender (F(1,90) = 51.397, p < 0.001) and time 
(F(2,180) = 14.637, p < 0.001). There was also a significant gender X treatment interaction 
(F(2,90) = 4.895, p < 0.01). The water intake followed a similar pattern to food intake with 
increases seen in the female rats treated with olanzapine (2 mg/kg and 4 mg/kg) 
compared to vehicle treated rats in week one (p < 0.05, p < 0.01) respectively and week 
two (p < 0.001, p < 0.05). In week three, only the female rats receiving olanzapine (2 
mg/kg) displayed significant increases versus vehicle treated animals (p < 0.05). The male 
rats did not show differences in any of the weeks (Fig. 3.2b). 
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Fig. 3.2 Effect of olanzapine on food and water intake in Sprague-Dawley rats. Effect of 
olanzapine (OLZ) (2mg/kg and 4 mg/kg) on (a) food intake and (b) water intake in female 
and male rats treated for 21 days B.I.D. Data shown represents mean ± SEM. Food and 
water intake shown as amount consumed per cage per day. *p < 0.05, **p < 0.01, ***p < 
0.001 significantly different versus vehicle group of same gender. #p < 0.05, ##p < 0.01 
versus OLZ (2 mg/kg) group of same gender. 
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Locomotor activity 
In the locomotor activity test there was a significant effect of time (F(3.45,144.68) = 221.217, 
p < 0.001) and of treatment (F(2,42) = 7.264, p < 0.01). Post-hoc analysis showed there was 
a reduction in locomotion in female rats treated with olanzapine (2 mg/kg) between both 
15 and 20 minutes (p < 0.001) and between 20 and 25 minutes (p < 0.05). The female rats 
treated with olanzapine (4 mg/kg) only displayed decreased activity between 15 and 20 
minutes (p < 0.05).  
The male rats treated with olanzapine (2 mg/kg and 4 mg/kg) exhibited reduced 
locomotor activity between the 5 minute and ten minute time points (p < 0.05), (p < 0.01) 
respectively. The male rats treated with olanzapine (2 mg/kg) further showed reduced 
movement between 15 and 20 minutes and 20 and 25 minutes (p < 0.05) (Fig. 3.3). 
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Fig. 3.3 Effect of olanzapine on locomotion in Sprague-Dawley rats. Effect of olanzapine 
(OLZ) (2 mg/kg and 4 mg/kg) on locomotor activity in (a) female and (b) male rats treated 
for 21 days B.I.D. Locomotion measured as distance moved. Data shown represent mean ± 
SEM. *p < 0.05 versus vehicle treated rats. 
Adipose Tissue  
Olanzapine treatment significantly increased visceral fat mass (F(2,42) = 16.042, p < 0.001) 
and there was a significant gender X treatment interaction (F(2,42) = 6.147 p < 0.01). 
Female rats treated with olanzapine (2 mg/kg and 4 mg/kg) had significantly increased 
visceral fat mass compared to vehicle treated animals (p < 0.01, p < 0.05) respectively.  
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The male rats receiving olanzapine (4 mg/kg) group showed significant increases in 
visceral fat compared to both the male vehicle treated group (p < 0.001) and the male 2 
mg/kg treated group (p < 0.05) (Fig. 3.4). 
 
 
Fig.3.4 Effect of olanzapine on visceral fat deposition in Sprague-Dawley rats. Effect of 
olanzapine (OLZ) ( 2mg/kg and 4 mg/kg) on proportion of visceral fat (gonadal + 
mesenteric fat deposits) in female and male rats treated for 21 days B.I.D. Data shown 
represents mean ± SEM. **p < 0.01, ***p < 0.001 significantly different versus vehicle 
group of same gender. #p < 0.05 significantly different versus OLZ (2 mg/kg) group of 
same gender. 
Olanzapine treatment also had a significant effect on CD68 expression (F(2,38) = 8.825, p < 
0.001) with an effect of gender (F(1,38) = 16.046 p < 0.001). Female rats treated with 
olanzapine (4 mg/kg) displayed significantly increased levels of CD68 mRNA compared to 
vehicle treated rats (p < 0.05). In the male rats, olanzapine treatment (2 mg/kg and 4 
mg/kg) resulted in increased levels of CD68 mRNA expression compared to vehicle 
treated animals (p < 0.05) (Fig. 3.5a). 
Interleukin (IL)-6 mRNA expression was significantly affected by gender (F(1,37) = 26.511 p 
< 0.001) and there was a significant gender X treatment interaction (F(2,37) = 3.886, p < 
0.05).  
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The female animals receiving olanzapine (4 mg/kg) had increased levels compared to the 
animals receiving olanzapine (2 mg/kg) (p < 0.05). The male rats treated with olanzapine 
did not show significant increases, though those treated with olanzapine (2 mg/kg) had a 
4 fold increase compared to vehicle treated rats.  
The male vehicle treated rats had significantly lower expression compared to female 
vehicle treated animals (p < 0.05) (Fig. 3.5b). 
Sterol-regulatory element binding protein 1c (SREBP-1c) expression was significantly 
affected by olanzapine treatment (F(2,34) = 4.90, p < 0.05). There was also a significant 
effect of gender (F(1,34) = 39.189, p < 0.001), and a significant gender, treatment 
interaction (F(2,34) = 3.481, p < 0.05). In female rats, those treated with olanzapine (4 
mg/kg) had a significant reduction in the mRNA expression of SREBP-1c compared to both 
the vehicle (p < 0.05) and olanzapine (4 mg/kg) groups (p < 0.01). This reduction was not 
seen in the male rats, though the male vehicle group had significantly lower levels than 
female vehicle treated animals (p < 0.05) (Fig. 3.5c).  
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Fig. 3.5 Effect of olanzapine on gene expression in adipose tissue in Sprague-Dawley 
rats. Effect of olanzapine (OLZ) (2 mg/kg and 4 mg/kg) on (a) CD68 mRNA expression (b) 
IL-6 mRNA expression and (c) SREBP-1c mRNA expression in female and male rats. Data 
shown represents mean ± SEM. *p < 0.05 significantly different versus vehicle group of 
same gender. #p < 0.05, ##p < 0.01 significantly different versus OLZ (2 mg/kg) group of 
same gender. $p < 0.05, $p < 0.01 female vehicle group versus male vehicle group. 
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Liver 
Liver weight as a percentage of body weight was significantly affected by olanzapine 
treatment (F(2,42) = 4.512, p< 0.05) and gender (F(1,42) = 26.466, p < 0.001). The female rats 
treated with olanzapine (2 mg/kg) were found to have significantly increased liver weight 
compared to the vehicle treated rats (p < 0.05). No differences were observed in the male 
rats (Fig. 3.6). 
 
 
Fig. 3.6 Effect of olanzapine on liver weight in Sprague-Dawley rats. Effect of olanzapine 
(OLZ) (2 mg/kg and 4 mg/kg) on relative liver weight in female and male rats treated for 
21 days B.I.D. Data shown represents mean ± SEM. *p < 0.05 significantly different versus 
vehicle group of same gender. 
SREBP-1c mRNA expression in the liver was not affected by treatment but was 
significantly affected by gender (F(1,42) = 143.439 p < 0.001). The male and female vehicle 
treated groups differed significantly from one another (p < 0.001) (Table 3.1).  
Carbohydrate regulatory element binding protein (ChREBP) mRNA expression was 
significantly affected by gender (F(1,46) = 50.085 p< 0.001) and male vehicle treated rats 
were significantly different from female vehicle treated animals (Table3.1).  
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TNF mRNA in the liver showed no significant differences following olanzapine treatment 
(Table 3.1). 
Gender Female Male 
Olanzapine Vehicle 2 mg/kg 4 mg/kg Vehicle 2 mg/kg 4 mg/kg 
SREBP-1c 1.0±0.16 0.73±0.07 0.70±0.08 3.26±0.16* 3.57±0.33 3.42±0.44 
Chrebp  1.0±0.16 1.09±0.17 0.99±0.17 2.40±0.21* 2.67±0.26 2.70±0.47 
TNF 1.0±0.09 0.89±0.14 0.90±0.08 1.82±0.42 0.89±0.20 0.86±0.11 
Table 3.1 Effect of chronic olanzapine on hepatic gene expression in Sprague-Dawley 
rast. Relative gene expression of SREBP-1c, ChREBP and TNF in liver of olanzapine and 
vehicle treated rats. Values normalised to female vehicle group. *p < 0.01 versus female 
vehicle group SREBP= sterol regulating element binding protein,ChREBP= carbohydrate 
regulating element binding protein, TNF= tumor necrosis factor 
Plasma cytokines and leptin 
Olanzapine treatment had a significant effect on the circulating plasma levels of IL-8 
(F(2,41) = 3.613 p < 0.05). The female rats treated with olanzapine (2 mg/kg) had increased 
levels compared to vehicle treated rats (p < 0.01) (Fig. 3.7a). 
Plasma levels of TNF-α were significantly affected by gender (F(1,41) = 102.024 p < 0.001) 
and there was a significant gender X treatment interaction following olanzapine 
treatment (F(2,41) = 7.049, p < 0.01). Male rats treated with olanzapine (4 mg/kg) showed a 
reduction in circulating levels of TNF-α (p < 0.05) (Fig. 3.7b). 
Plasma IL-6 levels were significantly affected by treatment (F(1,41) = 4.005, p < 0.05), and 
gender (F(1,41) = 7.473, p < 0.01). There was a significant gender X treatment interaction 
(F(2,41) = 5.86, p < 0.01).  
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Male animals treated with olanzapine (2 mg/kg and 4 mg/kg) had lower levels of IL-6 
compared to the male vehicle treated rats (p < 0.05, p < 0.01) respectively. The vehicle 
treated male animals had significantly higher levels than female vehicle treated rats (p < 
0.01) (Fig. 3.7c). 
IL-1β plasma levels were significantly affected by gender (F(1,41) = 5.575, p < 0.05) and 
there was a significant gender X treatment interaction (F(2,41) = 4.93, p < 0.05). In the 
female rats, those receiving olanzapine (2 mg/kg) had significantly elevated levels 
compared to vehicle treated rats (p < 0.05). The male vehicle treated rats had significantly 
higher levels than the female vehicle treated rats (p < 0.01) (Fig. 3.7d). 
 
Fig. 3.7 Effect of chronic olanzapine on plasma cytokines in Sprague-Dawley rats. Effect 
of olanzapine (OLZ) (2 mg/kg and 4 mg/kg) on plasma levels of (a) IL-8 (b) TNF-α (c) IL-6 
and (d) IL-1β in female and male rats treated for 21 days B.I.D. Data shown represents 
mean ± SEM. *p < 0.05, **p < 0.01 significantly different versus vehicle group of same 
gender. $p < 0.05, $$p < 0.01, significant difference between female vehicle group and 
male vehicle group. 
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Plasma leptin levels showed a significant effect of gender (F(1,42) = 12.636, p < 0.001).  The 
male vehicle treated animals had higher levels than female vehicle treated rats (p < 0.05) 
(Fig. 3.8). 
 
 
Fig.3.8 Effect of chronic olanzapine on plasma leptin in Sprague-Dawley rats. Effect of 
olanzapine (OLZ) (2mg/kg and 4 mg/kg) on plasma levels of leptin in female and male rats 
treated for 21 days B.I.D. Data shown represents mean ± SEM. *p < 0.05 female vehicle 
group versus male vehicle group. 
Peripheral and central ghrelin 
Olanzapine significantly affected plasma levels of total ghrelin (F(2,42) = 3.143, p = 0.05). 
There was also a significant effect of gender (F(1,42) = 9.109, p < 0.01). The female rats 
treated with olanzapine (2 mg/kg) had reduced circulating levels of ghrelin (p < 0.05) and 
those receiving olanzapine (4 mg/kg) also displayed a trend for reduced levels (p = 0.068). 
No significant effects were observed between male groups (Fig. 3.9). 
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Fig. 3.9 Effect of chronic olanzapine on plasma ghrelin in Sprague-Dawley rats. Effect of 
olanzapine (OLZ) (2mg/kg and 4 mg/kg) on plasma levels of total ghrelin in female and 
male rats treated for 21 days B.I.D. Data shown represents mean ± SEM. *p < 0.05 
significantly different versus vehicle group of same gender. 
Hypothalamic expression of the Ghrelin 1a receptor mRNA was significantly affected by 
gender (F(1,35) = 13.68, p < 0.01) and there was a significant gender X treatment 
interaction (F(2,35) = 6.973, p<0.01). The male rats treated with olanzapine (4 mg/kg) had 
significantly higher levels than the vehicle treated rats (p < 0.05) (Fig. 3.10).  
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Fig. 3.10 Effect of chronic olanzapine on hypothalamic ghrelin receptor expression in 
Sprague-Dawley rats. Effect of olanzapine (OLZ) (2mg/kg and 4 mg/kg) on growth 
hormone secretagogue 1a receptor mRNA expression in the hypothalamus in female and 
male rats treated for 21 days. Data shown represents mean ± SEM. *p < 0.05 significantly 
different versus vehicle group of same gender. 
Gut Microbiota 
The effects of chronic olanzapine on the microbial composition of the gut microbiota of 
the rats was elucidated through high throughput pyrosequencing (Roche-454 Titanium) of 
16S rRNA (V4) amplicons generated from faecal DNA obtained at study termination. 
Species richness, coverage, and diversity estimations were calculated for each data set. At 
the 97% similarity level, the Shannon index, a metric for community diversity, revealed a 
high level of overall biodiversity within all samples with values exceeding 4.2. The Good’s 
coverage at the 97% similarity level ranged between 84-98% for all datasets. The Chao1 
richness values indicate good sample richness throughout. 
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Assessment of the faecal microbiota, in terms of microbial phyla, revealed that 
olanzapine treatment in the female rats seemed to be associated with increased levels of 
Firmicutes following olanzapine 2 mg/kg (72.11 % versus 84.06 %) and olanzapine 4 
mg/kg (72.11% versus 88.12%), increases of 11.95 % and15.99 % respectively. Olanzapine 
treatment of 2 mg/kg and 4 mg/kg also appeared to reduce diversity compared to vehicle 
treated rats evidenced by reductions in the less represented phyla Actinobacteria (3.72 % 
versus 0.34 and 0.15 %) respectively and Proteobacteria (1.60 % versus 0.15 and 0.77 %) 
respectively. Animals treated with olanzapine 4 mg/kg also displayed evidence of reduced 
Bacteriodetes (17.57 % versus 10.88 %) (Fig. 3.11a). 
In the male rats, olanzapine treatment (2 mg/kg) appeared to impact the microbiota 
minimally with an apparent reduction in Proteobacteria (3.15 % versus 0.94 %). 
Olanzapine treatment of 4 mg/kg however seemed to cause an increase in Firmicutes 
(82.66 % versus 91.63 %) and a reduction on Bacteriodetes of a similar magnitude (14.08 
% versus 7.97 %) (Fig. 3.11b). 
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Fig. 3.11 Effect of chronic olanzapine on faecal microbiota composition of Sprague-
Dawley rats. Proportional composition of the faecal microbiota following 21 days of 
olanzapine treatment (2 mg/kg or 4 mg/kg) in (a) Females and (b) Males. Data represents 
the cumulative DNA of one pellet per cage for each group. 
Correlation Analysis 
In order to assess the possible relationship between the main physical alterations induced 
by olanzapine treatment in our model, and possible biochemical correlates, we carried 
out correlation analysis on body weight gain and a number of biochemical plasma 
markers. For the female rats, a significant correlation was found between body weight 
gain and plasma leptin, (Pearson correlation co-efficient = 0.457, r2 =0 .205, p < 0.05) (Fig. 
3.12a). A significant correlation was also found for body weight gain and plasma ghrelin 
(Pearson correlation co-efficient = -0.429, r2 = 0.185, p < 0.05). (Fig. 3.12b). A significant 
correlation was also observed for body weight gain and plasma IL-8 levels (Pearson 
correlation co-efficient = 0.702, r2 = 0.493, p < 0.001) (Fig. 3.12c).  
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Furthermore, a significant correlation was found between visceral fat mass and plasma IL-
8 (Pearson correlation co-efficient = 0.550, r2 = 0.303, p < 0.01) (Fig. 3. 12d). 
In the male rats, no significant correlation was observed between any of the measured 
physical and biochemical parameters. 
 
 
Fig.12 Correlation analysis. Correlation between percent body weight gain at day 23 and 
(a) plasma leptin, (b) plasma ghrelin (c) plasma IL-8. (d) Represents correlation analysis 
between visceral fat and plasma IL-8.  
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3.4 Discussion 
Here we show that olanzapine had significant effects on a number of physiological, 
inflammatory and microbial parameters in the rat and that many, but not all of these 
were more pronounced in females compared to males. Olanzapine induced rapid weight 
gain in female rats and not in male rats which is consistent with previous reports (Albaugh 
et al. 2006; Choi et al. 2007). Both male and female rats treated with olanzapine did 
however exhibit increased visceral fat, though in the males this was the case only at the 
higher dose. We also show, to our knowledge for the first time, specific alterations to the 
gut microbiota as a result of antipsychotic treatment, suggesting that microbiota may 
contribute to AAPD-induced metabolic dysfunction. 
The reason for the gender difference in body weight-gain at a preclinical level is currently 
unknown and its significance to the clinical presentation of AAPD-induced metabolic 
alterations is contentious. One reason for this being that clozapine , an antipsychotic that 
also causes considerable weight gain in humans, does not appear to do so in rats (Cooper 
et al. 2008b). There is considerable evidence however to suggest that females are more 
liable to incur antipsychotic induced weight gain (Hakko et al. 2006; Aichhorn et al. 2007; 
Haack et al. 2009) although this may reflect gender differences in drug pharmacokinetics 
(Harris et al. 1995; Beierle et al. 1999). In the present study we observed a number of 
gender differences in baseline levels of the plasma cytokines IL-1β and IL-6 as well as local 
levels of IL-6 in the adipose tissue which may impact on susceptibility to the effects of 
AAPDs. Gender dimorphism in immune function including cytokine release is well 
documented and our findings suggest these may have implications for antipsychotic side-
effects (Cannon and Pierre 1997; Bao et al. 2002; Yokoyama et al. 2005).  
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The complex nature of body weight regulation may explain why we did not observe a 
dose-response relationship in weight-gain with olanzapine treatment. This is supported 
by clinical findings in which lower doses are not necessarily associated with lower weight 
gain (Citrome et al. 2009a).  The mechanisms by which olanzapine causes weight gain as 
in the female rats in this study are unclear, but are largely attributed to its diverse 
pharmacological receptor profile (Roth et al. 2003; Matsui-Sakata et al. 2005; Newcomer 
2005; Silvestre and Prous 2005; Reynolds et al. 2006). Antagonism of central receptors 
including serotonin 5-HT2C and histamine H1 receptors, which play pivotal roles in appetite 
regulation as well as long-term energy balance (Tsuda et al. 2002; Masaki et al. 2004; Lam 
et al. 2008) have been particularly implicated in weight gain associated with antipsychotic 
treatment (Reynolds et al. 2002; Kroeze et al. 2003; Reynolds et al. 2006; Deng et al. 
2010). Hyperphagia was observed in the female rats and is believed to drive initial weight 
gain (Thornton-Jones et al. 2002). This is also seen in clinical studies in which increased 
appetite is commonly reported by patients initiating olanzapine therapy (Basson et al. 
2001b; Kluge et al. 2007; Treuer et al. 2009) and in non psychotic controls (Fountaine et 
al. 2010).  
Male and female animals treated with olanzapine displayed a significant accretion of 
visceral fat. Interestingly, the female rats treated with olanzapine (4 mg/kg) returned to 
control body weight but still had increased visceral fat. Furthermore the male rats treated 
with olanzapine (4 mg/kg) did not show increases in body weight gain but did however 
show increased adiposity.  
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This finding supports clinical and pre-clinical studies which found increased adiposity 
following olanzapine treatment with (Raskind et al. 2007; Ader et al. 2008; Victoriano et 
al. 2009) and without weight gain (Victoriano et al. 2009). Increased visceral mass is 
considered a key factor in the development of the metabolic syndrome and in particular 
the development of insulin resistance (Bjorntorp 1991; Demerath et al. 2008). Thus, these 
data emphasise that the metabolic threat posed by olanzapine goes beyond merely 
increases in body weight gain.  
Gonadal adipose tissue of female rats treated with olanzapine (4 mg/kg) and male rats 
treated with olanzapine (2 mg/kg and 4 mg/kg) displayed increased CD68 expression. 
CD68 is a glycoprotein which represents a marker of macrophage presence. Macrophage 
infiltration of adipose tissue is considered a key step in the development of obesity-
related inflammation and subsequent insulin resistance (Xu et al. 2003). Interestingly, 
CD68 expression did not mirror weight gain, even in the females. Thus, this suggests that 
olanzapine can predispose toward a pro-inflammatory state independent of effects on 
bodyweight per se. This may have important connotations for patient monitoring 
following the prescription of AAPDs. 
The adipose tissue of female rats treated with olanzapine (4 mg/kg) also displayed 
inflammation with increased IL-6 gene expression. Though not significant, the male rats 
receiving olanzapine (2 mg/kg) also displayed the same trend. Like CD68, IL-6 did not 
follow the pattern of weight gain.  
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However, sorted cell gene analysis of adipose tissue has previously suggested that 
macrophages and adipocytes secrete roughly equal amounts of IL-6, thus macrophage 
infiltration indicated by elevated CD68 expression likely led to elevated IL-6 expression 
(Wisse 2004). In vitro data suggests that IL-6 can directly confer insulin resistance (Rotter 
et al. 2003) and levels are associated with increased risk of Type II diabetes (Pradhan et al. 
2001).  
This further suggests therefore that olanzapine can confer risk of such metabolic 
abnormalities without overt weight gain and that IL-6 may be one mediator of this 
disguised threat. 
The female rats further displayed a pro-inflammatory phenotype with IL-8 and IL-1β being 
significantly elevated in plasma in the olanzapine (2 mg/kg) group. Increased circulating 
levels of each of these cytokines has been associated with obesity and implicated in 
insulin resistance (Straczkowski et al. 2002; Kim et al. 2006). Conversely, male rats treated 
with olanzapine displayed an anti-inflammatory phenotype with reductions in IL-6 and 
TNF-α observed. While this is initially surprising, anti-inflammatory effects of 
antipsychotics have been recognised for some time (Chedid 1954). Olanzapine has been 
shown to suppress TNF-α and Il-6 production in mice treated with lipopolysaccharide 
(Sugino et al. 2009). This discrepancy in circulating cytokines may reflect differences in 
their primary source of the cytokines (Trayhurn and Wood 2004) which could potentially 
account for the lack of an observed increase in the males and higher dose females.  
Together, these findings imply systemic inflammation associated with olanzapine occurs 
primarily as a result of body weight gain.  
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Intriguingly, the plasma levels of IL-8 in the female rats showed a significant correlation 
with body weight gain and visceral fat mass implicating this cytokine in particular as a 
possible link between inflammation and body weight gain and vice-versa and may 
potentially be a biomarker for recognising the induction of AAPD metabolic side effects. 
This systemic inflammation may also act to impair metabolism leading to insulin 
resistance and increased risk of metabolic syndrome and diabetes as a secondary effect. 
This emphasises the double–edged risk olanzapine confers on metabolic function with 
weight gain inducing systemic inflammation and the direct actions of the drug impacting 
on local inflammatory responses both of which can converge to induce insulin resistance.  
Further disruption to normal metabolic functioning was evidenced by reductions in sterol-
regulatory binding protein-1c (SREPB-1c) gene expression in the adipose tissue of female 
rats treated with 4 mg/kg of olanzapine. SREBP-1c is a key regulatory transcription factor 
which controls a number of genes involved lipid metabolism (Ferre and Foufelle 2007). 
Reduced expression of SREBP-1c in adipose tissue has been observed in obese patients, 
and subsequent weight loss was associated with increased expression (Kolehmainen et al. 
2001). These reductions are likely to be secondary to insulin resistance, as insulin is the 
major regulator of SREBP expression. However, antipsychotics have been shown to 
activate SREBP in vitro (Ferno et al. 2006; Raeder et al. 2006; Yang et al. 2007) and in a 
recent in vivo study of risperidone(Lauressergues et al. 2010).  
A recent study also demonstrated down regulation of SREBP-1c following an initial up-
regulation after acute olanzapine treatment (Jassim et al. 2011).  
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A study of clozapine administration was also associated with acute increases in SREBP and 
associated genes followed by a sustained down regulation (Ferno et al. 2009). Thus the 
long term affects of antipsychotics on SREBP system are not yet clear but seem to involve 
feed back mechanisms and this finding further supports the theory that olanzapine can 
directly affect lipid handling in the adipose tissue and thus directly contribute to fat 
deposition and dyslipidemia independent of weight gain (Ferno et al. 2011). 
Ghrelin is an orexigenic hormone released from the stomach and is known as the hunger 
hormone as it is involved in meal initiation (Cummings et al. 2001b; Schellekens et al. 
2010). We observed reductions in plasma levels of total ghrelin in the female olanzapine 
treated rats. The effect of antipsychotics on ghrelin has not been extensively studied, 
though increased levels with prolonged treatment has been found in human patients 
(Murashita et al. 2005; Sentissi et al. 2008). In our studies negative feedback may have 
occurred as a result of hyperphagia driven centrally. Intriguingly, in humans, higher basal 
plasma levels are associated with females (Greenman et al. 2004).  
Furthermore, ghrelin levels were found to be inversely correlated with fat mass and body 
mass index in females but not males in humans (Makovey et al. 2007). It must be 
remembered that ghrelin in vivo exists as acetylated and non-acetylated forms and only 
the acetylated form can cross the blood-brain barrier and activate central ghrelin 
receptors. Also, ghrelin displays a circadian rhythm such that the time of day the animals 
were sacrificed (morning) may have affected ghrelin levels. Thus total plasma ghrelin 
levels must be interpreted carefully.  
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Hypothalamic ghrelin 1a receptor mRNA was increased in the male olanzapine (4 mg/kg) 
treated animals. Central actions of ghrelin are associated with fat deposition (Riley et al. 
2005). Thus, these results imply alterations to the ghrelin system may be one mechanism 
by which olanzapine increases visceral fat and potentially also appetite and that these 
effects may be gender sensitive. Moreover, a significant inverse correlation was found 
between plasma ghrelin and body weight gain. 
Leptin is potent anorexigenic hormone with opposing effects to those of ghrelin. Though 
not significantly elevated in the treatment groups, a significant correlation was found 
between body weight gain and plasma leptin. While changes in circulating levels of these 
hormones likely represent secondary rather than direct actions of olanzapine (Baptista 
and Beaulieu 2002), they may potentially act as important markers for those at risk for 
sustained weight gain following commencement of antipsychotic therapy and are 
important considerations in the assessment of antipsychotics metabolic impact (Sentissi 
et al. 2008).  
The composition of the gut microbiota appeared to be considerably altered following 
treatment with olanzapine in the female rats and also in the male rats receiving 
olanzapine (4 mg/kg). In the female and male rats treated with olanzapine (4 mg/kg) the 
pooled samples at day 22 show a trend for increased Firmicutes and reduced 
Bacteriodetes compared to control animals. There was also evidence of reduced diversity 
at the phylum level in these olanzapine treated groups with reduced levels of 
Proteobacteria in both females and males and reduced Actinobacteria in the females.  
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The gut microbiota contributes to metabolism firstly by utilizing indigestible complex 
polysaccharides via fermentation for their own energy and thereby producing short-chain 
fatty acids (SCFA) which can then be digested and used by the host for energy (Hooper et 
al. 2002). The microbiota is also involved in cholesterol reduction and the biosynthesis of 
vitamins that can be used by the host. It is estimated that as much as 10% of our daily 
energy supply may be provided in this way (Flint et al. 2008).  
Furthermore, in their seminal work, Gordon and colleagues showed that germ-free mice 
(mice devoid of any microbiota) had 40% less body fat than their conventional 
littermates. Furthermore, colonisation of the germ-free mice with the microbiota of lean 
control mice led to a significant increase in body fat while colonisation with the 
microbiota of genetically obese mice (ob/ob) led to an even greater level of weight gain 
(Backhed et al. 2004; Turnbaugh et al. 2006). Furthermore, germ-free mice are resistant 
to diet-induced obesity (Backhed et al. 2007). This series of experiments also revealed 
that shifts in the predominant phyla of the microbiota were associated with obesity. An 
increase in the relative abundance of Firmicutes with a concordant decrease in 
Bacteriodetes was observed (Ley et al. 2005; Turnbaugh et al. 2008). This shift was also 
found in a human study of obese versus lean twins and in a study of Type II diabetic 
patients versus non-diabetics, independent of body weight (Turnbaugh et al. 2009; Larsen 
et al. 2010). 
Thus, our findings, while preliminary, are extremely interesting as they are closely in line 
with the above and other recent studies investigating the role of the microbiota in obesity 
and energy regulation (Cani et al. 2007b; Kalliomaki et al. 2008).  
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However, whether possible alterations to the gut microbiota are a direct result of 
olanzapine treatment or secondary to other effects is unclear. It is however, tempting to 
speculate that olanzapine may have influenced the gut microbiota via as yet unknown 
mechanisms and these changes could well contribute to, or exacerbate metabolic 
dysfunction induced by AAPDs, in particular fat accumulation. If this is the case 
modulation of the gut flora by antibiotic, prebiotic or indeed probiotic therapy may 
represent a useful adjunctive therapy for olanzapine-induced weight gain in the future. 
In this study systemic inflammation occurred in a gender dependent fashion and was only 
observed in female rats, and as such likely occurred secondary to weight gain which was 
also only seen in the females. Importantly however, both the female and male rats did 
incur a number of physiologically relevant changes including increased adipose tissue, 
local inflammation and alterations to the gut microbiota.  
Thus, this study brings into focus the need to consider the side effects of antipsychotics as 
a double threat involving not only weight gain, but also independent metabolic effects 
which may include modulation of the gut microbiota. Furthermore, appreciating 
differences between the sexes may have important clinical implications in not only the 
prescribing but also the monitoring of patients in the future (Seeman 2004).  
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Abstract 
Background: Atypical antipsychotics, such as olanzapine, are associated with weight gain 
and serious metabolic side effects, the mechanisms of which are poorly understood. The 
gut microbiota has been recognised in recent times as an important factor in energy 
regulation and metabolism. Thus, we investigated if ablation of the gut microbiota could 
prevent or ameliorate any of the metabolic side effects associated with chronic 
olanzapine treatment in female Sprague-Dawley rats.  
Methods: Animals were assigned to treatment with vehicle, olanzapine (2 mg/kg/day), or 
olanzapine (4 mg/kg/day) for 21 days, I.P, twice daily. In addition, animals received either 
vehicle or an antibiotic cocktail consisting of neomycin (250 mg/kg/day), metronidazole 
(50 mg/kg/day) and polymyxin B (9 mg/kg/day) by oral gavage, daily, beginning 5 days 
prior to drug treatment. Body weight and food intake were measured daily. At the end of 
the study, uterine fat deposits were dissected and weighed and samples collected.  
Results: As expected, treatment with the antibiotic cocktail resulted in a definitively 
different overall microbiota profile. The antibiotic treatment also significantly 
ameliorated the body weight gain and uterine fat deposition induced by olanzapine. 
Olanzapine-induced alterations in the expression of the liver lipogenic gene, fatty acid 
synthase as well circulating levels of free fatty acids were normalised by the antibiotics. 
Moreover antibiotic co-administration resulted in a reduced inflammatory phenotype.  
Conclusions: These results suggest that the gut microbiome is an important factor in 
certain antipsychotic-induced metabolic side effects, and could be a novel therapeutic 
target for preventing antipsychotic-induced metabolic disease.  
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4.1 Introduction 
Olanzapine and other atypical antipsychotics offer many advantages over older 
antipsychotics both in terms of efficacy and reduced propensity for extrapyramidal 
symptoms (EPS) (Jaffe and Levine 2003). However, olanzapine is associated with serious 
metabolic side effects, including weight gain and increased visceral fat (Newcomer 2004; 
Albaugh et al. 2010), which can lead to co-morbidities such as Type II diabetes mellitus 
and cardiovascular disease (Farwell et al. 2004; Correll et al. 2009). These metabolic side 
effects also contribute to poor adherence rates in schizophrenia treatment, meaning 
there is considerable impetus to tackle these adverse effects.  
The mechanisms underlying antipsychotic-induced weight gain and metabolic dysfunction 
are not fully understood, and evidence from clinical and preclinical studies suggest that 
multiple central and peripheral mechanisms are involved; for review see (Newcomer 
2005; Boyda et al. 2010). Initial increases in body weight are primarily driven by increases 
in appetitive drive (Davoodi et al. 2009) due to antagonism of central receptors involved 
in appetite regulation including 5-HT2c, histamine H1 and dopamine D2 receptors (Matsui-
Sakata et al. 2005; Kirk et al. 2009).  
Olanzapine, and other antipsychotics, can however cause metabolic dysregulation 
independently of effects on body weight (Minet-Ringuet et al. 2006). In particular, 
increases in visceral fat mass, a key component in the development of metabolic disease, 
have been seen in the absence of overt weight gain following olanzapine treatment in 
both clinical and preclinical studies (Zhang et al. 2004; Victoriano et al. 2009).  
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The gut microbiota comprises the approximately 100 trillion bacteria (as well as fungi, 
archaea and viruses) which have co-evolved with the human host to live symbiotically in 
the gastrointestinal tract (Backhed et al. 2005b). Recently, much focus has been turned to 
this ‘microbial organ’ as technological advances have allowed more in depth analysis of 
our oldest ancestors (Fraher et al. 2012). Gordon and colleagues have demonstrated, 
using germ-free mice (mice lacking any microbiota), the critical role played by the gut 
microbiota in normal weight gain and fat deposition (Backhed et al. 2004; Backhed et al. 
2007). Germ-free mice have 40% less total body fat than conventionally raised mice, and 
are resistant to diet-induced obesity (Backhed et al. 2004; Backhed et al. 2007). 
Moreover, some studies have found a link between obesity and the composition of the 
gut flora in humans (Nadal et al. 2009; Turnbaugh et al. 2009).  
We recently demonstrated an altered faecal microbiota profile in rats chronically treated 
with olanzapine, suggesting a possible role for the gut microbiota in olanzapine-induced 
effects (Davey et al. 2012). To investigate this hypothesis further, we used a cocktail of 
broad-spectrum antibiotics to examine if ablation of the gut microbiota could prevent or 
ameliorate any of the metabolic side effects associated with olanzapine. 
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4.2 Methods  
Animals 
Female Sprague-Dawley rats, 6 weeks old and weighing approximately 200g were used 
(Harlan, UK). Female rats are used as they have been shown by us and others to better 
model the elevated weight gain induced by atypical antipsychotics than male animals 
(Arjona et al. 2004; Cooper et al. 2005; Davey et al. 2012). Animals were allowed to 
habituate to the facility for 10 days. Animals were housed 5 per cage (56x38x17 cm) and 
allowed access to standard chow and water ad libitum. Animals were maintained on a 
12h light dark cycle, lights on 7.30 am. All experiments were approved by the Animal 
Experimentation Ethics Committee (AEEC) of University College Cork and carried out in 
accordance with the Cruelty to Animals Act 1876 and European Directive 86/609/EEC on 
the protection of animals used for experimental and other scientific purposes. 
Olanzapine administration 
Olanzapine (OLZ) (Discovery Fine Chemicals, UK) was dissolved in a minimal amount of 
glacial acetic acid (approx 0.1ml), made to volume with sterile water and pH adjusted to 
6.0 with 0.1M NaOH. Animals received 2 mg/kg/d or 4 mg/kg/d. Vehicle consisted of 
sterile water acidified with 0.1 ml of glacial acetic acid and pH adjusted to 6.0 with 0.1M 
NaOH. Drug solutions were prepared fresh daily and administered via intraperitoneal 
injection, B.I.D., for 21 days with the first injection between 9:00 and 10:00 am and the 
second between 4:00 and 5:00pm. Doses of olanzapine were selected based on previous 
studies from our laboratory and others in which they were found to best represent the 
clinical setting in terms of side effects (Fell et al. 2007; Davey et al. 2012).  
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Antibiotic cocktail (ABX) 
Neomycin (250 mg/kg), metronidazole (50 mg/kg) (Discovery Fine Chemicals, UK) and 
polymyxin B (9 mg/kg) (Sigma-Aldrich, Switzerland) were dissolved in sterile water and 
sonicated for 10 minutes to ensure complete dissolution. The antibiotic cocktail (ABX) was 
administered once daily per os in a volume of 4 ml/kg and was prepared fresh daily. 
Selection of antibiotics and doses was based on studies carried out to sterilise the gut of 
rats undergoing gastrointestinal surgery(Juno et al. 2003).  
Treatment groups 
Animals received either vehicle or antibiotic cocktail for 5 days prior to the 
commencement of olanzapine treatment and on all subsequent days. Animals received 
olanzapine (OLZ) (2 mg/kg/d), olanzapine (4 mg/kg/d) or vehicle (VEH) for 21 days. Hence, 
there were 6 treatment groups; VEH+VEH, VEH+ABX, OLZ (2 mg/kg)+VEH, OLZ (2 
mg/kg)+ABX, OLZ (4 mg/k)+VEH and OLZ (4 mg/kg)+ABX. Groups were weight matched 
prior to study commencement. n = 9/10. 
Sample collection 
All animals were fasted overnight (16 hours) prior to sacrifice. Uterine fat was quickly and 
carefully dissected and weighed to the nearest 0.001g. Trunk blood was collected in EDTA 
coated tubes and centrifuged at 6000 rpm for 15 minutes at 4oC. Plasma supernatant was 
then aliquoted and frozen. A sample of uterine fat and frontal lobe of the liver were snap-
frozen. All samples were stored at -80oC for later analysis. 
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Gut microbiota analysis 
For analysis of the microbial community composition, total DNA was extracted from 
faecal pellets, collected directly from the rats one day prior to sacrifice (n=6), using the 
QIAamp DNA stool mini kit (Qiagen, West Sussex, UK), coupled with an initial bead-
beating step. Universal 16SrRNA primers, designed to amplify from highly conserved 
regions corresponding to those flanking the V4 region, i.e. forward primer F1 (5’-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1 (5’-
TACCRGGGTHTCTAATCC), R2 (5’-TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing 
Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp) were used for Taq-based PCR 
amplification. Sequencing was performed on a Roche 454 GS-FLX using Titanium 
chemistry by the Teagasc454 Sequencing Platform. Resulting reads were quality trimmed, 
clustered, aligned and checked for chimeras using the Qiime suite of tools. A phylogenetic 
tree was generated using the FastTree package and principal coordinate analysis (PCoA), 
measuring dissimilarities at phylogenetic distances based on unweighted Unifrac analysis, 
was performed with Qiime.  
Plasma analysis 
Insulin was measured using a commercially available enzyme-linked immunosorbent 
assay (ELISA) (Mercodia, Sweden). Glucose was measured using a colorimetric assay 
(Bioassays, US). The quantitative insulin sensitivity check index (QUICKI) was calculated as 
the inverse log of the sum of fasting plasma insulin and fasting plasma glucose (Katz et al. 
2000).  
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Plasma free fatty acids were measured using a commercially available colometric assay 
(Bioassay Systems, U.S.). All samples were analysed in duplicate. 
Gene expression analysis 
Total RNA was extracted using a commercially available kit (Qiagen, US). mRNA was 
reverse transcribed using a high capacity cDNA reverse transcription kit (Applied 
Biosystems, US) in a G-Storm thermocycler (G-Storm, UK). Gene expression was analysed 
by qualitative real-time PCR using TaqMan Gene expression assays and the AB7300 
system (Applied Biosystems). The expression of each gene was normalised to β-actin. All 
samples were analysed in triplicate.  
Statistical analysis 
Data are expressed as mean  SEM. Body weight change and food intake were analysed 
using two-way repeated measures ANOVA and a Greenhouse-Geisser sphericity 
correction was applied. Two-way ANOVA was used for analysis of uterine fat, gene 
expression, QUICKI score and cytokine levels. Where a significant overall effect was 
observed, further analysis was carried with Fisher’s Least Significant Difference test. A p 
value < 0.05 was considered statistically significant. LSD was selected as an appropriate 
post-hoc test due the relatively small N numbers and expected effect sizes.   
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4.3 Results 
Body weight 
Olanzapine (OLZ) administration had a significant effect on body weight change (F(2,52) = 
8.32, p = 0.001). Antibiotic treatment (ABX) did not have a significant overall effect on 
body weight change but there was as a significant OLZ x ABX interaction (F(2,52) = 6.63, p < 
0.05).  
Animals treated with VEH+ABX had significantly greater weight gain compared to rats 
receiving VEH+VEH on days 8 and 12 (Fig. 4.1A). Furthermore, rats treated with OLZ (2 
mg/kg)+VEH had significantly greater weight gain compared to animals receiving OLZ (2 
mg/kg)+ABX on days 8-21 inclusive (p < 0.05) (Fig. 4.1B). Animals receiving OLZ (4 
mg/kg)+VEH displayed greater weight gain than those receiving OLZ (4 mg/kg)+ABX on 
days 11-16 inclusive (p < 0.05) (Fig. 4.1C).  
Area under the curve analysis demonstrated that the animals receiving OLZ (2 
mg/kg)+VEH showed significantly greater weight gain overall compared to VEH+VEH (p < 
0.001) as well as OLZ (2 mg/kg)+ABX treated rats (p < 0.05). Furthermore, rats treated 
with OLZ (4 mg/kg) + VEH had significantly greater increases in weight overall compared 
to VEH + VEH treated animals (p < 0.001) (Fig. 4.1D). 
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Fig. 4.1 Effect of olanzapine co-administered with an antibiotic cocktail on body weight. 
Percentage body weight change from baseline following administration of (A) vehicle 
(VEH) + vehicle or VEH + antibiotic cocktail (ABX) (B) olanzapine (OLZ) (2 mg/kg) with or 
without co-administration of ABX (C) olanzapine (4 mg/kg) with and without co- 
administration of ABX. (D) Area under the curve values for all treatment groups. Data 
analysed by Two-way ANOVA as 6 groups and represented separately for graphical 
reasons. *p < 0.05, *** p < 0.01, #p < 0.05 versus OLZ (2 mg/kg)+ABX. Data expressed as 
mean ± SEM. 
Food Intake 
There was significant effect of OLZ administration on food intake (F(2,66) = 37.25, p < 
0.001). There was no overall effect of antibiotic(ABX) treatment, however, there was a 
significant OLZ x ABX interaction (F(2,66) = 18.69, p = 0.01). Food intake was also 
significantly affected by Time (F(3,198) = 53.31, p < 0.001), and there was a significant Time 
x OLZ interaction (F(6,198) = 8.96, p < 0.001), and a significant Time x ABX interaction (F(3,198) 
= 13.19, p < 0.001).  
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Post-hoc analysis revealed that all animals treated with ABX had significantly reduced 
food intake compared to animals receiving VEH+VEH between days -5 and 0(p < 0.01) 
(Fig. 4.2). During the first week of olanzapine treatment (days 1-6 inclusive) animals 
receiving OLZ (2mg/kg)+VEH or OLZ (4 mg/kg)+VEH displayed significantly increased food 
intake compared to VEH + VEH treated rats (p < 0.001). Animals receiving olanzapine (2 
mg/kg)+ABX or olanzapine (4 mg/kg)+ABX also showed increased food intake during this 
period compared to animals receiving VEH+ABX (p < 0.01 and p < 0.001) respectively. 
Animals receiving OLZ (2 mg/kg)+VEH or OLZ (4 mg/kg) + VEH further displayed increased 
food intake between days 7 and 13 compared to VEH + VEH treated rats(p < 0.05,p < 
0.001) (Fig.4.2). 
Fig. 4.2 Effect of olanzapine co-administered with an antibiotic cocktail on food intake. 
Effect of vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or OLZ (4 mg/kg) co-administered with 
vehicle (VEH) or an antibiotic cocktail (ABX) on food intake. **p<0.01, ***p< 0.001 versus 
VEH+VEH. ##p< 0.01 ###p < 0.001 versus VEH+ABX. Data represent mean ± SEM. 
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Faecal output  
None of the groups showed signs of diarrhoea, as measured by the number and 
consistency of pellets produced, with all groups having an average faecal output of < 0.5 
pellets over a 30 minute period (data not shown). 
Microbiota profile 
Following total genomic DNA extraction, a total of 60,276 pyrosequencing reads from the 
V4-V5 region of 16S rRNA gene were generated with 454 sequencing, representing an 
average of 1487 reads per sample. Rarefaction analysis, using both Shannon diversity and 
Chao1 distances, indicated sufficient depth of sequencing (data not shown). Principal-
coordinate analysis (PCoA), based on unweighted Unifrac distance revealed that all three 
groups receiving the antibiotic cocktail had co-clustered, showing an altered overall gut 
microbiota, compared with the three groups who did not receive the cocktail (Fig. 4.3). 
More specifically, PCoA plots demonstrate a distinct gut microbiota composition of 
groups receiving the antibiotic cocktail versus those who did not. 
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Fig 4.3. Effect of olanzapine co-administered with an antibiotic cocktail on the overall 
microbiota profile. Principle coordinate analysis of each sample showing the clustering of 
animals receiving the antibiotic cocktail (squares) compared to those not (circles). clear= 
vehicle(VEH), pink = olanzapine (OLZ) (2 mg/kg) purple= OLZ (4 mg/kg) 
Further analysis of the specific microbiota composition showed that olanzapine 2 mg/kg 
and 4 mg/kg treated rats had a trend for increased Firmicutes (82.9% and 79.4%) 
respectively, compared to VEH+VEH treated animals (76.5%). Olanzapine treated animals 
also had a concomitant trend for decreased Bacteriodetes (10.0% and 10.6% compared to 
14.3%) (Fig. 4.4). 
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Administration of the antibiotic cocktail was associated with a dramatic reduction in 
Firmicutes compared to vehicle treated rats (57.6% versus 76.5%).  
This reduction was also seen between OLZ+VEH and OLZ ABX treated groups (82.9% vs. 
66.7%) and (79.4% vs. 64.8%) for 2 mg/kg and 4 mg/kg doses, respectively (Fig 4.4). 
 
Fig. 4.4 Effect of olanzapine co-administered with an antibiotic cocktail on microbiota 
composition in Sprague-Dawley rats. Percent abundance of the major phyla in the faecal 
microbiota of rats treated for 21 days with olanzapine(OLZ) with and without co-
administration of an antibiotic cocktail (ABX). 
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Adipose Tissue 
Uterine Fat Weight 
OLZ administration had a significant effect on uterine fat mass (F(2,52) = 14.553, p <0.001) 
and when measured as a percentage of body weight (F(2,52) = 13.24, p < 0.001). ABX 
treatment also had a significant effect on real values (F(1,52) = 40.753, p < 0.001) and as a 
percentage of body weight (F(1,52) = 44.93, p < 0.001).  
Post-hoc analysis revealed that animals treated with VEH+ABX had significantly less 
uterine fat compared to those receiving VEH+VEH (real value, p < 0.05, % value p < 0.01). 
Animals receiving OLZ (2 mg/kg)+VEH and those receiving OLZ (4 mg/kg)+VEH displayed 
increased levels of uterine fat compared to VEH+VEH treated rats (p < 0.05 and p < 0.01 
respectively for both real and % values). Furthermore, the OLZ (2 mg/kg)+ABX treated 
animals had significantly lower uterine fat than the OLZ (2 mg/kg)+VEH group (p < 0.05 for 
both real and % values). Similarly, the OLZ (4 mg/kg)+ABX treated animals had 
significantly less uterine fat compared to OLZ (4 mg/kg)+VEH treated rats (p < 0.01 for 
both real and % value) (Fig. 4.5A). 
CD68 Expression 
CD68 expression was significantly increased by OLZ (F(2,52) = 5.55, p , 0.01). Post-hoc 
analysis showed that the animals receiving OLZ (2 mg/kg)+VEH or OLZ (4 mg/kg)+VEH had 
significantly increased expression of CD68 compared to VEH+VEH treated rats (p < 0.05). 
However, the OLZ (2 mg/kg)+ABX treated rats had significantly lower expression 
compared to OLZ (2 mg/kg)+VEH, and there was a similar trend between the OLZ (4 
mg/kg)+ABX and OLZ (4 mg/kg)+VEH groups (p = 0.06) (Fig. 4.5B). 
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Fig. 4.5 Effect of olanzapine and antibiotic cocktail gene expression in adipose tissue.  
Effect of vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or OLZ (4 mg/kg) co-administered with 
vehicle (VEH) or an antibiotic cocktail (ABX) on (A) Uterine fat percentage and (B) CD68 
mRNA expression in adipose tissue. *p < 0.05, **p < 0.01 compared to the VEH+VEH 
group. #p < 0.05, ##p < 0.01 versus ABX treated animals receiving same dose of olanzapine. 
$p < 0.05 versus VEH+ABX group. Data represent mean ± SEM. 
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Liver gene expression 
Sterol-regulatory element binding protein (SREBP) 1c expression in the liver was 
significantly affected by both OLZ (F(2,52) = 5.45, p < 0.001) and ABX treatment (F(1,52) = 
6.79, p < 0.05).  
Post-hoc analysis revealed that the OLZ (2 mg/kg)+ABX and OLZ (4 mg/kg)+ABX treated 
animals had significantly increased expression compared to the VEH+ABX treated rats (p < 
0.05). Furthermore, the OLZ (2 mg/kg)+ABX treated group had significantly increased 
expression compared to OLZ (2 mg/kg)+VEH group (p < 0.05). The OLZ (4 mg/kg)+ABX 
treated group also had significantly increased expression levels compared to OLZ (4 
mg/kg)+VEH (p < 0.05) treated rats (Fig. 4.6A). 
The expression of fatty acid synthase (FAS) was significantly affected by OLZ 
administration (F(2,52) = 3.09 p = 0.05) and ABX treatment (F(1,52) = 6.72, p < 0.05). There 
was also a significant OLZ x ABX interaction, (F(2,52) = 4.05, p < 0.05). Further analysis 
revealed OLZ (2 mg/kg)+VEH and OLZ (4 mg/kg)+VEH treated animals had significantly 
increased expression compared to VEH+VEH treated rats (p < 0.05). The animals receiving 
OLZ (2 mg/kg)+VEH displayed significantly increased expression compared to OLZ (2 
mg/kg)+ABX treated rats (p < 0.05). Similarly, the animals treated with OLZ (4 
mg/kg)+VEH had increased levels compared to those receiving OLZ (4 mg/kg)+ABX (p < 
0.05) (Fig. 4.6B). 
The expression acetyl Co-A carboxylase (ACC) was also significantly affected by both OLZ 
administration (F(2,50) = 4.74, p < 0.05) and ABX treatment F(1,50) = 7.99, p < 0.01). The OLZ 
x ABX interaction did not quite reach significance however, F(2,50) = 2.99, p = 0.059). 
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Post-hoc analysis revealed that the animals receiving OLZ (2 mg/kg)+ABX or OLZ (4 
mg/kg)+ABX had significantly increased expression of ACC compared to the VEH+ABX 
treated group (p < 0.01).  
Furthermore, the OLZ (2 mg/kg)+ABX treated rats had increased levels compared to OLZ 
(2mg/kg)+VEH (p < 0.05) and similarly the OLZ (4 mg/kg) +ABX had increased levels 
compared to OLZ(4 mg/kg)+VEH treated rats (p < 0.05) (Fig. 4.6C). 
 
Fig. 4.6 Effect of olanzapine co-administered with an antibiotic cocktail on gene 
expression in the liver. Effect of vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or OLZ (4 
mg/kg) co-administered with vehicle (VEH) or an antibiotic cocktail (ABX) on (A) sterol 
regulatory binding protein-1c (SREBP-1c) (B) fatty acid synthase (FAS) and (C) acetyl Co-A 
carboxylase (ACC) expression in the liver.*p< 0.05 versus VEH+VEH, $p< 0.05 versus 
VEH+ABX, #p < 0.05 versus same drug dose + VEH. Data represent mean ± SEM.   
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Plasma Profile 
Quantitative Insulin Sensitivity Check Index (QUICKI) 
OLZ administration significantly affected QUICKI score (quantitative insulin sensitivity 
check index) (F(2,49) = 22.70, p < 0.001). Post-hoc analysis revealed that the animals 
receiving OLZ (2 mg/kg)+VEH or OLZ (4 mg/kg)+VEH had significantly lower QUICKI scores 
compared to the VEH+VEH treated rats (p < 0.001). Furthermore, the animals that 
received OLZ (2 mg/kg)+ABX or OLZ (4 mg/kg)+ABX also had reduced QUICKI scores 
compared to both the VEH+VEH group (p < 0.001, p < 0.05 respectively) and the VEH + 
ABX treated rats (p < 0.05) (Fig. 4.7A).  
Free Fatty Acids (FFA) 
OLZ treatment had a significant effect on plasma free fatty acids (FFA) (F(2,50) = 6.393, p < 
0.01). Further analysis showed that animals receiving OLZ (2 mg/kg)+VEH or OLZ (4 
mg/kg)+VEH had significantly elevated levels of free fatty acids compared to VEH+VEH (p 
< 0.01 and P < 0,05 respectively). Animals receiving OLZ (2 mg/kg)+VEH also had increased 
levels compared to the OLZ (2mg/kg)+ABX treatment group (p < 0.05) (Fig. 4.7B). 
Cytokines 
Plasma levels of tumour necrosis factor (TNF) were significantly affected by OLZ 
administration, (F(2,52) = 5.20, p < 0.01) and there was a non-significant trend for an OLZ x 
ABX interaction, (F(2,52) = 2.71, p = 0.07). Further analysis revealed that the animals 
receiving OLZ (4 mg/kg)+VEH had significantly elevated levels compared to both the 
VEH+VEH and the OLZ (4 mg/kg)+ABX treated rats (p < 0.05) (Fig. 4.7C). 
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Plasma interleukin (IL)-1β levels were significantly affected by ABX treatment (F(1,52) = 
26.66, p < 0.001) and there was a significant OLZ x ABX interaction, (F(2,52) = 5.90, p < 
0.01). Post-hoc analysis revealed that the animals receiving OLZ (4 mg/kg)+VEH had 
significantly elevated levels compared to both the VEH+VEH group (p < 0.05) and the OLZ 
(4 mg/kg)+ABX treated rats (p < 0.01) (Fig. 4.7D). 
 
Fig.4. 7 Effect of olanzapine and antibiotic cocktail on metabolic parameters in plasma. 
Effect of vehicle (VEH), olanzapine (OLZ) (2 mg/kg) or OLZ (4 mg/kg) co-administered with 
vehicle (VEH) or an antibiotic cocktail (ABX) on (A) Plasma free fatty acids (FFA), (B) 
Quantitative Insulin Sensitivity Check Index (QUICKI) scores, (C) plasma TNF levels and (D) 
plasma IL-β levels. *p < 0.05,***p < 0.001 compared to VEH+VEH group, #p < 0.05 versus 
OLZ (of same dose)+ABX , $p < 0.05 compared to VEH+ABX group. Data expressed as mean 
± SEM. 
.   
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4.4 Discussion 
In the present study, olanzapine induced rapid body weight gain and significant accretion 
of visceral fat in line with previous reports (Fell et al. 2007; Davey et al. 2012). Herein, we 
show that a combination of broad spectrum antibiotics attenuates certain clinically 
relevant side effects of olanzapine in an animal model. This novel finding supports recent 
work showing antibiotic treatment can prevent weight gain in diet-induced obesity 
models in mice (Cani et al. 2008; Murphy et al. 2012).  
Importantly, we demonstrated using 454 pyrosequencing that the antibiotic cocktail 
resulted in markedly different overall microbiota profile which clustered distinctly and 
separately from the microbiota of animals not receiving the antibiotics.  
Moreover, the composition of faecal microbiota of olanzapine-treated rats showed a 
trend for increases in the phyla Firmicutes and concomitant decreases in Bacteriodetes, a 
trend observed previously (Davey et al. 2012). Whether such changes are a direct result 
of antipsychotic treatment or indicative of an obese phenotype is unclear, however 
similar shifts in the major phyla of the microbiota have been associated with weight gain 
in animal and human studies (Ley et al. 2005; Turnbaugh et al. 2009). Due to the diversity 
of the microbiota at species level, and the fact that many functions are conserved across 
phyla, whether these changes in our and other studies are pathogenic or merely 
indicative of metabolic dysfunction remains to be determined (Conterno et al. 2011). This 
said, these alterations to the gut flora support the theory that the microbiota has a 
functional role to play in metabolic complications associated with olanzapine. 
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In further support of this theory, the antibiotic cocktail, which ameliorated weight gain, 
was associated with the opposite trend with decreases Firmicutes and increases 
Bacteriodetes observed. Hence, with increasing evidence and impetus being focused on 
the microbiome-gut brain axis (Bravo et al. 2011; Cryan and O'Mahony 2011; Cryan and 
Dinan 2012), these data highlight the emerging potential for adjunctive therapies which 
more specifically target the gut microbiota to ameliorate antipsychotic-induced weight 
gain. 
The mechanisms underlying the prevention of body weight gain observed in this study 
appear to be independent of food intake as the antibiotic cocktail did not reduce food 
consumption over the course of olanzapine treatment. The reduction in body weight was 
therefore most likely accounted for by a reduction in fat mass, as the antibiotic cocktail 
prevented increases in uterine fat. This is particular relevant to the clinical setting as 
increased visceral fat is a key determinant in the development of insulin resistance and 
the metabolic syndrome (Jensen 2008). While the uterine fat represents are relatively 
small proportion of the overall fat mass, it is one of the major visceral deposits and is 
commonly used as representative of visceral fat in rodents (Coccurello et al. 2008; Amuzie 
et al. 2011). 
An intriguing temporal element was observed as the antibiotic cocktail resulted in 
amelioration of weight gain for both doses of olanzapine initially, but only the lower, 2 
mg/kg, dose by the study’s end. This discrepancy is possibly due to subsiding weight gain 
observed for the higher olanzapine dose in the final week of treatment, a phenomenon 
previously observed (Davey et al. 2012).  
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Interestingly, reduced fat mass was also seen in animals receiving antibiotics only, in line 
with germ-free studies (Backhed et al. 2004).  
While this may seem paradoxical, as these animals also displayed a trend for increased 
body weight, it is worth noting this phenomenon has been utilised in the agricultural food 
industry for many decades, as low-dose antibiotics have been used and abused as growth 
promoters in to produce larger, leaner animals (Kamphues 1999).  
The adipose tissue is intimately involved in the development of metabolic syndrome in 
part due to its ability to release a number of pro-inflammatory mediators both locally and 
systemically (Fantuzzi 2005). A crucial step in this inflammatory process is the recruitment 
of macrophages which infiltrate the fat tissue and together with the adipocytes release 
pro-inflammatory cytokines including IL-6 and TNF (Weisberg et al. 2003). We found 
increased expression of CD68, a macrophage marker, in the adipose tissue of animals 
receiving olanzapine but not in those receiving both olanzapine and the antibiotic 
cocktail. The reason for macrophage infiltration is not clear though it may be the result of 
adipose tissue hypertrophy, as dying adipocytes release signals that recruit macrophages 
(Cinti et al. 2005). Thus, by preventing increases in fat mass, antibiotics may indirectly 
prevent macrophage infiltration and the subsequent pro-inflammatory response.  
This reduction in adipose inflammation was also reflected systemically, as the antibiotic 
treated rats did not display the increases in circulating TNF or IL-6 observed in response 
to the higher, 4 mg/kg dose of olanzapine. 
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The molecular mechanisms underlying the microbiota’s role in fat deposition have been 
investigated in other models including germ-free, diet-induced and genetically obese 
(ob/ob) mice (Backhed et al. 2004; Turnbaugh et al. 2006; Murphy et al. 2010).  
Some studies have indicated that the microbiota can influence the expression of a 
number of lipogenic genes ultimately resulting in increased triglyceride synthesis which 
are subsequently stored in adipocytes (Cani and Delzenne 2009).  
Antibiotic treatment prevented olanzapine-induced increases in one such gene, fatty acid 
synthase (FAS). Increased FAS expression was recently associated with another 
antipsychotic, risperidone (Lauressergues et al. 2010). Increased expression of SREBP-1c 
and ACC-1 were only observed in animals receiving both olanzapine and antibiotics. This 
is contrary to what one might expect, and may be the result of a positive feedback 
mechanism due to a reduction in short chain fatty acids (SCFA) being absorbed in the 
antibiotic treated animals, or the fact the animals were fasted overnight, which is known 
to decrease SREBP-1c expression in the rat (Gosmain et al. 2005).  
Increased levels of circulating FFA were found in association with olanzapine treatment in 
line with previous reports of both patients (Wang et al. 2006) and animals (Jassim et al. 
2012) and moreover these increases were prevented by antibiotic treatment. Increased 
plasma levels FFA are correlated with obesity in humans and involved in the pathogenesis 
of metabolic dysfunction in part by stimulating lipogenic enzymes in the liver (Pegorier et 
al. 2004).  
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As such, effects of antibiotic administration on FFA, lipogenic genes and on visceral fat 
highlights that the gut microbiota can influence the full cycle of energy metabolism and 
thereby play a role in the spectrum of metabolic dysfunction associated with certain 
antipsychotics.  
Additionally, we used the quantitative insulin sensitivity check index (QUICKI) as a 
measure of insulin sensitivity as this model is viewed as the most appropriate for animal 
models, especially when estimating whole-body insulin resistance (Cacho et al. 2008). 
Insulin resistance represents the pathogenic hallmark of metabolic syndrome and type II 
diabetes mellitus and glucose dysregulation and insulin resistance have been associated 
with olanzapine treatment in clinical and preclinical studies (Houseknecht et al. 2007; 
Smith et al. 2009). We found that olanzapine treatment resulted in reduced insulin 
sensitivity in support of previous studies (Houseknecht et al. 2007; Smith et al. 2009). 
While not statistically significant, there was evidence to suggest that the antibiotic 
treatment improved insulin sensitivity. This possibility is supported by work in which 
antibiotic treatment ameliorated insulin resistance (Cani et al. 2008). 
There are potentially other mechanisms involved in the observed effects of the 
antibiotics, including pharmacokinetics as considerable alteration of the gut flora as in 
this potentially impacts drug absorption and metabolism. Hence, active levels of the drug 
may have diminished, and moreover, interventions such as this one could therefore 
conceivably impact on the efficacy of the antipsychotic, a concern that warrants 
investigation in the future.  
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Of course, widespread use of broad-spectrum antibiotics as an adjunctive therapy cannot 
be advocated due to the well-known problem of antibiotic resistance. Moreover, ablating 
the gut flora inevitably has other consequences that can lead to gastrointestinal 
problems, such as diarrhoea, resulting in weight loss. In the present report however, 
assessment of faecal output should no signs of any such effects (Data not shown). 
Future studies, such as caecal transplant of olanzapine-treated rats to rats that have 
received antibiotics, may provide further elucidation of the scale of the contribution of 
the microbiota in antipsychotic-induced metabolic dysfunction, as similar methods have 
been used to demonstrate the microbiota’s role in both obesity and stress (Turnbaugh et 
al. 2008; Bercik et al. 2012).  
Clinical data supporting this hypothesis do not exist at present, this is most likely due to a 
lack of investigation, and antibiotic administration administered in normal clinical practice 
to patients receiving antipsychotics would be unlikely to produce effects such as those 
described herein. However, further understanding of the full metagenomic potential of 
specific members of the microbiota may allow for a safer and more targeted approach.  
We have recently shown that olanzapine impacts on the gut microbiota and hypothesised 
that this may contribute to its metabolic liabilities including weight gain and increased 
visceral fat (Davey et al. 2012). Taken together, these findings represent an exciting 
proof-of-principle that manipulation of the gut flora potentially represents a new 
therapeutic strategy for tackling the serious clinical problem of antipsychotic-induced 
metabolic dysfunction.  
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Furthermore, the emergence of probiotic-based as potential therapies for a variety of 
medical conditions including obesity (Clarke et al. 2012; Mallappa et al. 2012) encourages 
the development of such strategies for not only antipsychotic-induced weight gain but 
obesity and the metabolic syndrome in general.  
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Abstract 
Background: Olanzapine is associated with a number of detrimental metabolic side 
effects including weight gain and visceral fat deposition. The mechanisms of these side 
effects, as well as effective ways to combat them, remain mostly elusive. The gut 
microbiota is now recognised as a major physiological regulator of certain aspects of 
metabolism including fat deposition. Moreover, we have demonstrated that olanzapine is 
associated with an altered faecal microbial profile in rats and that the microflora is 
required for some aspects of olanzapine-induced metabolic dysfunction.  
Methods: Female Sprague-Dawley rats were administered olanzapine (2 mg/kg/d) or 
vehicle by intraperitoneal injection twice daily. Animals also received one of vehicle, 
rifaximin (30 mg/kg) or vancomycin (50 mg/kg) per os for 26 days, beginning 5 days prior 
to the commencement of antipsychotic treatment. Body weight and food intake were 
monitored daily. Liver, adipose, and caecal contents were collected, frozen and later 
analysed.  
Results: Rifaximin, but not vancomycin, attenuated olanzapine-induced weight gain. 
Rifaximin and vancomycin both prevented olanzapine-induced increases in uterine fat 
mass and liver weight. Olanzapine administration was associated with alterations in the 
gut flora including increases in Actinobateria which was reversed by rifaximin treatment, 
while vancomycin profoundly altered the microbiota including reductions in the 
abundance of Firmicutes.  
Conclusions: These data further demonstrate the potential of the gut microbiota as a 
therapeutic target for antipsychotic-induced side effects.   
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5.1 Introduction 
The gut flora, or microbiota, represents the circa 100 trillion microorganisms that inhabit 
the gastrointestinal tract (Lupp and Finlay 2005) and is extremely consistent across 
mammals (Ley et al. 2008b). The gut microbiota, comprising mainly bacteria, has co-
evolved with the human host to occupy this environmental niche in a manner that is 
mutually beneficial (Ley et al. 2008b).  
The role of the gut microbiota in energy regulation and metabolism has received much 
attention and produced compelling results. Studies utilising several animal models 
including germ-free, genetically obese (ob/ob) and diet-induced obesity have elegantly 
demonstrated the significant influence the microbiota can have on metabolism, fat 
deposition, body weight and insulin resistance (Backhed et al. 2004; Backhed et al. 2005b; 
Backhed et al. 2007; Turnbaugh et al. 2008; Membrez et al. 2010).  
The mechanisms behind the microbiota’s influence on metabolism are multiple, 
interlinked and not fully elucidated. They include the fermentation of otherwise 
indigestible polysaccharides to absorbable short chain fatty acids (scfa) (Macfarlane and 
Macfarlane 2003), which contribute up to 10% of ones daily energy intake (Flint et al. 
2008). Furthermore, the microbiota can affect inflammatory processes (Souza et al. 2004; 
Maslowski et al. 2009) and expression of key genes involved in lipogenesis in the liver and 
adipose tissue (Backhed et al. 2007). 
Atypical antipsychotics are the mainstay of treatment for schizophrenia and other 
schizoaffective disorders.  
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These drugs are associated with a myriad of metabolic complications including weight 
gain, increased visceral fat and insulin resistance (Allison et al. 1999; Newcomer 2007; 
Newcomer et al. 2009). Such side effects are a major clinical problem due to the 
development of co-morbidities such as Type II diabetes mellitus and cardiovascular 
disease, as well as contributing to patient non-adherence to treatment (Osby et al. 2000; 
Starrenburg and Bogers 2009). Moreover, at present, preventative or interventive 
therapies to tackle these side effects are lacking. 
Thus, given the emerging evidence implicating the microbiota in a number of animal 
models of obesity, we investigated the possible role of the microbiota in a drug-induced 
obesity model using the atypical antipsychotic, olanzapine, which, alongside clozapine, is 
one of the two antipsychotics most associated with weight gain and metabolic 
dysfunction (Allison et al. 1999).   
We recently demonstrated that olanzapine treatment in the rat is associated with an 
altered faecal microbiota profile (Davey et al. 2012) and that ablation of the microbiota 
prevents certain metabolic adverse effects induced by olanzapine (Davey et al., 
submitted).  
Rifaximin is a semi-synthetic analogue of rifampacin and is known to target both Gram 
positive and Gram negative bacteria (Scarpignato and Pelosini 2005). Vancomcyin is a 
glycopeptide antibiotic and specifically targets Gram positive bacteria (Nagarajan 1991). 
Vancomycin was recently associated with reduced weight gain in diet-induced obese mice 
(Murphy et al. 2012) further supporting this approach.  
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In the present study, we therefore investigated if rifaximin or vancomycin, two non-
absorbable antibiotics could attenuate olanzapine-induced weight gain or associated 
complications.  
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5.2 Methods 
Animals 
Female Sprague-Dawley rats, 6 weeks old and weighing approximately 200g were used 
(Harlan, UK). Animals were allowed to habituate to the facility for 10 days. Animals were 
housed 5 per cage (56x38x17 cm) and allowed access to standard chow and water ad 
libitum. Animals were maintained on a 12h light dark cycle, lights on 7.30 am. All 
experiments were approved by the Animal Experimentation Ethics Committee (AEEC) of 
University College Cork and carried out in accordance with the Cruelty to Animals Act 
1876 and European Directive 86/609/EEC on the protection of animals used for 
experimental and other scientific purposes. 
Drugs 
Olanzapine (OLZ) (Discovery Fine Chemicals, UK) was dissolved in a minimal amount of 
glacial acetic acid (approx 0.1ml), made to volume with sterile water and pH adjusted to 
6.0 with 0.1M NaOH. Animals received 2 mg/kg/d via inter-peritoneal injection, B.I.D., 
with the first injection at approximately 9:00 am and the second at approximately 4:30 
pm. This dose regimen was selected based on previous reports by our lab and others 
showing its effects are in line with those observed in the clinic.(Fell et al. 2007; Weston-
Green et al. 2011a; Davey et al. 2012). Vehicle (VEH) consisted of sterile water acidified 
with a minimal amount of glacial acetic acid and pH adjusted to 6.0 with 0.1M NaOH. 
Rifaximin (RIF), 30 mg/kg (Sigma, UK) and vancomycin (VAN), 50 mg/kg (Sigma, UK) were 
dissolved in sterile water and briefly sonicated to ensure complete drug dissolution. 
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Animals received antibiotics per os once daily at approximately 12:00 noon. Vehicle (VEH) 
consisted of sterile water. 
Daily Measurements 
Body weight and food intake were measured daily, in the morning, to the nearest 0.01g 
using an electronic balance. 
Sample collection 
Immediately following sacrifice, liver and caecal contents were removed and weighed, 
with a portion of the frontal lobe being frozen along with the caecal contents. Peri-
uterine fat tissue was carefully dissected and weighed, a small portion of which was then 
frozen.  
Gut microbiota analysis 
For analysis of the microbial community composition, total DNA was extracted from 
caecal contents, collected aseptically immediately following sacrifice, using the QIAamp 
DNA stool mini kit (Qiagen, West Sussex, UK), coupled with an initial bead-beating step. 
Universal 16SrRNA primers, designed to amplify from highly conserved regions 
corresponding to those flanking the V4 region, i.e. the forward primer F1 (5’-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1 (5’-
TACCRGGGTHTCTAATCC), R2 (5’-TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing 
Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp) were used for Taq-based PCR 
amplification.  
181 
 
Sequencing was performed on a Roche 454 GS-FLX using Titanium chemistry by the 
Teagasc454 sequencing platform. Resulting reads were quality trimmed, clustered, 
aligned and checked for chimeras using the Qiime suite of tools. A phylogenetic tree was 
generated using the FastTree package and principal coordinate analysis (PCoA), 
measuring dissimilarities at phylogenetic distances based on unweighted Unifrac analysis, 
was performed with Qiime.  
Gene analysis 
RNA from adipose and liver samples was extracted for gene analysis using a commercially 
available kit (QIAGEN, Valencia, CA, USA). mRNA was reverse transcribed using High 
capacity cDNA reverse transcription Kit (Applied Biosystems) in a G-storm thermocycler 
(G-storm, Surrey, UK). Gene expression was analysed using TaqMan Gene Expression 
Assays and the AB7300 system (Applied Biosystems). The expression value of each gene 
was normalised to that of β-actin. All samples were analysed in triplicate. 
Short chain fatty acid analysis  
Approximately 300 mg caecal content was mixed with 3.0 mL Milli-Q water and, after 
standing for 10 min at room temperature, centrifuged at 4700 rpm for 10 min. 1.0 mM 2-
ethylbutyric acid (Sigma) was added to the supernatant as internal standard and samples 
were then filtered. Calibration was done using standard solutions containing 10.0 mM, 
8.0 mM, 4.0 mM, 2.0 mM, 1.0 mM and 0.5 mM of acetic acid, propionic acid, iso-butyric 
acid and butyric acid (Sigma). The concentration of S.C.F.A. was determined using a 
Varian 3800 GC flame ionization system, fitted with a DB-FFAP column (30 m x 0.32 mm x 
0.25 µm; Phenomenex). Helium was used as the carrier gas at a flow rate of 1.3 mL/min. 
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The initial oven temperature was 100C for 0.5 min, raised to 180C at 8C/min and held 
for 1 min, then increased to 200C at 20C/min, and finally held at 200C for 5 min. The 
temperature of the detector and the injector were set at 250C and 240C, respectively. 
Peaks were integrated using the Varian Star Chromatography Workstation version 6.0 
software. Standards were included in each run to maintain the calibration. 
Statistical analysis 
Body weight and food intake were analysed using a two-way repeated measures with 
olanzapine administration and antibiotic administration as factors. Gene expression and 
s.c.f.a. concentrations were analysed using a two-way anova. Where a significant was 
found, additional analysis was carried out using a Least Significant Difference (LSD) post-
hoc test. Given the number of groups, N numbers and anticipated effect sizes, LSD was 
considered an appropriate post-hoc test. A p value < 0.05 was considered statistically 
significant. Data are expressed as mean ± SEM.  
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5.3 Results 
Body weight 
OLZ treatment had a significant effect on body weight change (F(1,52) = 6.493, p < 0.05) as 
did time (F(26,1352) = 119.91, p < 0.001). There was a significant time x OLZ effect (F(26,1352) = 
25.794, p < 0.001).  
Post-hoc analysis revealed that OLZ treated rats displayed greater weight gain on days 2 
to 7 and days 9 to 21 (inclusive) (p < 0.05 to p < 0 01) compared to VEH+VEH treated 
animals (Fig. 5.1A). RIF treatment alone did not affect body weight (Fig 5.1B). However, 
OLZ+RIF treated rats displayed significantly reduced increases in body weight compared 
to those receiving OLZ+VEH on days 1-9 and days 16-21 inclusive (p < 0.05) (Fig 5.1C). 
VAN+VEH treated rats did not show alterations in body weight compared to VEH+VEH 
treated animals, similarly, VAN+OLZ treated rats did not display differences compared to 
VEH+OLZ (Fig. 5.1D). 
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Fig. 5.1. Effect of olanzapine, rifaxamin and vancomycin on body weight. Body weight 
change in female rats following treatment with (A) Olanzapine (OLZ) 2 mg/kg/d (B) 
Rifaximin 50 mg/kg (C) Olanzapine co-administered with or without rifaximin and (D) 
Olanzapine co-administered with or without vancomycin (VAN) (50 mg/kg).Data shown 
represents mean ± SEM. *p < 0.05, **p < 0.01 compared to bottom line on each respective 
graph. 
Food intake 
OLZ administration had a significant overall effect on food intake (F(1,66) = 59.533, p < 
0.001) and there was a significant OLZ x antibiotic interaction (F(2,66) = 3.294, p < 0.05). 
Time also had a significant effect (F(3,198) = 35.820, p < 0.001) and there was a significant 
time x OLZ (F(3,198) = 9.075, p < 0.001);time x antibiotic (F(6,198) = 12.348, p < 0.001) and 
time x OLZ x antibiotic interaction (F(6,198) = 4.23, p < 0.001).  
Post-hoc analysis revealed that animals receiving VAN+VEH had reduced food intake 
compared to VEH+VEH over days -5-0 (p < 0.01).  
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Following commencement of olanzapine treatment, animals receiving OLZ+VEH displayed 
increased food intake compared to VEH+VEH treated rats in all subsequent time bins (p < 
005 to p < 0.01) (Fig 5.2).  
Animals receiving RIF+OLZ displayed increased food intake compared to RIF+VEH treated 
rats during days 8-14 (p < 0.05) but had decreased intake compared VEH+OLZ treated rats 
over days 15-20 (p < 0.05). Similarly, RIF+VEH treated rats had decreased food intake 
compared VEH+VEH treated animals over days 15-20 (p < 0.05).  
VANC+OLZ treated animals had increased food intake compared to VANC+VEH treated 
group over days 1-7 and 8-14 (p < 0.001) (Fig. 5.2) 
 
Fig. 5.2 . Effect of olanzapine, rifaximin and vancomycin on food intake. Food intake over 
5/6 day time bins following administration of vehicle (VEH)+VEH, VEH+olanzapine (OLZ), 
rifaximin (RIF)+VEH, RIF+OLZ, vancomycin (VAN)+VEH or VAN+OLZ in female rats. Data 
shown represents mean ± SEM. *p < 0.05, **p < 0.01, compared to VEH+VEH; ##p< 0.01, 
###p < 0.001 versus animals receiving same antibiotic without olanzapine; $p < 0.05 versus 
Veh+OLZ.  
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Tissue weights 
Hepatic index 
OLZ treatment had a significant effect on hepatic index (defined as liver weight as 
percentage of total body weight) (F(1,52) = 16.541, p < 0.001) as did antibiotic treatment 
(F(2,52) = 5.424, p < 001).  
Post-hoc analysis revealed that VEH+OLZ treated rats had increased hepatic index 
compared to VEH+VEH treated animals (p < 0.05). Moreover, RIF+OLZ treated rats had 
reduced hepatic index compared to VEH+OLZ animals (p < 0.05). VAN+OLZ treated group 
also displayed reduced hepatic index versus VEH+OLZ treated rats while still being 
increased compared to VAN+VEH treated animals (p < 0.05) (Fig. 5.3A).  
Uterine fat 
OLZ treatment had a significant effect on uterine fat weight (F(1,52) = 9.382, p < 0.01) as did 
antibiotic treatment (F(2,52) = 6.354, p < 0.01). Further analysis revealed VEH+OLZ 
treatment increase uterine fat compared to VEH+VEH as well compared to RIF+OLZ and 
VAN+OLZ treatments (p < 0.05). VAN+VEH treatment also displayed reduced uterine fat 
mass compared to VEH+VEH (Fig 5.3B). 
Caecal content mass 
OLZ had a significant overall effect (F(1,52) = 9.232, p < 0.01) as did antibiotic treatment 
(F(2,52) = 157.211, p < 0.001). Post-hoc analysis revealed VEH+OLZ treated rats had 
reduced caecal content compared to VEH+VEH treated rats (p < 0.05) as well compared to 
RIF+OLZ treated animals (p < 0.05).  
187 
 
VAN+VEH treated rats had increased caecal content compared to VEH+VEH (p < 0.001) 
and VAN+OLZ had significantly increased caecal content compared to VEH+OLZ treated 
animals (Fig. 5.3C). 
 
Fig. 5.3. Effect of olanzapine, rifaximin and vancomycin on specific tissue weights. Effect 
of olanzapine (OLZ) co-administered with rifaximin (RIF) or vancomycin (VAN) on (A) 
hepatic index (B) uterine fat and (C) caecal content. Data shown represents mean ± SEM. 
*p < 0.05, ***p < 0.001 versus VEH+VEH; #p < 0.05, ###p < 0.001 versus Veh+OLZ; $p < 
0.05 Vanc+Veh  
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Short chain fatty acids (scfa) 
OLZ administration did not have an overall effect on any of the short chain fatty acids 
measured. However antibiotic administration significantly affected acetate (F(2,49) = 
260.535, p < 0.001), propionate (F(2,52) = 17.11, p < 0.001) and n-butyrate (F(2,50) = 75.05, p 
< 0.001). Further analysis revealed that VAN+ VEH or VAN+OLZ administration resulted in 
significantly reduced levels of acetate, propionate and n-butyrate compared to VEH+VEH 
and VEH+OLZ, respectively (p < 0.01)(Fig. 5.4). 
Fig. 5.4 Effect of olanzapine, rifaximin and vancomycin on short chain fatty acid 
concentrations. Effect of olanzapine (OLZ) co-administered with rifaximin (RIF) or 
vancomycin (VAN) on (A) hepatic index (B) uterine fat and (C) caecal content. Data shown 
represents mean ± SEM. **p < 0.01, ***p < 0.001 versus VEH+VEH, ##p < 0.01, ###p < 0.001 
versus VEH+OLZ 
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Adipose Genes 
OLZ significantly affected cannabinoid 1 receptor (CB1R) expression (F(1,51) = 7.127, p < 
0.01). Post-hoc analysis showed that VEH+OLZ treated rats had significantly increased 
CB1R mRNA levels compared to VEH+VEH treated group (p < 0.01). However, animals 
receiving RIF+OLZ or VAN+OLZ did not display such increases and had significantly lower 
expression compared to VEH+OLZ treated animals (p < 0.05) (Fig. 5.5A). 
Olanzapine also had a significant effect on fatty acid synthase expression (FAS) (F(1,52) = 
5.653, p < 0.05). Post-hoc analysis revealed VEH+OLZ treatment led to increased FAS 
expression compared to that of VEH+VEH (p <0.01). Furthermore, administration of 
RIF+OLZ reduced FAS expression compared to VEH+OLZ (p < 0.01) while VAN+OLZ 
displayed a similar trend (p = 0.06) (Fig. 5.5B). 
 
Fig. 5.5 Effect of olanzapine, rifaximin and vancomycin on gene expression in adipose 
tissue. The effect of olanzapine (OLZ) or co-administered with vehicle (VEH), rifaximin (RIF) 
or vancomycin (VAN) on mRNA expression of (A) Cannabinoid 1 (CB1) receptor and (B) 
Fatty acid synthase (FAS) in adipose tissue. **p < 0.01 versus VEH+VEH, #p< 0.05, ##p<0.01 
versus VEH+OLZ.   
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Liver Genes 
OLZ had a significant effect on hepatic expression of fatty acid synthase (FAS) (F(1,50) = 
5.641, p < 0.05). Further analysis revealed that VEH+OLZ treatment increased FAS 
expression compared to that of VEH+VEH (p < 0.01). RIF+OLZ however displayed reduced 
expression compared to VEH+OLZ (p < 0.05). VAN+OLZ treated rats also displayed 
increased expression compared to VAN+VEH treated animals (p < 0.05) (Fig. 5.6A). 
Neither olanzapine treatment nor antibiotic treatment alone had an overall effect on 
PPARγ expression. However, there was significant olanzapine x antibiotic interaction 
(F(2,51) = 5.407, p< 0.01). Further analysis revealed that VEH+OLZ treatment increased 
PPARγ expression compared to that of VEH+VEH (p < 0.01). However, no such increase 
was observed in rats receiving either RIF+OLZ or VAN+OLZ which displayed reduced 
PPARγ expression compared to VEH+OLZ treated rats (p < 0.01) (Fig. 5.6B). 
 
Fig. 5.6 Effect of olanzapine, rifaximin and vancomycin on hepatic gene expression. 
Effect of olanzapine (OLZ) 2 mg/kg/d in female rats co-administered with rifaximin (RIF) or 
vancomycin (VAN) on hepatic expression of (A) fatty acid synthase (FAS) or (B) Peroxisome 
proliferator-activated receptor gamma (PPARγ). Data shown represents mean ± SEM. *p < 
0.05, **p < 0.01 compared to VEH+VEH, #p < 0.05, ##p<0.01 versus VEH+OLZ, $p< 0.05 
versus VAN+VEH  
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Gut Microbiota 
Pyrosequencing of the caecal flora revealed shifts in the composition of the microbiota at 
both the phyla and family level. As expected, antibiotic treatment resulted in an altered 
flora. Surprisingly, RIF+VEH treated animals had a seemingly unaltered abundance of the 
major phyla, Firmicutes and Bacteriodetes (Fig 5.7A). However, at the phyla level, there 
was an emergence of Verrucomicrobia (Fig 5.7B), as well as a 7-fold increase in the 
abundance of Actinobacteria (Fig 5.7B). Additionally, at the family level, there were 
increases in Bifidobacteriaceae and Rikenellaceae, albeit in lesser represent families (Fig 
5.7D).  
Vancomycin treatment alone (VAN+VEH) resulted in a profoundly different microbiota 
with changes in the predominant phyla including reductions in the abundance of 
Firmicutes and a bloom of Tenericutes (Fig 5.9A). At the family level, Vancomycin also 
induced several alterations including substantial reductions in the abundance of 
Lachnospiraceae and Ruminococcaceae and concomitant increases in Lactobacillaceae 
(Fig 5.9C) and Alcaligenaceae (Fig. 5.9D). 
Olanzapine altered the caecal microflora to a lesser degree, with increases in the 
Actinobacteria (7-fold) phylum observed (Fig 5.9B). At the family level, olanzapine 
treatment resulted in a number of increases in the abundance of lesser represented 
families including Alcaligenaceae (3 fold), Bifidobacteriaceae (5-fold) and 
Peptostreptococcaceae (4-fold). 
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Intriguingly, administration of olanzapine in addition to either antibiotic resulted in 
alterations not observed in the VEH+VEH or respective antibiotic treatment groups. 
RIF+OLZ treated rats did not display increased abundance of the Actinobacteria phylum 
despite both olanzapine and rifaximin increasing levels of this phylum independently (Fig. 
5.9B). Furthermore, RIF+OLZ treated animals had several alterations compared to 
VEH+OLZ treated animals at the family level including a reversal of the increases in 
Peptostreptococcaceae and Bifidobacteriaceae, as well as increased abundance of 
Prevotellaceae (Fig 5.7D). 
Similarly, VAN+OLZ treated animals displayed a number of discrete alterations compared 
to the VEH+OLZ treated group. As observed in the VAN+VEH group, VAN+OLZ treatment 
resulted in reductions in the abundance of Firmicutes and a bloom in Tenericutes (Fig 
5.7A). Additionally VAN+OLZ treatment was associated with a unique reduction on the 
family Prevotellaceae (Fig 5.7D). 
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Fig. 5.7 Composition of the caecal microbiota. The composition of the caecal microbiota 
in female rats treated with vehicle (VEH) + VEH, VEH + olanzapine (OLZ), rifaximin (RIF) + 
VEH, RIF+OLZ, vancomycin(VAN)+ VEH and VAN + VEH.(A) Abundance of major phyla (B) 
Abundance of lesser represented phyla (C) Abundance of major families (D) Abundance of 
lesser represented families. 
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5.4 Discussion 
In the present study, we demonstrate that olanzapine-induced weight gain in the rat is 
attenuated by the non-absorbable antibiotic rifaximin. Moreover, both rifaxamin and 
vancomycin were able to attenuate other aspects indicative of metabolic dysfunction, 
including, uterine fat deposition and expression of lipogenic genes. Crucially, rifaximin 
and vancomycin are almost entirely non-absorbable, and were administered per os, 
therefore the observed effects were almost certainly microbiota-driven. These novel 
findings, in conjunction with previous reports from our lab, further open the possibility 
that the gut microbiota represents a viable therapeutic target for antipsychotic-induced 
weight gain and metabolic dysfunction. 
Olanzapine treatment resulted in shifts in the abundance of certain members of the gut 
microbiota, although primarily in less represented phyla and families. These changes at 
the phylum level did not mirror previously observed shifts (Davey et al. 2012). However, 
the current report measured caecal microbiota as opposed to faecal microbiota as 
previously reported, and that these two sites differ is well established (Pang et al. 2012). 
The alterations in the caecal microbiota observed with olanzapine were subtle but 
reduced caecal content observed in these rats suggests that these changes were 
physiologically relevant. Moreover, increased abundance of Actinobacteria as seen with 
olanzapine treatment has been reported to correlate with obesity in humans (Turnbaugh 
et al. 2009). This said, the alterations observed were minimal in terms of the overall 
composition of the flora and it remains possible that small alterations observed are 
secondary to other metabolic effects of olanzapine.  
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Regardless, manipulation of the flora that produced a beneficial therapeutic effect may 
be clinically relevant. It must also be remembered that the gut microbiota is a complex 
ecosystem and the entire metagenome acts in concert to influence the physiology of the 
host and hence subtle changes could potentially have knock-on and broader 
consequences. 
As one would expect, antibiotic treatment effected the composition of the microbiota. 
The two antibiotics had vastly different effects on the gut flora although this is 
unsurprising as they act by different mechanisms and certain bacteria are susceptible to 
one but not the other (Lundstrom and Sobel 2004; DuPont 2011). 
Intriguingly however, administration of rifaximin or vancomycin in conjunction with 
olanzapine resulted in a number of differences in the microbiota profile compared to 
olanzapine treatment alone. Moreover, the changes in microbiota observed between 
rifaximin and vancomycin co-administered with olanzapine were markedly different from 
one another, and this may explain there divergent effects on body weight gain.  
Rifaxamin prevented the increased abundance in Actinobacteria that occurred with 
olanzapine administration suggesting this phylum may have obesogenic potential. 
Vancomycin did not ameliorate olanzapine-induced weight gain, despite preventing diet 
induced obesity in mice (Murphy et al. 2012). Reasons for this discrepancy may be species 
related, however, it must be noted that vancomycin did attenuate other metabolic effects 
of olanzapine which may be more clinically relevant than body weight gain per se.  
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Aside from weight gain, both antibiotics were able to prevent a number of metabolic 
alterations induced by olanzapine including fat deposition and expression of lipogenic 
genes. We investigated if differences in energy extraction may underlie such effects. 
While rifaxamin did not affect scfa concentrations, vancomycin had a dramatic effect on 
acetate, propionate and n-butyrate. Thus, it is possible that the overlapping effects of 
rifaximin and vancomycin occurred via different mechanisms with reduced energy 
extraction central to those of vancomycin but not rifaximin.  
Prevention of increases in visceral fat by both antibiotics is in line with several reports 
showing that the microbiota can influence fat deposition (Backhed et al. 2004; Turnbaugh 
et al. 2006; Backhed et al. 2007; Murphy et al. 2010).  
One potential mechanism linking the microbiota to adiposity previously identified is via 
the cannabinoid 1 receptor (Cani et al. 2010).  
In support of this link, we found that both rifaximin and vancomycin prevented increases 
in the expression of the cannabinoid 1 receptor. The CB1 receptor is known to impact on 
gut permeability and blockade of the CB1 receptor prevents obesity (Gary-Bobo et al. 
2007). Moreover, selective alterations in the microbiota using prebiotics have shown to 
alter the expression of CB1R in adipose tissue (Muccioli et al. 2010). Given CB1R’s 
identified role in promoting lipogenesis in both liver and adipose tissue (Cota et al. 2003; 
Osei-Hyiaman et al. 2005; Gary-Bobo et al. 2006), it is extremely interesting that 
olanzapine increased CB1R mRNA in adipose tissue. Furthermore, the prevention of this 
increase by rifaximin and vancomycin highlight this as potential mechanistic link between 
the antibiotic therapy and reduced visceral fat accretion.  
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Additionally, FAS was found to be upregulated by olanzapine administration in both liver 
and adipose tissue. FAS is an enzyme that plays an integral role in lipogenesis and thus 
seems to be involved in increased de novo lipogenesis in hepatic tissue and the 
subsequent increased storage of energy as triglycerides that contributes to olanzapine-
induced fat deposition. Both vancomycin and rifaximin prevented increases in the 
expression of FAS suggesting a direct mechanism whereby alterations of the gut 
microbiota can influence accumulation of visceral fat. 
The expression of another lipogenic enzyme, PPARγ, was found to be increased in the 
liver of olanzapine treated rats. PPARγ is adipogenic and increased expression is indicative 
of a fatty liver and metabolic dysfunction (Gavrilova et al. 2003). However no such 
increases were observed when olanzapine was co-administered with vancomycin or 
rifaximin. This indicates that manipulation of the gut flora by either antibiotic affected 
lipogenic pathways that prevented or attenuated metabolic dysfunction. These effects 
may be secondary to effects on visceral fat as prevention of fat deposition may have 
prevented at the spiral of metabolic consequences associated with expanding adipose 
tissue. 
Importantly, neither antibiotic reduced the expression of these genes when administered 
alone.  
This suggests an interaction whereby the microbiota can affect both sides of the energy 
balance equation and under conditions of metabolic dysfunction act in such a way as to 
prevent processes that contribute to metabolic disturbances.  
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This view point is supported by this and other reports in which antibiotic administration 
can reduce body weight gain under certain conditions (Cani et al. 2008; Murphy et al. 
2012) whereas the agricultural food industry has utilised antibiotics as growth promoters 
for generations (Kamphues 1999). 
It must be remembered that the gut microbiota is a complex ecosystem and correlating 
shifts in individual phyla with changes in metabolic outcomes of the host may represent 
an oversimplified approach to understanding how dysbiosis of the gut microbiota drives 
physiological outcomes. However, what is clear is that alterations in the composition of 
the gut microbiota can have considerable consequences for the host. The precise 
mechanisms underpinning the microbiota’s role in attenuating the effects of olanzapine 
as observed in this study remain to be determined, though further understanding of host-
microbiota cross talk may identify pathways that allow the microbiota to influence 
adipose and liver tissue physiology. 
More importantly, further development of prebiotic and probiotics that can affect the gut 
microbiota without the known drawbacks of antibiotics will open the door to utilising the 
therapeutic potential of the gut microbiota in a range of diseases (Clarke et al. 2012)and 
this may extend to antipsychotic-induced metabolic dysfunction. 
These data therefore suggest that the gut microbiota is an important contributing factor 
in certain aspects of the metabolic dysfunction induced by olanzapine and that 
manipulation of this microbial organ offers a potential approach to ameliorate such 
dysfunction.
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Abstract 
Background: Antipsychotic associated weight gain and metabolic dysfunction is a serious 
clinical concern. The mechanisms underlying these complications are multifactorial, with 
central and peripheral mechanisms involved. The gut microbiota can contribute to energy 
balance and body weight through a variety of direct and indirect mechanisms and we 
have recently demonstrated that olanzapine causes an altered microbiota in the rat, and 
that antibiotics can attenuate certain olanzapine-induced metabolic effects. As such, the 
gut microbiota is a potentially novel mechanism and therapeutic target in antipsychotic-
induced weight gain.  
Methods: Female Sprague-Dawley rats received risperidone (1 mg/kg/d) or vehicle via 
twice-daily I.P. injections for 3 weeks. Additional groups also received rifaximin (30 
mg/kg) in addition to vehicle or risperidone, per os. Body weight and food intake were 
measured daily. Caecal microbiota profile was assessed by 454 pyrosequencing.  
Results: Risperidone administration caused rapid weight gain and was also associated 
with increased visceral fat and elevations in mRNA expression in adipose and liver tissues 
indicative of inflammation and metabolic dysfunction. Co-administration of the antibiotic 
rifaximin did not attenuate risperidone-induced weight gain but did prevent other aspects 
of metabolic dysfunction including fat deposition. 
Conclusions: These results further strengthen the link between the gut microbiota and 
metabolic dysfunction and more specifically that the flora may be a viable therapeutic 
target for antipsychotic-induced metabolic dysfunction.  
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6.1 Introduction 
Atypical antipsychotics are the mainstay treatment for schizophrenia. However, several 
atypical antipsychotics, including risperidone, are associated with several metabolic side 
effects including weight gain, increased visceral fat and insulin resistance (Bobes et al. 
2003b; Chintoh et al. 2009b; Albaugh et al. 2012). These side effects are a significant 
clinical problem due to their contribution to co-morbidities such as Type II diabetes and 
cardiovascular disease in a patient population already at increased risk of such disorders 
(Allison et al. 2009; Starrenburg and Bogers 2009; Li et al. 2011). Furthermore, these side 
effects contribute to the alarmingly high rate of non-adherence to treatment observed in 
schizophrenic patients (Ascher-Svanum et al. 2008). 
The mechanisms underpinning these side effects are several and converging, comprising 
both central and peripheral effects that produce increases in food intake, body weight, 
adiposity and glucose dysregulation leading to insulin resistance (Minet-Ringuet et al. 
2006; Fell et al. 2007; Scheen and De Hert 2007; Cooper et al. 2008b; Chintoh et al. 
2009a; Albaugh et al. 2011a). To date, there has been very limited success in attempts to 
prevent or attenuate antipsychotic-induced metabolic effects. 
The gut microbiota has been recognised in recent years as an important contributor to 
metabolism in both healthy and disease states (Uribe et al. 1994; Souza et al. 2004; Abt 
and Artis 2009; Turnbaugh et al. 2009). Indeed, the gut microbiota can affect both sides 
of the energy balance equation (Turnbaugh et al. 2006; Cani and Delzenne 2009).  
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As such, the gut microbiota has received increasing attention in investigations of both the 
pathogenesis and potential treatment of several metabolic related disorders including 
obesity and Type II Diabetes (Cani et al. 2007a; Membrez et al. 2010; Rabot et al. 2010). 
We therefore recently investigated the potential contribution of the microbiota to 
antipsychotic-induced weight gain and metabolic dysfunction, and demonstrated that 
olanzapine alters the faecal microbiota of rats (Davey et al. 2012) and antibiotic 
manipulation of the flora can attenuate certain aspects of olanzapine-induced metabolic 
dysfunction (Davey et al., submitted; chapter 5).  
The gut microbiota has the potential therefore to be a novel therapeutic target for the 
prevention or amelioration of antipsychotic-induced metabolic dysfunction and weight 
gain. However, whether this is case for antipsychotics other than olanzapine needs to be 
established.  
We therefore investigated if risperidone, an atypical antipsychotic associated with 
metabolic dysfunction and weight gain (Wirshing et al. 2001; Farwell et al. 2004; Lin et al. 
2006) affects the gut microbiota in rats. Moreover, we investigated if rifaximin, a non-
absorbable, semi-synthetic antibiotic (Scarpignato and Pelosini 2005) could attenuate any 
observed metabolic dysfunction.  
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6.2 Methods 
Animals 
Female Sprague-Dawley rats, 6 weeks old and weighing approximately 200g were used 
(Harlan, UK). Animals were allowed to habituate to the facility for 10 days. Animals were 
housed 5 per cage (56x38x17 cm) and allowed access to standard chow and water ad 
libitum. Animals were maintained on a 12h light dark cycle, lights on 7.30 am. All 
experiments were approved by the Animal Experimentation Ethics Committee (AEEC) of 
University College Cork and carried out in accordance with the Cruelty to Animals Act 
1876 and European Directive 86/609/EEC on the protection of animals used for 
experimental and other scientific purposes. 
Drug Administration 
Risperidone (RISP) (Discovery Fine Chemicals, UK) was dissolved in a minimal amount of 
glacial acetic acid (approx 0.1ml), made to volume with sterile water and pH adjusted to 
6.0 with 0.1M NaOH. Animals received risperidone, 1 mg/kg/d, or vehicle (VEH) via 
interperitoneal injection, B.I.D. Vehicle consisted of sterile water acidified with 0.1 ml of 
glacial acetic acid and pH adjusted to 6.0 with 0.1M NaOH. Drug solutions were prepared 
fresh daily and injections took place between 9:00 and 10:00 am and between 4:00 and 
5:00 pm. Doses of risperidone and gender of animals were selected based on previous 
studies in which they were found to best represent the clinical setting in terms of side 
effects (Fell et al. 2007). 
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Rifaximin (RIF), 30 mg/kg, was administered daily, per os in a volume of 4 ml/kg beginning 
5 days prior to vehicle or risperidone treatment. The dose of rifaximin was selected based 
on studies in our laboratory in which this dose attenuated certain metabolic effects of 
olanzapine (Davey et al., in preparation). 
Locomotor Activity Test 
To assess possible levels of sedation, rats were placed in clear plastic boxes (60x50x40 
cm) for 30 minutes and recorded using tracking software (Ethovision, Noldus, 
Netherlands). The test was carried out two days prior to the end of the study and animals 
were moved to the testing room one hour before the start of the test. 
Sample Collection 
Following sacrifice, uterine fat was quickly and carefully dissected and weighed to the 
nearest 0.001g. Caecal contents and the liver were removed and weighed. Trunk blood 
was collected in EDTA coated tubes and centrifuged at 6000 rpm for 15 minutes at 4oC. 
Plasma supernatant was then aliquoted and frozen. A sample of uterine fat, frontal lobe 
of the liver, caecal contents and a portion of the soleus muscle were collected and snap-
frozen. All samples were stored at -80oC for later analysis. 
Microbiota Analysis 
For analysis of the microbial community composition, total DNA was extracted from 
caecal contents, collected aseptically immediately following sacrifice, using the QIAamp 
DNA stool mini kit (Qiagen, West Sussex, UK), coupled with an initial bead-beating step.  
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Universal 16SrRNA primers, designed to amplify from highly conserved regions 
corresponding to those flanking the V4 region, ie the forward primer F1 (5’-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1 (5’-
TACCRGGGTHTCTAATCC), R2 (5’-TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing 
Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp) were used for Taq-based PCR 
amplification. Sequencing was performed on a Roche 454 GS-FLX using Titanium 
chemistry by the Teagasc454 sequencing platform. Resulting reads were quality trimmed, 
clustered, aligned and checked for chimeras using the Qiime suite of tools. A phylogenetic 
tree was generated using the FastTree package and principal coordinate analysis (PCoA), 
measuring dissimilarities at phylogenetic distances based on unweighted Unifrac analysis, 
was performed with Qiime.  
Plasma analysis 
Endotoxin was measured using the commercially available ToxinSensor chromogenic LAL 
assay (Genscript, U.S) following manufacturer’s instructions. Briefly, plasma samples were 
diluted and heated in pyrogen-free tubes before adding of limulus amebocyte lysate (LAL) 
and incubated for 45 minutes at 37oC. Chromogenic substrate is then added and samples 
incubated at 37oC for a further 6 minutes. Stop solution is then added and absorbance 
measured at 535 nm. Samples were analysed in duplicate. 
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Gene expression analysis 
Total RNA was extracted using a commercially available kit (Qiagen, US). mRNA was 
reverse transcribed using a high capacity cDNA reverse transcription kit (Applied 
Biosystems, US) in a G-Storm thermocycler (G-Storm, UK).  
Gene expression was analysed by qualitative real-time PCR using TaqMan Gene 
expression assays and the AB7300 system (Applied Biosystems). The expression of each 
gene was normalised to β-actin. All samples were analysed in triplicate.  
Statistical analysis 
Data are expressed as mean  SEM. Body weight change and food intake were analysed 
using two-way repeated measures ANOVA. Two-way ANOVA was used for analysis of 
uterine fat, gene expression. Where a significant overall effect was observed, further 
analysis was carried with Fisher’s Least Significant Difference test. Given the number of 
groups, N numbers and anticipated effect sizes, LSD was considered an appropriate post-
hoc test.   
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6.3 Results 
Body weight and food Intake 
RISP treatment significantly increased body weight (F(1,31) = 13.422, p =0.01). There was 
no significant overall effect of RIF treatment. RISP only treated animals displayed greater 
weight gain compared to vehicle treated animals on days 4-11 and days 13-22 (inclusive) 
(p < 0.05-p < 0.001) (Fig.6.1A). The RISP+RIF treated group displayed greater weight gain 
compared to RIF+VEH treated rats on days 5-22 (inclusive) (p < 0.05-p < 0.01) (Fig.6.1B).  
RISP also significantly increased food intake (F(1,44) = 70.73, p < 0.001). This hyperphagia 
was evident compared to VEH+VEH treated animals during all weeks of risperidone 
administration (p<0.05-p < 0.01) (Fig. 1C). Similarly, RISP+RIF also caused increases in 
food intake compared with RIF+VEH treated animals (p < 0.05-p < 0.001) (Fig.6.1C). 
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Fig. 6.1 Effect of risperidone and rifaximin on body weight and food intake. Effect of 
chronic risperidone (RISP) (1 mg/kg) on body weight gain in female rats (A) Effect of 
risperidone co-administered with rifaximin (RIF) (30 mg/kg) on body weight gain (B) and 
effects of risperidone co-administered with rifaximin (RIF) (30mg/kg) or vehicle (VEH) on 
food intake (C). Data expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
compared to VEH + VEH. #p< 0.05, ##p < 0.01, ###p<0.001 to RIF + VEH. 
  
209 
 
Locomotor activity 
RISP treatment had a significant effect on locomotor activity (F(1,35) = 4.098, p = 0.05). 
Overall, RISP+VEH treated rats had significantly reduced locomotion compared to 
VEH+VEH treated animals (p < 0.05) (Fig 6.2A). Further analysis revealed that the 
RSIP+VEH treated rats had reduced locomotor activity between 0-5, 15-20 and 25-30 
minutes respectively (p < 0.05) (Fig 6.2B). 
 
 
Fig. 6.2 Effect of risperidone and rifaximin on locomotor activity. (A) Total distance 
moved over a 30 minute time period following administration of risperidone (RISP) (1 
mg/kg/d) co-administered with rifaximin (RIF) (30mg/kg/d) or vehicle (VEH)(B) Distance 
moved over 5-minute time bins following administration of risperidone (1 mg/kg/d) with 
or without co-administration of rifaximin (30mg/kg/d). Data represent mean ± SEM.*P < 
0.05 versus VEH+VEH group. 
Tissue weights 
Uterine fat  
RISP significantly increased uterine fat mass (F(1,35) = 27.087, p < 0.001) while RIF 
treatment was associated with a significant reduction in uterine fat (F(1,35) = 4.417, p < 
0.05). Moreover, there was a significant RISP x RIF interaction (F(1,35) = 7.259, p < 0.05). 
RISP treated animals had significantly greater uterine fat mass compared to vehicle 
treated animals (p < 0.01) as well as those receiving RIF+RISP (p < 0.05) (Fig. 6.3A). 
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Liver  
RISP treatment resulted in significantly increased liver weight (F(1,35) = 9.177, p < 0.01) 
whereas RIF administration was associated with an overall significant reduction in liver 
mass (F(1,35) = 10.952, p < 001). RISP+VEH treated rats had increased liver weight 
compared to both the VEH+VEH (p < 0.01) and RIF+RISP (p < 0.01) groups (Fig. 6.3B). 
Caecal contents 
RISP administration was not associated with a significant effect on caecal content mass, 
however, RIF treatment was associated with a significant overall increase (F(1,35) = 10.269, 
p < 0.01). RIF+RISP treated animals had greater caecal mass compared to risperidone only 
treated group (p <.01) (Fig. 6.3C). 
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Fig. 6.3 Effect of risperidone and rifaximin on specific tissue weights. Effect of 
risperidone (RISP) (1 mg/kg) co-administered with rifaximin (RIF) (30 mg/kg) or vehicle 
(VEH) on (A) uterine fat mass percentage (B) hepatic index (liver weight percentage) and 
(C) caecal content mass. Data expressed as mean ± S.E.M. **p < 0.01 versus VEH+VE, #p< 
0.05, ##p < 0.01 versus RIF + RISP. 
  
212 
 
Inflammatory markers 
Plasma endotoxin  
RIF had a significant impact on plasma endotoxin levels (F(1,14) = 5.043, p < 0.05) (Fig. 
6.4A). A number of samples in the VEH+RIF and RIF+RISP groups were found to be below 
the limit of detection. Post-hoc analysis revealed that the RIF+RISP treated animals had 
reduced levels of circulating endotoxin compared with RISP+VEH treated animals. 
Adipose gene expression  
RISP treatment had a significant overall effect on CD68 mRNA expression in adipose tissue 
(F(1,34) = 7.832, p < 0.001). Post hoc analysis revealed that VEH+RISP treatment resulted in 
increased expression compared to VEH+VEH treated rats (p< 0.05) and moreover this was 
significantly reduced by co-administration of rifaximin (Fig. 6.4B). No significant difference 
was observed in the expression of IL-6 mRNA (Fig. 6.4C). 
 
Fig. 6.4 Effect of risperidone and rifaximin on inflammatory markers. Effect of 
risperidone (RISP) (1 mg/kg/d) co-administered with rifaximin (RIF) (30 mg/kg) or vehicle 
(VEH) on (A) plasma endotoxin (B) Adipose tissue expression of CD68 and (C) Adipose 
tissue expression of IL-6. Data expressed as mean ± SEM. *p < 0.05 versus VEH + VEH, #p < 
0.05 versus RIF+RISP.  
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Toll-like receptor 4 (TLR 4) Expression 
Adipose Tissue 
RISP treatment was associated with a significant effect on toll-like receptor (TLR)-4 
expression in adipose tissue (F(1,34) = 4.24, p < 0.05). Post-hoc analysis revealed that 
risperidone treated animals had reduced TLR-4 expression compared to both VEH+VEH 
treated rats and those receiving RIF+RISP (Fig. 6.5A). 
Skeletal Muscle 
RISP treatment was not associated with an overall effect on TLR-4 expression in muscle 
tissue, however, rifaximin treatment resulted in increased expression levels (F(1,34) = 
9.412, p < 0.01). RIF+RISP treated animals displayed increased expression compared to 
those receiving VEH+RISP (p < 0.05) (Fig.6.5B). 
Fig. 6.5 Effect of risperidone and rifaximin on TLR-4 expression. Effect of chronic 
risperidone (RISP) co-administered with rifaximin (RIF) (30 mg/kg) or vehicle (VEH) on TLR-
4 mRNA expression in (A) Adipose tissue and (B) Skeletal Muscle tissue. Data expressed as 
mean ± SEM. *p < 0.05 compared to VEH + VEH, #p< 0.05 compared to RIF+RISP. 
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Gut microbiota 
Pyrosequencing revealed that risperidone treatment caused subtle alterations in 
composition of the caecal microbiota. Risperidone administration did not affect the major 
phyla (Fig. 6.6A) but was associated with increased levels of the phyla Actinobacteria (3.5 
fold) (Fig. 6.6B). Additionally, at the family level risperidone treatment was associated 
with reduced abundance of Lachnospiraceae compared with vehicle treatment (52% 
versus 40%, respectively) (Fig. 6.6C). Animals receiving rifaxamin co-administered with 
risperidone treatment did not display either of these alterations and also had increased 
levels of Terenicutes (5 fold) and an absence of Verrucomicrobia (Fig. 6.6B). 
 
Fig. 6.6 Composition of the caecal microbiota. Effect of risperidone (RISP) co-
administered with rifaximin (RIF) (30 mg/kg) or vehicle (VEH) on (A) Major phyla (B) Less 
represented phyla and (C) Major families of bacteria.  
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6.4 Discussion 
In the present study, risperidone induced raid weight gain and hyperphagia in female rats 
in line with previous reports (Fell et al. 2007). This weight gain was associated with 
increases in both adipose tissue and liver weight signifying metabolic dysfunction. 
Rifaximin, a non-absorbable antibiotic, was able to attenuate several metabolic 
abnormalities induced by risperidone including accretion of visceral fat and macrophage 
infiltration. This further strengthens the evidence that the microbiota may be an 
important factor contributing to the metabolic effects of atypical antipsychotics and 
furthermore that it may be a novel therapeutic target for ameliorating such effects. 
Rifaximin did not, however, attenuate risperidone-induced weight gain as was previously 
observed for the antipsychotic olanzapine (Davey et al., submitted; chapter 5). The lack of 
effect of rifaximin on risperidone-induced weight gain may reflect differences in the 
mechanisms underlying metabolic-dysfunction between olanzapine and risperidone. 
Risperidone and olanzapine have previously been shown to have divergent effects on 
metabolic parameters including triglycerides, adiponectin and cholesterol, potentially 
explaining the difference observed in this study compared to the previous study of 
olanzapine (Scheen et al. 2010; Wampers et al. 2012). 
However, as in our previous reports with olanzapine (Davey et al, in preparation; chapter 
5), rifaximin did lead to a reduction in both uterine fat mass and liver weight compared to 
drug treated animals. This supports the hypothesis that the microbiota contributes to the 
dysfunction in energy regulation observed with antipsychotic treatment.  
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These findings are in line with data from other animal models of metabolic dysfunction 
such as diet induced obesity and genetic obesity in which the gut microbiota has been 
shown to be crucial for the development of obesity and that antibiotic treatment can 
improve metabolic health in such models (Backhed et al. 2004; Cani et al. 2008) 
In the present report, the non-absorbable antibiotic rifaximin was able to attenuate 
risperidone induced increases in uterine fat.  
Expansion of visceral fat is a central step in the development of the metabolic syndrome 
through its role as an endocrine organ (Mohamed-Ali et al. 1998; Galic et al. 2010). 
Inflammatory processes are well established as being central in obesity and metabolic 
dysfunction (Dandona et al. 2004; Bastard et al. 2006b) and visceral adiposity is central to 
this increased inflammatory tone observed in obesity. Hence, reductions in visceral fat 
seen with antibiotic treatment may have important clinical implications, especially given 
that rifaximin also reduced expression of the macrophage marker CD68. Macrophage 
infiltration of adipose tissue is central to the proinflammatory response of expanding 
adipose tissue. Thus, reductions in CD68 suggest that rifaximin was able to prevent 
macrophage infiltration, an effect that was likely secondary to preventing increased fat 
mass.  
Therefore, manipulation of the gut flora may be able to reduce visceral fat accretion, 
thereby ameliorating the proinflammatory response associated with risperidone and 
preventing ensuing metabolic anomalies. Support of this is also seen in the liver, where 
risperidone was associated with increased liver weight, indicative of fatty liver which was 
not the case in animals co-administered rifaximin.  
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Though not statistically significant, there was a trend for increased endotoxin levels in 
risperidone treated rats, suggesting metabolic endotoxemia may have contributed to the 
observed metabolic dysfunction. Further evidence of a reduced inflammatory phenotype 
was evidenced by reduced levels of circulating endotoxin which were associated with 
rifaximin treatment. Endotoxin is known to be associated with metabolic dysfunction in 
rodents and reduced levels have been associated with improvements in metabolic 
phenotype of mice (Cani et al. 2007a; Cani et al. 2008; Cani and Delzenne 2009) 
LPS, the endotoxin, is a ligand for the TLR-4 receptor and is proposed to be involved in the 
relationship between inflammation and metabolic dysfunction (Shi et al. 2006). 
Contradictory to this theory, we found reduced expression of TLR-4 in adipose tissue in 
response to risperidone. This down-regulation may reflect negative feedback over the 
course of chronic administration. Interestingly, no such reduction was seen in animals 
receiving risperidone co-administered with rifaximin, suggesting that antibiotic treatment 
was able to prevent the metabolic disturbance that led to decreased levels following 
risperidone administration.  
Risperidone alone was associated with subtle alterations in the microbiota. Intriguingly 
one such change was increased abundance of the phyla Actinobacteria, which was 
previously associated with obesity in humans (Turnbaugh et al. 2009) and was also found 
to be increased following olanzapine administration (Davey et al. in preparation; chapter 
5). 
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The specific contribution of changes in a single phylum or family is extremely difficult to 
discern as the microbiota represents a complex ecosystem. The entire population 
ultimately makes up the metagenome of the microbiota which impacts on the health of 
the host and several functions are conserved across the different phyla. However, these 
findings highlight the possibility that dysbiosis of the gut microbiota may be a clinically 
relevant feature of antipsychotic therapy and that the microbiota may therefore 
represent a viable therapeutic target for addressing metabolic effects of these drugs.  
Of course, whether shifts in the microbiota are secondary to other metabolic effects of 
antipsychotic compounds remains to be determined. Regardless, manipulation of the gut 
flora may be beneficial due to effects on factors involved in the mechanisms of 
antipsychotic-induced metabolic dysfunction. 
Of course, in humans targeting the flora is made more difficult by the heterogeneous 
diets of patients as well as effects of sex, location and age, all of which impact on the 
make-up of the gut microbiota (Wu et al. 2011; O’Toole 2012). However, advancements 
in development of probiotics and prebiotics for a range of disorders (Clarke et al. 2012) 
may one day allow for targeted and effective use of gut flora as tool to tackle not only 
antipsychotic-induced metabolic dysfunction but the obesity epidemic in general. 
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Chapter 7 
General Discussion 
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7.1 Overview and summary 
In this thesis, we have demonstrated that antipsychotic-induced metabolic adverse effects 
are associated with alterations to the gut microbiota composition. Moreover, we have 
demonstrated that modulation of the gut microbiota can prevent or attenuate certain 
aspects of the metabolic dysfunction associated with these compounds, including body 
weight gain. This research has therefore opened the door to the possibility of microbiota-
targeted therapeutics as adjunctive therapies for antipsychotic-induced metabolic side 
effects in the future, and also strengthens the evidence for such approaches in the 
treatment and prevention of obesity in general. 
Summary of discussion topics  
Key topic Section 
Why are atypical antipsychotics still used given their known metabolic 
liabilities? 
7.2 
Can clinically relevant side effects of antipsychotics be modelled in animals? 7.3 
What metabolic effects of olanzapine and risperidone were observed in our 
studies? 
7.4 
What alterations to the microbiota were observed in response to 
antipsychotics and what is their potential relevance  
7.5 
What effect does alteration of the gut microbiota have on antipsychotic-
induced metabolic dysfunction and what mechanisms potential underlie any 
such effects 
7.6-7.8 
Does the microbiota represent a viable therapeutic target of the future for 
metabolic disorders and antipsychotic-induced side effects 
7.9 
Table 7.1. Summary of central discussion topics. 
Antipsychotics represent the most effective tool available to tackle the devastating 
condition of schizophrenia. As such, they are set to remain the mainstay of treatment for 
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psychiatric disorders such as schizophrenia and bipolar disorder. However, the 
therapeutic benefits of these drugs come at a considerable metabolic cost to the patient. 
Patients with schizophrenia have three times the mortality risk of the general population, 
and their life expectancy is reduced by 16-25 years (Brown et al. 2010; Tiihonen et al. 
2011). As with any pharmacological intervention, the rewards must out-weigh the risks 
and antipsychotic medication reduces this mortality risk compared to untreated patients, 
as well as improving quality of life (Foley and Morley 2011). However, treated patients 
maintain a much greater risk of mortality compared to the general population, and while 
a large increase in the rate of suicide is a considerable contributor to this (Brown et al. 
2010), in fact, cardiometabolic disease is the major cause of morbidity and mortality in 
patients with schizophrenia (Osby et al. 2000; Brown et al. 2010; Foley and Morley 2011). 
Indeed, up to 60% of deaths in schizophrenia are linked to metabolic disease (Osby et al. 
2000). Moreover, the survival gap between schizophrenia patients and the general 
population is ever widening, making the physical health of the mentally ill an increasingly 
important issue (Capasso et al. 2008; Tiihonen et al. 2011). 
There are several factors that contribute to the high rate of metabolic dysfunction in 
schizophrenia patients including a high rate of smoking, poor diet and physical inactivity. 
However, antipsychotics are associated with several aspects metabolic dysfunction 
including weight gain, increases in abdominal fat as well as lipid and glucose 
abnormalities (Farwell et al. 2004; Correll et al. 2009; Citrome et al. 2011b). Hence, the 
detrimental metabolic effects of antipsychotics makes this already vulnerable group at 
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even greater risk of developing co-morbidities such as type II diabetes mellitus and 
cardiovascular disease (Farwell et al. 2004; Correll et al. 2009; Citrome et al. 2011b).  
Thus, it is has become apparent that tackling the causes of metabolic disease in 
schizophrenia patients is a clinical imperative, and ways to ameliorate the metabolic 
effects of antipsychotics is a top priority in this regard (Foley and Morley 2011; Tiihonen 
et al. 2011). 
The gut microbiota plays a role in energy regulation and metabolism in normal physiology 
but also in pathological states such as obesity and type II diabetes (Backhed et al. 2004; 
Backhed 2011; Burcelin et al. 2011). Investigations into the involvement of the gut 
microbiota in body weight, fat deposition and related diseases have increased rapidly in 
recent years owing to technological advances in measuring and monitoring the gut 
microbiota (Fraher et al. 2012).  
This increased research has also been fuelled by growing evidence supporting a 
substantial effect of the gut microbiota on aspects of metabolism in both animal models 
and humans (Backhed et al. 2007; Cani et al. 2007a; DiBaise et al. 2008; Armougom et al. 
2009; Turnbaugh et al. 2009; Ding et al. 2010; Schwiertz et al. 2010).  
Given the link between the gut microbiota and metabolic function and the documented 
metabolic dysfunction associated with antipsychotics, we set out to investigate if the gut 
microbiota may represent a novel mechanism involved in the metabolic side effects of 
certain atypical antipsychotics, and moreover, if the microbiota could potentially 
represent a therapeutic target for ameliorating such effects. 
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To this end, we observed that both olanzapine and risperidone alter the composition of 
the gut microbiota in rats. This is intriguing, especially given the lack of confounding 
factors such as diet or environment in our experiments,  that are encountered in clinical 
studies. These changes in gut flora occurred in concert with other aspects of metabolic 
dysfunction commonly associated with these antipsychotics including weight gain, 
increased abdominal fat and evidence of abnormalities in lipid handling, glucose 
regulation and inflammatory processes. It is not currently possible to say whether these 
changes are cause or consequence of the ensuing metabolic dysfunction caused by the 
antipsychotics.  
Furthermore, the changes in microbiota composition observed were relatively subtle and 
thus the true clinical relevance of the observed alterations remains to be determined.  
This said, growing evidence suggests that increases and/or decreases in specific bacterial 
groups correlate with metabolic alterations and the diversity of the microbiota means 
differences across studies is to be expected.  
The contribution of specific bacterial groups compared with the impact of the overall 
composition of the flora on metabolic systems remains unclear and understanding the 
link between microbial dysbiosis and metabolic phenotype of the host remains an 
ongoing challenge. 
However, we also demonstrate that ablation of the gut flora using a cocktail of broad-
spectrum antibiotics attenuates olanzapine-induced body weight gain as well as other 
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metabolic abnormalities. This provides evidence that the gut microbiota can influence, 
either directly or indirectly, antipsychotic associated metabolic dysfunction. 
In further support of this, we show that a non-absorbable antibiotic, rifaximin, also 
ameliorates olanzapine-induced weight gain in the rat, albeit to a modest degree. 
Moreover, rifaximin, and another non-absorbable antibiotic vancomycin, attenuated 
metabolic dysfunction associated with olanzapine administration including increases in 
visceral fat, pro-inflammatory responses and alterations in the expression of lipogenic 
enzymes.  
We have highlighted therefore that the gut microbiota is another factor to be considered 
when evaluating the milieu of metabolic complications induced by atypical antipsychotics.  
More importantly, we have shown that the microbiota can be targeted therapeutically to 
ameliorate the ensuing weight gain and metabolic dysfunction, especially visceral fat 
deposition. Hence, this work opens the door for further studies utilising agents such as 
probiotics and prebiotics to help prevent or reduce the metabolic liability of 
antipsychotics and therefore improve patients’ physical health and ultimately result in 
better long-term outcomes. 
These findings have broader implications beyond antipsychotic-induced effects as obesity 
reaches epidemic proportions worldwide (Ogden et al. 2006; Berghoefer et al. 2008; de 
Onis et al. 2010). The complex interactions of metabolic and inflammatory pathways 
underpinning antipsychotic-induced metabolic dysfunction represent the same 
physiological pathways involved in obesity and associated co-morbidities in the general 
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population. Thus, our data strengthen the evidence for a critical role played by the gut 
microbiota in energy balance and support the development of microbiota based 
therapeutics for obesity prevention and treatment in the future  
7.2 Advantages of atypical antipsychotics  
Atypical antipsychotics are indicated for the treatment of first-episode schizophrenic 
patients (Mortimer '03). Thus, a large increase in the prescription of atypical over typical 
antipsychotics has taken place in recent times (Verdoux et al. '10). Given the adverse 
events associated with atypical antipsychotics, one could wonder why they continue to be 
the drugs of choice in first line treatment of schizophrenia. However, as is the case for any 
pharmacological intervention, clinicians must weigh all benefits against costs of any 
medication before assigning an antipsychotic (Meltzer 2001; Meltzer et al. 2002).  
As previously mentioned, atypical antipsychotics were heralded as a breakthrough in the 
treatment of schizophrenia due to their reduced propensity to cause extra- pyramidal 
symptoms (EPS), and were even defined as a drug class based on this property. However, 
atypical antipsychotics seem to offer further advantages over their typical counterparts. 
While not conclusive, studies indicate that atypical antipsychotics, including olanzapine, 
offer greater efficacy in terms of rate to respond and overall efficacy (Bobes et al. 2003a; 
Lieberman et al. 2003).  
The prescribing of an antipsychotic agent is extremely patient specific based on the 
clinician’s assessment of a wide range of factors including medical history, age, sex and 
symptom profile. Thus, while a preference for the prescription of an antipsychotic with a 
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better metabolic-side effect profile, such as aripiprazole (Pae 2009), can be made, patient 
differences in response to alternative drugs means such alternatives may not be a 
suitable option in many cases. Hence, drugs such as olanzapine, clozapine and risperidone 
are set to remain valuable agents in the treatment of schizophrenia (Leucht et al. '09). 
Several studies have indicated that olanzapine and other atypical antipsychotics offer 
benefits in improving cognitive deficits associated with schizophrenia (Keefe et al. 1999; 
Woodward et al. 2005). Cognitive impairment is a serious complication of schizophrenia 
and is inter-related with traditional negative symptoms (Sharma and Antonova 2003). 
Indeed, cognitive impairments remain a major barrier for societal integration, even when 
positive symptoms are under control. Atypical antipsychotics have recently been shown 
to be superior to typical antipsychotic in improving psychosocial aspects of cognition 
(Fujimaki et al. 2012).  
In particular, atypical drugs have shown an ability to improve verbal fluency, fine motor 
functions and executive functions (Keefe et al. 1999). Thus, an ability of atypical 
antipsychotics to improve aspects of cognitive functions may be highly beneficial to the 
patient.  
The mechanisms underlying such effects of atypical antipsychotics are unclear, though 
their diverse receptor pharmacology seems to be at the core. In particular, effects on the 
serotonergic system in discrete brain regions appears to be involved (Martyn 2005).  
227 
 
It should also be noted that not all studies have found beneficial effects of atypicals on 
cognition, although, given the complex nature of the disease and the heterogeniet of 
both patients and treatment regimens, this is perhaps unsurprising (Keefe et al. 2007). 
Schizophrenia patients have an alarmingly high rate of non-adherence to treatment. 
Atypical antipsychotics are associated with better treatment adherence and persistence 
compared to typical drugs (Ascher-Svanum et al. 2006; Ascher-Svanum et al. 2008). 
Dropout rates from clinical studies as a result of adverse effects have also been found to 
be reduced with atypical compounds compared to typical counterparts (Martin et al. 
2006). 
Atypical antipsychotics, in particular olanzapine, clozapine and amisulpirde, are also 
purported to reduce negative symptoms in schizophrenia patients, a major advantage 
over typical drugs which do not treat, or even worsen, negative symptoms (Collaborative 
Working Group On Clinical Trial 1998; King 1998; Murphy et al. 2006; Curtis et al. 2008).  
Mechanisms underlying these effects seem to include preferential effects of atypical 
drugs in the different dopamine pathways, in particular, increasing dopamine release in 
the pre-frontal cortex relative to subcortical areas which occurs with olanzapine and 
clozapine but not haloperidol (Li et al. '98). 
At present, atypical antipsychotics therefore remain the preferred choice over typical 
drugs in many patients on the basis of not only reduced EPS liability but also the 
aforementioned advantages. Hence, drugs such as olanzapine, clozapine and risperidone 
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are set to continue to dominate the treatment of schizophrenia, emphasising the need to 
understand and prevent the metabolic side effects of these drugs.  
7.3 Modelling antipsychotic-induced metabolic dysfunction in rodents 
In order to reliably produce clinically relevant animal studies investigating the effects of 
antipsychotics, a number of challenges must be overcome. One such difficulty 
encountered with atypical antipsychotics is half-life. Antipsychotics have considerably 
shorter half-lives in rodents than in humans, reducing from between 24-48 hours in 
humans (Callaghan et al. 1999) to between 2-4 hours in rodents (Aravagiri et al. 1999). 
Hence, this issue must be addressed and the route of administration as well as dosing 
regimen must be carefully considered when designing preclinical studies using 
antipsychotics, and also when interpreting the results of such studies.  
One potential solution that has been employed in some studies is the use of osmotic-mini 
pumps which are implanted subcutaneously at the start of a study, and steadily release a 
drug over a period of time.  
While this may seem ideal at first, a number of antipsychotics, including olanzapine, are 
unstable in solution such that the potency of these drugs after the first few days becomes 
questionable (van der Zwaal et al. 2008).  
Administration of antipsychotics via food or water has been employed in order to try and 
ensure consistent dosing (Albaugh et al. 2006). However, as a main effect of these drugs 
is increased food and indeed water intake, the treated animals would presumably 
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increase their dose automatically, possibly influencing experimental outcomes in studies 
interested in metabolic parameters.  
In our studies, we administered the drugs in more than one dose each day i.e. twice-daily 
injection (B.I.D) in order to off-set the effects of the decreased half life. While this option 
was preferable to a single injection, pharmacokinetic studies have suggested that 4-daily 
injections would be required to match receptor occupancy profiles observed in humans, 
which would be logistically problematic to say the least (Kapur et al. 2003).  
Overall, the use of rodents remains critical to investigating the side effects of 
antipsychotics and ways to counteract them. While not perfect, the methods employed in 
our investigations reflected the clinical situation as closely as possible in terms of dosing 
and administration protocols allowing for potentially clinically- relevant conclusions to be 
drawn. 
7.3.1 Species differences in susceptibility to antipsychotic side effects  
Of course, preclinical work must be translational in order to draw any clinically relevant 
conclusions. We have investigated the impact of antipsychotics in both mice and rats and 
found that mice were resistant to antipsychotic-induced weight gain. 
This phenomenon has been observed previously (Arjona et al. 2004; Albaugh et al. 2006). 
This may have been due to inadequate dosing or duration of treatment, as, in some cases, 
mice have shown a propensity to gain weight when treated with atypical antipsychotics at 
considerably higher doses than those used in our studies (Cope et al. 2005). However, 
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evidence of metabolic dysfunction was observed in mice, including alterations in fat 
deposition.  
Importantly, as mice failed to display a propensity for weight gain in response to 
olanzapine as is seen clinically, we subsequently focused our work in rats. This precluded 
the use of germ-free mice, a common model for investigating the influence of the gut 
microbiota in disease states.  
Furthermore, germ-free rats facilities are an extremely rare commodity for several 
practical and logistical reasons, thus alternative approaches to germ-free were utilised in 
our investigations. 
We subsequently found that rats incur more robust and more reproducible responses to 
antipsychotic administration in terms of weight gain and metabolic dysfunction in line 
with several other reports (Cooper et al. 2005; Fell et al. 2007; Fell et al. 2008).  
The reason for this species difference remains unclear, although the important factor is 
which most reliably provides a template for the clinical setting. Olanzapine and 
risperidone both produced rapid hyperphagia and increases in body weight reflecting the 
clinical situation.  
Thus rats were used in further studies, allowing for clinical relevant investigations of ways 
to ameliorate certain metabolic effects associated with atypical antipsychotics. 
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7.3.2 Sex-specific responses to antipsychotic treatment 
In addition to species differences, we observed a definitive effect of sex on olanzapine-
induced weight gain in rats and also fat deposition in mice. This has previously been 
observed (Albaugh et al. 2006; Albaugh et al. 2010) though the reasons and implications 
of this has not been fully explored. This anomaly in relation to sex effects have led some 
authors to suggest that the present animal models of antipsychotic induced weight gain 
are not relevant to the clinical situation, hence rendering any conclusions invalid (Pouzet 
et al. 2003). However, additional metabolic effects associated with these drugs in the 
absence of weight gain, mean that weight gain per se is not essential for a valid animal 
model of antipsychotic-induced side effects.  
These effects include increased fat accumulation, dyslipidemia and hyperglycemia 
(Coccurello et al. '06; Minet-Ringuet et al. '06; Lykkegaard et al. '08; Albaugh et al. '10), 
which correlate with clinical setting demonstrating that rodent models are appropriate 
for studying the mechanisms of these side effects (Weston-Green et al. 2011b).  
In line with this, we found that female mice and male rats both showed signs of metabolic 
dysfunction without the occurrence weight gain, in line with recent reports (Victoriano et 
al. 2009; Albaugh et al. 2010). 
Sex differences in the side effects incurred by patients remain somewhat unclear. A 
review by Aichhorn et al 2007, found the incidence of weight gain and the metabolic 
syndrome to be more frequent in females and that this correlated with higher drug 
plasma levels in women for olanzapine and clozapine. This strongly indicates the 
existence of a sex difference; however another study of olanzapine found that males had 
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a higher frequency of weight gain (Basson et al. 2001a) and a number of clinical studies 
have found been inconclusive (Haack et al. 2009).  
Several other factors have been found to be associated with increased risk of 
antipsychotic-induced weight gain. These include baseline weight and  genetic factors 
which may therefore mask, or indeed emphasise, a sex bias (Basson et al. 2001a).  
A number of mechanisms potentially underlie the sex bias observed in preclinical studies. 
Male rats display a much steeper growth curve compared to females and this may 
therefore represent a ceiling effect on body weight gain at in rats of this age.  
Male gender, smoking and gene variants are all associated with lower corrected plasma 
concentrations, meaning females have higher circulating plasma levels for a given dose of 
an antipsychotic (Callaghan et al. 1999; Kelly et al. 1999; Seeman 2004). This is likely due 
to sex differences in metabolic enzyme systems such as cytochrome enzymes CYP3A4 and 
CYP1A2 (Parkinson et al. 2004). 
CYP1A2 is the main metabolising enzyme for olanzapine, and is less active in women than 
men (Kelly et al. 1999; Gex-Fabry et al. 2003). Thus, the male rats in our experiments may 
have had lower circulating levels of olanzapine which may have accounted for their lack 
of weight gain in this and other studies. Moreover, sex differences in hepatic drug 
metabolism are more robust in rodents than humans (Waxman and Celenza 2003). Thus, 
the sex-specific differences in drug pharmacokinetics and pharmacodynamics may impact 
on side effect susceptibility in humans, and it is possible that these are reflected more 
clearly when translated to animals. 
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Of course, notable gender differences in hormones may influence the propensity to incur 
metabolic effects of antipsychotics, especially as olanzapine has known and considerable 
effects on the reproductive function in female rats (Fell et al. 2005). However, 
ovarectomised rats gain excessive weight when treated with olanzapine (Park et al. 2010), 
suggesting hormonal differences do not play a direct role in the observed sex-differences 
of antipsychotic-induced weight gain. 
It should be noted that male rats can be induced to gain excessive weight when given 
high doses for long periods and in addition to a high-fat diet (Shobo et al. 2011).  
Interestingly, Kluge et al, found a delayed onset of weight gain in male patients compared 
to females (Kluge et al. 2009) which is in someway reflected in the longer protocol 
required for weight gain in the recent study by Shobo and colleagues <Shobo, 2011 
#225>. Therefore, we cannot rule out that the male rats may have shown increases in 
weight if treated for a longer period or given a higher dose. 
In support of a clinically relevant effect of sex, we identified a number of physiological 
differences between the male and female rats that may have contributed to the 
divergence in response to antipsychotic treatment. These included baseline differences in 
circulating levels of the orexigenic hormone ghrelin, a difference that is mirrored in 
humans (Greenman et al. 2004). 
These results therefore highlight the need for greater attention to be placed on 
appropriate prescribing of antipsychotics, taking sex into account (Seeman 2004). Patient 
monitoring following prescription of certain antipsychotics could also be tailored taking 
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sex into consideration, with women receiving more regular clinical assessment for the 
presence of metabolic dysfunction.  
7.4 Metabolic effects of olanzapine and risperidone 
Olanzapine and risperidone both induced metabolic effects in the rat reminiscent of those 
observed clinically (Table 7.2). These effects allowed us to assess whether novel potential 
mechanisms contributing to this metabolic dysfunction i.e. the gut microbiota  
Parameter Olanzapine Risperidone 
Body weight ↑↑↑ ↑↑ 
Food intake ↑↑↑ ↑↑ 
Locomotor activity ↓ ↓ 
Liver weight ↑ ↑ 
Visceral adiposity ↑↑ ↑ 
Macrophage infiltration ↑ ↑ 
Inflammation# ↑ ↑ 
Insulin sensitivity ↓   -* 
Microbiota ↑↓ ↑↓ 
Table 7.2. Summary of the effects of olanzapine and risperidone in the rat. *Measured 
as mRNA expression, cytokine levels or circulating endotoxin, #not measured in our studies 
but previously reported to be reduced (Chintoh et al. 2009a). Number of arrow indicates 
scale of change. 
As can be seen from Table 7.1, both drugs induced weight gain in rats, which was slightly 
greater for olanzapine, as is the case clinically (Allison et al. 1999; Foley and Morley 2011). 
Furthermore, both compounds induced evidence of metabolic dysfunction in line with 
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previous studies in rats and also reflecting the clinical situation (Lin et al. 2006; Smith et 
al. 2009; Lauressergues et al. 2010; Citrome et al. 2011b; Zugno et al. 2012). Hence, in our 
experiments, a valid template was established that allowed us to examine whether such 
dysfunction was also associated with dysbiosis of the gut microbiota. 
7.5 Antipsychotic-associated alteration in the gut microbiota  
Administration of olanzapine and risperidone was associated with shifts in certain 
microbial constituents of the gut microbiota. Initial investigations of the faecal microbiota 
of olanzapine treated rats highlighted a trend for shifts in the major phyla with increases 
in Firmicutes and concomitant decreases in Bacteriodetes. This finding was particularly 
exciting as this trend was first described as the ‘signature’ of an obese microbiome in 
seminal studies by Gordon and colleagues (Ley et al. 2005).  
A similar trend was subsequently observed in a follow-up experiment. Strikingly, in this 
experiment, co-administration of the antibiotic cocktail resulted in a reversal of this shift, 
with decreased Firmicutes and increased Bacteriodetes. Thus, as the ratio of these phyla 
is thought to be indicative of an obese phenotype, this trend supports the hypothesis that 
an aberrant microbiota is a feature of antipsychotic induced weight gain. 
Other studies have found a similar trend in humans (Turnbaugh et al. 2009). However, 
several recent reports have not identified this shift in ether animals or humans, and in 
some cases the opposite has been observed (Murphy et al. 2010; Schwiertz et al. 2010). 
Thus, it still remains to be determined if such a phylogenetic switch has a role to play in 
obesity in certain cases.  
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A lack of consistency across studies does not necessarily rule out an important influence 
of such shifts in phyla, as the direct effect of various shifts in phyla on the overall 
metabolic functioning of the gut microbiota is yet to be elucidated and studies to date 
have been primarily descriptive.  
This means that the alterations in microbiota observed in different cohorts, while 
different from one another, could produce the same ultimate effects that impact on host 
energy balance. Hence, when trying to correlate a phenotypic trait as globally pervasive 
as energy metabolism, it may not be surprising that different studies show different 
results in terms of microbial populations correlating with obesity. This is particularly 
plausible as different phyla contain a large and heterogeneous population of bacteria and 
metabolic functions are conserved across diverse species. Hence, shifts in the major phyla 
may represent important indicators of obesity, or may indeed play an etiological role in a 
non-specific fashion (Cummings et al. 2004) 
Perhaps unsurprisingly therefore, we did not observe the same shifts in the caecal 
microbiota of olanzapine treated rats. In fact, the caecal microbiota is known to differ 
considerably from the faecal microbiota (Pang et al. 2012). 
We did however find more subtle changes in the caecal microbiota in the less 
represented phyla, including increased Actinobacteria.  
Increases in Actinobacteria have been described previously in obese humans (Turnbaugh 
et al. 2009). Intriguingly, risperidone treatment resulted in similar increases in 
Actinobacteria.  
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Additional, albeit minor, changes in the gut flora were observed for both antipsychotics at 
the family level. Differences between control animals, as well as antipsychotics treated 
animals, were observed across studies.  
This arguably makes interpretation of the results somewhat difficult. However, this in 
itself is not surprising considering the complex interplay between the intestinal 
microbiota and the immune system, endocrine system, energy homeostasis and lipid 
metabolism (Conterno et al. 2011). 
Thus, it remains to be determined if antipsychotics such as olanzapine and risperidone 
directly affect the composition of the gut microbiota or whether such changes are a result 
of other metabolic abnormalities that then feed into the cycle of dysfunction associated 
with these drugs. Either way, these results suggest that antipsychotic therapy causes 
dysbiosis of the gut microbiota in conjunction with many other metabolic disturbances 
implying that the microbiota represents another aspect of metabolic liability associated 
with these compounds that requires investigation as a therapeutic target. 
7.6 Ameliorating the metabolic side effects of antipsychotics 
A number of drugs have been investigated as adjunctive therapies aimed at ameliorating 
the metabolic side effects of atypical antipsychotics. Of these, metformin, an anti-diabetic 
drug, is the only widely used clinically as it has been shown to be the most consistent 
(Maayan et al. '10). Reboxetine, a selective noradrenaline reuptake inhibitor, has also 
shown promise in attenuating olanzapine induced weight gain (Poyurovsky et al. '07).  
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A number of other co-therapies have been have shown promise recently as potential 
treatments to counteract the metabolic liabilities of these compounds (Table 7.3). None 
of the current therapies work in all patients and none completely attenuate weight gain 
(Maayan et al. '10). Thus, while these interventions may be useful tools for individual 
patients, they are not a long-term clinical solution at present. 
Intervention Mode of Action Species Main Finding Reference 
Metformin 
Hepatic-insulin 
sensitizer 
Human 
Reduced olanzapine-
induced weight gain in 
patients 
(Wu et al. 
2008) 
Reboxetine 
selective 
noradrenaline 
reuptake inhibitor 
Human 
Reduced olanzapine-
induced increases in 
appetite and body weight  
(Poyurovsky 
et al. 2007) 
Naltrexone Opioid antagonist Rat 
Ameliorated olanzapine-
induced increases in body 
weight and food intake 
(Kurbanov et 
al. 2012) 
Betahistine 
H1 agonists/H3 
antagonists 
Rat 
Attenuated olanzapine-
induced weight gain and 
reduced feeding efficiency 
(Deng et al. 
2012) 
Omega-3 
fatty acid 
Effects on TG 
synthesis 
Rat 
Omega-3 deficiency 
augmented risperidone-
induced metabolic effects 
(McNamara 
et al. 2012) 
Sibutramine 
5-HT-NA reuptake 
inhibitor 
Rat Prevented olanzapine-
induced motivation for 
palatable food 
(van der 
Zwaal et al. 
2012) 
BGP-15 
Heat shock 
protein co-inducer 
Rat Prevented olanzapine-
induced weight gain 
insulin resistance 
(Literati-Nagy 
et al. 2012) 
Melatonin 
Increases 
circulating levels 
of melatonin 
Rat Attenuated olanzapine-
induced weight gain 
(Raskind et al. 
2007) 
Mifepristone 
Glucocrticod 
antagonist 
Humans Reduced olanzapine and 
risperidone- induced 
weight gain 
(Gross et al. 
2009; Gross 
et al. 2010) 
Table 7.3 Therapies investigated as adjunctive therapies to antipsychotic to prevent 
metabolic side effects. TG, triglycride, 5-HT, serotonin, NA, noradrenaline 
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Co administration of other atypical drugs with little or no weight-inducing tendencies, 
such as ziprasidone or aripiprazole, have even been shown to attenuate the hyperphagic 
effects of olanzapine in rats, presumably via competitive effects on central receptors such 
as the serotonergic system (Snigdha et al. 2008).  
 
Importantly, trends in developing newer antipsychotics are focused on narrowing the 
pharmacological profile of atypical compounds without altering efficacy and at the same 
time avoiding a return to EPS-like side effects seen with first-generation drugs. One such 
drug is lurasidone, which has no affinity for histamine H1 or muscarinic M1 receptors, but 
has high affinity for D2 and 5-HT2A receptors. Thus far, in clinical trials, lurasidone has 
shown comparable efficacy to ziprasidone with a seemingly negligible side effect profile 
(Meyer et al. '09). Asenapine has also been recently approved for acute schizophrenia and 
bipolar disorder, and while it does not seem to offer superior efficacy, it has displayed a 
promising side effect profile (Tarazi and Shahid '09). Aripriprazole is the first ‘third 
generation’ antipsychotic to be approved and has minimal effects on metabolism (Pae 
2009).  
Only time will tell if these drugs are suitable replacements for the current ensemble of 
atypical compounds, in particular in relation to long-term efficacy and tolerability. 
Interestingly, nutritive therapy i.e. dietary changes, alongside exercise, can effectively 
attenuate antipsychotic-induced weight (Skouroliakou et al. 2009; Ball et al. 2011). As 
already mentioned, schizophrenia patients have poorer metabolic health regardless of 
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antipsychotic therapy and hence this form of intervention could be beneficial to the 
patients on more than one front. Increased exercise and improvements in diet could not 
only attenuate drug-induced side effects but allow the patient to have a healthier lifestyle 
additionally improving their long term outcomes in terms of morbidity and mortality.  
Unfortunately however, as we have learned from the obesity epidemic in the general 
population, the use of exercise and good diet as a long term tool is easier said than done, 
and this is likely to prove even more difficult in a psychiatric patient population.  
Whether therefore lifestyle intervention is a viable option in most cases is questionable, 
but of course should always be encouraged. 
7.6.1 Microbial approaches to attenuate antipsychotic-induced metabolic side 
effects 
In the past number of years, modulating the gut microbiota with antibiotics has been 
shown to reduce weight gain, improve insulin resistance and reduce inflammation in a 
number of experimental models including ob/ob and diet-induced obese mice (Cani et al. 
2008; Membrez et al. 2008; Carvalho et al. 2012; Murphy et al. 2012). However, whether 
such effects extend to antipsychotic-induced weight gain and metabolic dysfunction such 
had not been explored. 
In the studies described herein, we therefore employed three antibiotic based 
approached to investigate if the gut microbiota could be targeted therapeutically to 
attenuate the effects of the atypical antipsychotics, olanzapine or risperidone. The nature 
and effects of these approaches is summarised in Table 7.4. 
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Intervention Bacterial target Main findings 
Antibiotic cocktail: 
neomycin, metronidazole, 
polymyxin B 
Broad coverage of Gram-
positive and negative 
anaerobes and aerobes 
Attenuated olanzapine-
induced weight gain & fat 
deposition 
Non-significant 
improvement in insulin 
resistance 
Rifaximin 
Gram positive and negative 
anaerobes 
Attenuated olanzapine but 
not risperidone-induced 
weight gain 
Normalised expression of 
key lipogenic enzymes 
Vancomycin Gram positive, mainly Bacilli 
Reduced scfa production, 
prevention of increased 
adiposity 
Table 7.4 Antibiotic approaches to attenuate antipsychotic-induced metabolic 
dysfunction. scfa, short-chain fatty acids 
We first used a cocktail of broad-spectrum antibiotics to ablate the gut flora and 
investigated if this reduced the metabolic liability of olanzapine. The cocktail of antibiotics 
employed are known to effectively destroy the gut flora of rats (Juno et al. 2003). The 
antibiotic cocktail not only altered the microbiota but also reversed the changes in the 
faecal microbiota associated with olanzapine treatment.  
To ensure that any benefits of microbiota manipulation were in fact microbiota-driven, 
we subsequently used two non-absorbable antibiotics, administered per os, to further 
test our hypothesis.  
Rifaximin and vancomycin produced vastly different effects on the gut flora, with 
vancomycin having much more profound effects. This is to be expected as the two 
compounds act via differing mechanisms and target different bacteria.  
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Vancomycin reduced the abundance of the major phyla Firmicutes, were as rifaximin did 
not. The more subtle effects of rifaximin most likely reflect its bacterial coverage in 
relation to the commensal flora. Nevertheless, both antibiotics caused significant 
alterations in the overall make-up of the microbiota as evidenced by principle co-ordinate 
analysis (data not shown). 
As discussed earlier, correlating the specific effects of these antibiotics, or indeed ones 
used in other studies, with changes in host metabolism is likely an over-simplistic view of 
the complex interactions within the microbiota environment and the subsequent equally 
complex interaction of the microbiota with the host via immune endocrine and hormonal 
systems.  
Indeed, as recent reports from the human microbiome project 
(http://www.hmpdacc.org/) indicates, what bacteria are there may not be as important 
as what genetic potential is present, i.e. the metagenome (Turnbaugh et al. 2007; 
Arumugam et al. 2011). As mentioned, several metabolic functions are conserved across 
bacterial groups making changes in the composition of the flora difficult to interpret. 
Studies of the metagenome have revealed that diseases such as type II diabetes correlate 
with not only changes in the composition of the flora but also with specific function such 
as reduced butyrate production and increased sulphate reduction (Qin et al. 2012). 
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7.7 Effects of antibiotic administration on antipsychotic-induced weight gain 
In our experiments, antibiotic treatment attenuated or prevented several aspects of 
clinically-relevant metabolic dysfunction induced by the atypical antipsychotics, 
olanzapine and risperidone. This included the attenuation of olanzapine–induced weight 
gain by both a cocktail of antibiotics and the antibiotic rifaximin. Whether the scale of the 
reduction in weight gain observed reflects a clinically significant change is debatable, 
however these findings represent an exciting proof-of-principle highlighting that 
modulation of the gut flora can impact on olanzapine-induced weight gain. Other issues 
not fully resolved included the temporal effects on weight of the co-administration of 
antibiotics and the differences observed at different doses of olanzapine.  
Atypical antipsychotics undoubtedly act centrally to increase appetite leading to 
hyperphagia and rapid weight gain, as has been seen several times in both animals, 
healthy volunteers and patients (Davoodi et al. 2009; Fountaine et al. 2010). Thus, the 
contribution of the gut microbiota through effects on peripheral mechanisms may be 
unable to influence these initial, central effects. This may explain the lack of an effect of 
antibiotics on body weight in the first week of olanzapine administration. In line with this 
possibility, the antibiotics did not ameliorate olanzapine-induced hyperphagia. Hence, it 
may be the case that the contribution of the microbiota cannot be used therapeutically 
until additional metabolic anomalies, stemming in part from weight gain, begin to occur. 
The antibiotic cocktail had a lesser effect on body weight gain in rats receiving the higher 
dose (4 mg/kg) of olanzapine, compared to the lower dose (2 mg/kg).  
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While the reasons for this remain obscure, it is worth noting that in our studies, like 
others, a dose dependent effect of olanzapine was not observed in relation to weight gain 
(Citrome et al. 2009a). Indeed, similar to the clinical setting, olanzapine-induced weight 
gain plateaued after approximately two weeks. The antibiotic administration showed 
little effect on body weight when administered alone and in fact showed a trend for 
increasing body weight. Thus, it would seem that the contribution of the microbiota to 
normal energy homeostasis becomes apparent under situations of metabolic dysfunction. 
Hence, as the plateau effect was more evident for the higher dose, this may go some way 
to explain why the effects of the antibiotics were less robust at the 4 mg/kg dose.  
Rifaximin attenuated olanzapine-induced weight gain while this was not the case for 
risperidone treatment. While initially surprising, this is perhaps not too unexpected as 
these drugs differ pharmacologically and this difference in pharmacology likely 
corresponds to differences in the peripheral mechanisms belying their respective 
metabolic effects. Indeed, a number of studies have found differential effects of 
risperidone and olanzapine on metabolic parameters in including triglycerides, 
adiponectin and cholesterol, suggesting divergent effects, particularly on adipose tissue 
physiology (Smith et al. 2009; Scheen et al. 2010; Smith et al. 2010; Wampers et al. 2012).  
Unlike rifaximin, the antibiotic vancomycin did not reduce olanzapine-induced weight 
gain. This is in contrast to a recent report in which vancomycin attenuated weight gain in 
diet-induced obesity in mice (Murphy et al. 2012).  
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The reasons for this are unclear as the mechanisms involved in vancomycin’s effects in 
the mouse model remain unclear. However, as will be discussed below, the microbiota 
can impact on host metabolism and energy balance in several ways, and the phenotypic 
outcome of this interaction is likely to be different under different paradigms of 
metabolic disease.  
Crucially, it has been realised in recent times that antipsychotics such as olanzapine can 
have profound negative metabolic effects in the absence of over weight gain. This 
includes effects on adiposity as well as lipid and glucose regulation which contribute 
substantially to the cardiometabolic threat posed by these drugs. Hence, tackling these 
metabolic threats, in conjunction with, or even aside from, tackling body weight gain is 
extremely important.  
7.8 Potential mechanisms of microbiota attenuation of antipsychotic-induced 
metabolic dysfunction 
Our investigations have revealed that the gut microbiota can influence the metabolic 
liabilities of antipsychotics via several overlapping and converging mechanisms (Fig. 7.1). 
These mechanisms include nutrient handling, energy storage and inflammation (Fig 1.10).  
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Fig. 7.1 Working model in which the gut microbiota may attenuate the metabolic 
dysfunction associated with antipsychotics based on our studies 
7.8.1 Visceral fat accumulation 
All three antibiotics used in our studies significantly attenuated or even prevented 
olanzapine-induced increases in peri-uterine fat, and rifaximin did the same for 
risperidone. This finding was remarkably consistent across studies and reinforces the 
potential of microbiota-targeted interventions have for antipsychotic-induced metabolic 
dysfunction. 
The peri-uterine fat pad, along with the mesenteric and peri-renal fat, makes up the 
visceral fat of rats. Visceral fat is now recognised as much more than an energy repository 
and can be viewed as an endocrine organ as it is capable of producing and releasing 
hormones and cytokines, especially proinflammatory mediators  (Mohamed-Ali et al. 
1998; Trayhurn and Beattie 2001; Trayhurn and Wood 2004).  
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Increased release of proinflammatory mediators as well as free fatty acids from an 
expanding adipose mass put visceral fat at the centre of the spiral of metabolic 
dysfunction linking increased weight, inflammation and insulin resistance (Trayhurn et al. 
2011). 
A number of possible mechanisms have been shown to link the gut microbiota to adipose 
tissue development in different experimental models. In a series of elegant experiments, 
Backhed and colleagues showed that germ-free mice are resistant to diet-induced obesity 
and that this was due to two seemingly independent mechanisms (Backhed et al. 2007). 
Firstly, fasting-induced adipose factor (Fiaf) was reduced following conventionalisation of 
germ-free mice, leading to increased lipoprotein lipase (LPL) activity and subsequent 
triglyceride accumulation in adipocytes (Backhed et al. 2004). Secondly, inactivation of 
AMP-activated kinase (AMPK), a key cellular fuel gauge, was found to be reduced in the 
presence of the gut microbiota thereby indirectly promoting energy storage over 
utilisation (Backhed et al. 2007). 
7.8.2 Lipogenesis 
Central to the mechanisms of fat deposition is the process of lipogenesis, i.e. de novo 
synthesis of lipids which occurs primarily in the liver but also in adipose tissue itself. 
Sterol regulatory element binding protein-1c (SREBP-1c) is an insulin-sensitive, master 
transcription factor which, in concert with other genes, controls lipogenesis. SREBP-1c 
exerts this control via activation of lipogenic enzymes, in particular, fatty acid synthase 
(FAS) and acetyl-coA carboxylase (ACC) (Ferre and Foufelle 2007).  
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In our studies, we found that olanzapine increased the expression of FAS in both hepatic 
and adipose tissues. Moreover, antibiotic administration prevented these increases. Thus, 
the microbiota either directly or indirectly inhibited olanzapine’s ability to drive 
lipogenesis, thereby reducing subsequent fat deposition.  
One of the ways olanzapine leads to increased lipogenesis is via centrally driven increases 
in food intake. Increased food intake leads to increased delivery of carbohydrates to the 
liver where they are converted to lipids (lipogenesis) and subsequently stored as fat. 
Thus, given the microbiota’s known role in energy extraction, altering the microbiota may 
have led to reduced nutrient absorption such that increased food did not equate to 
increased carbohydrate absorption. This is therefore one mechanism whereby 
manipulation of the microbiota could reduce fat deposition. This hypothesis is supported 
by the fact that antibiotic treatment alone did not alter FAS expression. In further support 
of a role of FAS, increased FAS expression has previously been implicated in risperidone 
induced metabolic dysfunction (Lauressergues et al. 2010) 
Intriguingly, in the case of ACC the opposite phenomenon was observed, as only animals 
receiving olanzapine and the antibiotic cocktail had increased hepatic expression levels. 
While initially surprising, this also suggests that the impact of the microbiota was only 
apparent in the context of metabolic dysfunction. As in the case of FAS, effects on energy 
extraction could have impacted on ACC expression levels, and while reduced levels would 
be expected, in the presence of olanzapine-induced changes there may be competing or 
compensatory mechanisms that led to the observed increases. 
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In support of this theory, we also found increased expression of peroxisomal proliferator-
activated receptor gamma (PPARγ) in the adipose tissue of olanzapine treated rats but 
unchanged levels in those also given an antibiotic.  
PPARγ is the master regulator of adipogenesis (Bays et al. 2004), thus this finding is 
consistent with a microbiota-driven mechanism whereby reduced hepatic lipogenesis 
results in decreased delivery of triglycerides to the adipose tissue and no expansion of 
adipose tissue (adipogenesis). 
7.8.3 Energy absorption 
A major way in which the microbiota contributes to energy balance is via the 
fermentation of indigestible dietary fibres into short-chain fatty acids (scfa). The primary 
scfa produced are acetate, propionate and butyrate which account for approximately 80% 
of all scfa in the gut (Cummings et al. 1987). Butyrate is used primarily as the preferred 
energy substrate of the colonic epithelium (Roediger 1980). Acetate and propionate on 
the other hand are delivered to the liver where they affect hepatic lipid processing in 
opposite ways, with acetate a lipogenic substrate and propionate inhibiting lipogenesis 
(Conterno et al. 2011). Interestingly, these affects are mediated, at least in part, via 
affects on the expression of FAS (Agheli et al. 1998). 
We therefore investigated if the antibiotics, rifaximin or vancomycin, impacted on the 
production of scfa by measuring the levels acetate, propionate and butyrate in the caecal 
content of treated rats. Surprisingly, vancomycin, but not rifaximin, dramatically reduced 
the concentration of scfa, especially acetate and butyrate.  
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Thus, this suggests that vancomycin administration through alterations in the gut flora 
resulted in not only reduced acetate, but also an increased propionate/acetate ratio 
thereby inhibiting hepatic de novo lipogenesis in olanzapine-treated animals and 
preventing increased fat storage. 
This does however suggest that vancomycin and rifaximin prevented olanzapine-induced 
effects via separate mechanism. This is entirely possible and highlights the diverse ways in 
which the microbiota can influence host physiology. However, is should also be noted 
that while rifaximin did not alter the caecal concentrations of scfa, it could conceivably, 
have altered their absorption (Tremaroli and Backhed 2012).  
Thus, while not fully elucidated, the microbiota’s impact on energy absorption and 
subsequent effects on lipogenic enzymes appears strong enough to significantly 
attenuate olanzapine-induced lipogenesis and fat storage. 
7.8.4 Insulin resistance 
We also found that the co-administration of an antibiotic cocktail reduced the plasma 
levels of free fatty acids (FFA). Circulating free fatty acids are released from the adipose 
tissue as the storage capacity of adipocytes becomes reduced in the face of continued 
energy storage (overflow hypothesis).  
Plasma free fatty acids are then stored in ectopic sites such as liver and muscle, 
exacerbating insulin resistance (Yki-Jarvinen 2002; Eckel et al. 2005). In addition, we 
found that antipsychotic treatment resulted in increased liver weight as a proportion of 
body weight, indicative of a fatty liver. Antibiotic treatment prevented such increases in 
line with the finding of reduced FFA.  
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It should be noted that the role of FFA in metabolic dysfunction is not entirely clear and 
the current concept is challenged by the fact the adipose tissue release of FFA mainly 
stems form subcutaneous fat not visceral fat (Karpe et al. 2011). This said, antipsychotics 
such as olanzapine effect lipid handling in both visceral and subcutaneous adipose tissue 
(Albaugh et al. 2010), such that our findings may also reflect similar dysfunction lipid 
handling in subcutaneous tissue though further studies would be required to confirm this 
7.8.5 Inflammation 
The microbiota’s role in inflammation and metabolism also involves endotoxin, also 
known as lipopolysaccharide (LPS). LPS is a component of the cell wall in gram-neagative 
bacteria and  increased plasma levels of LPS has been found to correlate with type II 
diabetes in humans (Creely et al. 2007). LPS is potently proinflammatory and increased 
levels contributing to metabolic dysfunction has been coined ‘metabolic endotoxemia’ 
(Cani et al. 2007a).  
As already mentioned, the adipose tissue is now viewed as an endocrine organ which can 
play an active role in metabolic dysfunction. Thus, the prevention of antipsychotic-
induced increases in visceral fat could have indirectly produced other beneficial effects 
observed.  
The adipose tissue is responsible for the release of proinflammatory cytokines but does 
so in concert with, and in response to, macrophages, which infiltrate the adipose tissue in 
conditions of obesity or metabolic dysfunction (Xu et al. 2003). This infiltration is seen as 
a key step in development of obesity-related inflammation which contributes to ensuing 
insulin resistance and metabolic dysfunction (Xu et al. 2003).  
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The infiltration of macrophages into adipose tissue is thought to be a response to signals 
released from dying adipocytes as the adipose tissue hypertrophies (Cinti et al. 2005).  
Thus, it is highly likely that the reduction in macrophage infiltration observed in animals 
co-administered an antibiotic was an indirect result of preventing the expansion in 
adipose mass.  
In addition, we observed that antibiotic treatment attenuated systemic inflammation 
induced by olanzapine, in particular TNF. This too was most likely a result of preventing 
visceral fat expansion and subsequent lack of macrophage infiltration. Over the course of 
our studies, we did however observe inconsistent effects of olanzapine on circulating 
cytokines. A key difference between these studies, however, was that in one case the 
animals were fasted and in another they were not. Fasting is known to have acute effects 
on the levels of cytokines, in particular in cases of underlying metabolic dysfunction such 
as type II diabetes (Esposito et al. 2002). Hence, the effects of fasting may explain the 
variability between our studies in this parameter.  
We found evidence of increased levels of LPS following risperidone treatment though this 
did not reach statistical significance, possibly due to a number of samples falling below 
the level of detection, especially in the control groups. Intriguingly, in line with a reduced 
microbial load expected with antibiotic treatment, rifaximin treated animals had reduced 
levels circulating LPS. This suggests another distinct mechanism whereby manipulation of 
the flora could conceivably attenuate the proinflammatory effects of antipsychotics. Of 
course, further research is needed to discern whether antipsychotics do result in 
increased levels of LPS and if this is due to increased gut permeability.  
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Increased gut permeability is associated with obesity and increases in visceral fat (de La 
Serre et al. 2010; Gummesson et al. 2011).  
It is still unclear whether systemic inflammation leads to epithelial barrier dysfunction 
which results in increased LPS, or whether increased permeability via other mechanisms 
such as stimulating the secretion of the chemokine Ccl5 stimulate adipose tissue 
inflammation (Tremaroli and Backhed 2012). 
Increased levels of LPS nevertheless contribute to the cycle of metabolic abnormalities 
leading to insulin resistance. LPS stimulates Toll-like receptor (TLR) 4 receptors on 
macrophages, adipose tissue and other tissues causing further release of inflammatory 
mediators, such as TNF, which induce insulin resistance. We investigated this link by 
examining TLR 4 mRNA expression in adipose and muscle tissue. We observed reduced 
TLR 4 expression in adipose tissue of risperidone treated animals, but not in animals also 
receiving rifaximin. Reduced expression following risperidone treatment may have been a 
result of receptor internalization due to chronic stimulation although this cannot be 
assumed and further investigation of the contribution of an LPS-TLR 4 mechanism in 
antipsychotic-induced insulin resistance is warranted. 
Several studies in mice have highlighted that reducing levels of LPS impacts positively on 
the metabolic health of animals in a number of paradigms (Cani et al. 2007a; Cani and 
Delzenne 2009). This therefore lends weight to the possibility that the reductions in LPS 
observed in response to rifaximin may have reduced the proinflammatory tone in 
risperidone treated rats, though whether this was via TLR4, potentially in other tissues, 
remains to be elucidated. 
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7.8.6 Endocannabinoid system 
Another mechanism shown to be involved in the link between the microbiota, gut 
permeability and obesity is the endocannabinoid (eCB)system (Cani et al. 2010). Research 
found that obesity in mice is associated with a dysregulated eCB tone. Increased eCB tone 
i.e. increased receptor levels of cannabinoid receptor 1 (CB1) as well as increased tissue 
levels of endocannabinoids, were associated with increased adipogenesis and the 
development of visceral fat mass (Muccioli et al. 2010). Moreover, these investigators 
demonstrated that the gut microbiota influences eCB tone in such a way as to control gut 
permeability and consequently low grade inflammation and fat deposition.  
We therefore investigated in our model, if olanzapine-induced increases in fat mass could 
involve the endocannabinoid system and found that the mRNA expression of CB1 was up-
regulated in olanzapine treated rats. Moreover, antibiotic treated animals did not show 
any such increases in response to olanzapine, strongly supporting a link between the gut 
microbiota the endocannabinoid system and fat deposition. Indeed, a combination of 
antibiotics, or indeed prebiotics, was previously shown to reduce CB1 expression and fat 
mass development in genetically obese mice (Cani et al. 2010). It must be noted however, 
that contrary to our observations, these authors also found increased expression of FAS 
and PPARγ in conjunction with increased CB1 expression. Given the complex regulation of 
adipogenesis, this difference may reflect the different models of metabolic dysfunction 
under investigation.  
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It is therefore clear from our studies, that the gut microbiota is an important factor in the 
cycle of metabolic dysfunction via a number of mechanisms both direct and indirect, 
involving energy absorption, inflammation and metabolism. Moreover, we have 
demonstrated that these mechanisms also extend to antipsychotic-induced metabolic 
dysfunction, at least in rats. 
The converging effects of this metabolic dysregulation lead to insulin resistance which 
ultimately lead to type II diabetes and increased cardiovascular risk in patients. We found 
that the antibiotic cocktail, while not normalising it, did appear to improve insulin 
sensitivity in olanzapine-treated rats. Thus the beneficial effects observed throughout our 
investigations, if reproduced in humans, may well act to decrease the risk of morbidity 
and mortality in patients receiving atypical antipsychotics.  
The considerable complexity and indeed implications of this trialogue between the 
immune system, metabolism and the gut microbiota is only beginning to be unravelled 
(Shulzhenko et al. 2011), and further understanding of these interactions will no doubt 
lead to greater understanding of the underlying mechanisms as well opportunities for 
intervention in several disease states, including metabolic disease, such as that caused by 
certain antipsychotics. 
7.9 Microbiota as a therapeutic target 
As has been outlined in the previous section, we have utilised different antibiotics to 
manipulate the gut microbiota and thereby attenuate certain effects of atypical 
antipsychotics.  
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This potentially opens the door for therapeutics that target the gut flora as means to 
prevent or ameliorate the side effects of these drugs thereby improving patient outcomes 
by reducing morbidity and mortality as well as improving compliance.  
While we have shown that antibiotics can influence the microbiota in such a way as to 
produce beneficial effects in rats, the use of such agents in humans is complicated by 
issues of antibiotic resistance as well as potential gastrointestinal side effects of their 
own.  
This said, our studies have provided an exciting proof-of-principle that the microbiota is a 
viable drug target in antipsychotic-induced metabolic dysfunction, supporting similar 
findings in other paradigms (Cani et al. 2007b; Cani et al. 2010; Muccioli et al. 2010; 
Murphy et al. 2012).  
In addition to the mechanisms already discussed, manipulation of the gut microbiota has 
the potential to improve metabolic health by a number of mechanisms (Table 7.5). A 
number of these mechanisms are secondary to effects already mentioned. For instance, 
scfa are ligands for G-protein receptors, GPR41 and GPR43, which when activated 
stimulate the release of PYY (Musso et al. 2010b) which not only slows gastric transit but 
also contributes to short-term satiety following a meal (Beglinger and Degen 2006). 
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Mechanism Mode of action Ref 
↑ CLA Synthesis of CLA (Wall et al. 2009) 
Neurotransmitter 
synthesis 
Release of GABA (Barrett et al. 2012) 
↑ Dopamine (Asano et al. 2012) 
↑ 5-HT (Wikoff et al. 2009) 
↑ Gut peptide 
release 
↑ PYY (Musso et al. 2010b) 
↑ GLP-1 (Cani et al. 2009a) 
↑ GLP-2 (Cani et al. 2009b) 
↓ Inflammation 
↑ IL-10production (Ueda et al. 2010) 
↑ IL-12 production (Takeda et al. 2006) 
↓ Levels of LPS (Cani et al. 2008) 
Improved gut 
barrier function 
↑ Butyric acid production 
(Van Immerseel et al. 
2010) 
↑ Defensins (Wehkamp et al. 2004) 
Table 7.5 Mechanisms linking the modulation of the gut microbiota to improvements in 
metabolic health. CLA, conjugated linoleic acid; GABA, gamma-amino butyric acid; 5-HT, 
serotonin; PYY, peptide YY; GLP-1, glucagon-like pepetide-1; GLP-2 glucagon-like pepetide-
2; IL-10, interleukin-10; IL-12, interleukin 12; LPS, lipopolysaccharide 
Importantly, a number of probiotics/prebiotics have been shown to propagate the above 
mechanisms in animal studies (Grangette et al. 2005; Cani et al. 2009a; Burcelin et al. 
2010; Van Immerseel et al. 2010). These mechanisms allow the microbiota to influence 
both sides of energy balance, affecting appetite, nutrient absorption and energy storage. 
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7.9.1 Probiotics 
Probiotics are defined as live microorganisms which when administered in adequate 
amounts confer a health benefit to the host. Probiotics therefore consist of bacterial 
strains perceived to be beneficial, such as bifidobacterium and lactobacillus. Such 
probiotics have shown promise in a range of conditions, especially inflammatory bowel 
disease and irritable bowel syndrome (Clarke et al. 2012; Veerappan et al. 2012). 
In humans, probiotics have shown both positive and negative results in trials of obesity 
(Gobel et al. 2012; Million et al. 2012). Lactobacillus gasseri (LG 2055) reduced body 
weight and adiposity in adults (Kadooka et al. 2010). 
The use of probiotics as therapeutics is in its infancy, and to this end there is currently no 
FDA or EFSA approved probiotic health claim. This is likely due in part to the complex task 
of categorising a probiotic as either a drug, food supplement, medical food or biologic 
(Degnan 2008).  
In the coming years, more robust data will become available for probiotics already in use 
and increased understanding of specific probiotic-host and probiotic-disease interactions 
will no doubt allow the development of more targeted and efficacious probiotics which 
can then be judged fairly as tools against diseases such as obesity. 
7.9.2 Prebiotics  
Prebiotics are selectively fermented ingredients that result in specific changes to the 
composition and/or activity of the gut microbiota thus conferring benefit(s) to the host. 
Prebiotics most commonly include inulin and fructose oligosaccharides.  
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As with probiotics, these products have thus far been primarily focused on promoting the 
growth of bifidobacterium or lactobacillus, and studies in humans have provided mixed 
results (Brownawell et al. 2012). Hence, also like probiotics, no prebiotic health claim has 
so far been approved by the FDA or ESFA, as debate over what constitutes a normal 
microbiota and proof of cause and effect in response to such treatments continues 
(Brownawell et al. 2012). 
7.9.3 Faecal microbiota transplantation (FMT) 
Another intriguing intervention that offers an opportunity for manipulation of the gut 
microbiota is faecal microbiota transplantation (FMT). FMT has in fact been used in 
selected cases for over 50 years (Eiseman et al. 1958). FMT involves the transferring of a 
donor microbiota to a recipient via filtered faecal content, generally administered by 
transcolonoscopic infusion (Borody and Khoruts 2012). Unlike probiotic or prebiotics, FMT 
aims to completely replace or repair the entire microbiota of the individual.  
At present, FMT is used primarily for Clostridium difficile infection that is recalcitrant to 
antibiotic therapy. However, exciting case studies suggesting efficacy of FMT in a range of 
diseases including ulcerative colitis and even multiple sclerosis are emerging (Borody et 
al. 2011). Moreover, FMT has also sown promise in metabolic disorders with improved 
insulin resistance reported in obese subjects receiving FMT from lean donors (Vrieze et al. 
2010) replicating findings in mice (Membrez et al. 2010). A recent support also 
demonstrated diverging microbiota between diabetes-prone and diabetes-resistant rats 
(Serino et al. 2012) emphasising the possibility that microbiota transfer could be a viable 
therapeutic strategy for diseases such as type II diabetes in the future. 
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Whilst the evidence for FMT in a range of diseases is gathering (Aroniadis and Brandt 
2012), a number of potential hurdles are yet to be fully addressed including issues over 
safety, donor selection and administration. This said, fears of the ‘yuck’ factor have 
perhaps caused the greatest delay in the area of research (Zipursky et al. 2012) though 
research suggests that despite its unappealing nature, patients are indeed willing to 
consider FMT if it potentially offers disease relief. 
Thus, further studies investigating the potential use of FMT in metabolic disease and 
indeed in antipsychotic-induced metabolic side effects may prove revealing. 
Characterisation of an obese-microbiome or even an antipsychotic-related microbiome as 
reported in several previous reports and continued herein, will prove essential to 
designing and carrying out such investigations. 
It is now apparent therefore that the gut microbiota does indeed represent a therapeutic 
target of immense, thus far untapped, potential (Jia et al. 2008). Considerable 
advancements in recent years have accelerated this area of research and will no doubt 
continue to do so. It seems therefore only a matter of time until probiotic and prebiotic 
products can be utilised in such a way as to be of benefit to patients with, or at risk of, a 
range of conditions including obesity and metabolic dysfunction.  
Given the ever growing appreciation of the complexity of the gut microbiota ecology and 
interaction with the host, such treatments of the future may rely on prior analysis of an 
individuals’ microbiota.  
262 
 
Of course, given the microbiota’s susceptibility to changes in diet, stress, age and 
location; targeting the microbial organ on a global scale, as seen with conventional 
pharmaceuticals is going to be a considerable challenge over the next number of years. 
7.10 Overall conclusions and future perspectives 
We have investigated whether the gut microbiota contributes to the metabolic 
dysfunction associated with certain atypical antipsychotics, and whether it therefore 
represents a novel therapeutic target. 
We have demonstrated that olanzapine and risperidone when administered chronically 
induce alterations in the gut microbiota of rats, in conjunction with several other 
metabolic abnormalities including weight gain, increased visceral fat, and a 
proinflammatory phenotype. Thus, this novel finding highlights yet another paradigm in 
which altered microbiota has been observed and adds to the ever growing list of human 
pathologies in which the microbiota has been implicated. 
Whether changes in the gut flora in response to antipsychotics are a cause or effect of 
weight gain and/or other metabolic effects remains unknown. However, we undertook a 
proof-of-principle approach using a cocktail of broad-spectrum antibiotics to investigate if 
gut microbiota has a substantive role in the side effects of olanzapine. Indeed, co-
administration of the antibiotic cocktail did attenuate olanzapine induced weight gain to a 
limited degree. Moreover, and arguably more importantly, the antibiotic cocktail 
produced dramatic effects on adiposity; preventing olanzapine-induced increases in peri-
uterine fat and associated macrophage infiltration.  
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This novel finding supports previous work of others in which antibiotics had similar 
beneficial effects in other paradigms of obesity and metabolic dysfunction (Cani et al. 
2008; Muccioli et al. 2010). 
One question that remained following the use of the antibiotic cocktail was to show that 
the effects were indeed driven by the microbiota, as systemic effects of antibiotics on 
metabolism have been reported (Takamoto et al. 2003). We therefore investigated if two, 
non-absorbable antibiotics could, when delivered per os, reproduce any of the effects 
observed with antibiotic cocktail. 
Both rifaximin and vancomycin prevented olanzapine-induced increases in visceral fat, 
while rifaximin also attenuated olanzapine-induced weight gain to a modest but 
significant degree. Several other features of antipsychotic related metabolic dysfunction 
were also normalised showing that the gut microbiota does indeed feed into the complex 
cycle of metabolic derangement observed following antipsychotic treatment.  
We have also shown that the involvement of the gut microbiota also extends to the 
atypical antipsychotic, risperidone, with similar effect observed in response to rifaximin 
on adiposity and inflammation. 
Given the recognised importance of visceral fat accumulation and low grade inflammation 
in the myriad of complications observed in the metabolic syndrome, our findings are of 
considerable clinical interest.  
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Thus our studies add impetus to research investigating the microbiota as a therapeutic 
target in obesity and metabolic disease by opening an entirely new avenue for the use of 
such treatments i.e. antipsychotic-induced metabolic dysfunction.  
Much work is yet to be done, and translating promising animal data into humans is a 
considerable and crucial challenge yet to be met. What is emerging, however, is that the 
gut microbiota appears to be altered in obesity (including antipsychotic-induced) or on 
obese-type diets and that this aberrant microbiota can impact on various physiological 
mechanisms that regulate energy metabolism, lipid homeostasis, and immune function of 
the host. Moreover, dietary components can be used to modulate this aberrant 
microbiota and their interactions with the host. However, despite strong data from 
animal studies, the ability to modulate the gut microbiota for improved human energy 
homeostasis remains to be confirmed in well-powered human intervention studies  
Moving forward therefore a number of challenges remain. Specifically, whether an 
aberrant microbiota exists in patients receiving antipsychotics should be established. 
However, as studies in humans have already shown, assigning a correlation between 
faecal microflora and host phenotype may not be as easy as once hoped.  
However, showing that dysbiosis exists in patients is the first step in exploring if the 
microbiota can be targeted in the more complex situation presented by humans.  
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Our research also adds further support to the growing work linking the microbiota to the 
development, exacerbation and potential treatment of obesity and the metabolic 
syndrome. Obesity is an ever growing global epidemic and new approaches are 
desperately needed to curb its ever increasing burden on public health.  
Probiotics and prebiotics may offer an exciting new weapons in combating obesity in the 
near future, and as newer probiotics and prebiotics are developed, investigating if these 
have use in antipsychotic-induced metabolic side effects should be a high priority. 
Thus, this thesis has added to the ever burgeoning realisation that our oldest ancestor, 
the gut microbiota, is much more than an invisible tenant. The potential for microbiota 
targeted interventions in antipsychotic-induced side effects, in addition to many other 
metabolic related diseases, suggests that with future research, the microbiota is set to 
become a major part of the pharmacological landscape. 
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Appendix I 
Pilot study investigating the effects of 
haloperidol and olanzapine on body weight 
in mice   
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Abstract 
Background: Atypical antipsychotics are called such due to their reduced liability for extra 
pyramidal side effects (EPS) which occur commonly with the older, typical antipsychotics. 
However, just as atypical drugs can cause EPS, typical antipsychotics have been associated 
with metabolic dysfunction. Thus, efforts are needed to understand both the liability and 
potential mechanistic differences between the alternative drug classes in causing 
metabolic dysfunction.  
Methods: Male C57Bl/6 mice received either vehicle, olanzapine (2 mg/kg) or haloperidol 
(1 mg/kg) via intra-peritoneal injection (I.P.) for 34 days. Bodyweight was measured daily 
and food intake was measured for 2 days each week. Activity was monitored using 
activity monitoring suites and body composition was analysed at the end of the study. 
Results: Haloperidol treatment was associated with reduced locomotor activity, but no 
differences in body weight or body composition. Olanzapine showed evidence of 
increased food intake but a trend for a reduction in bodyweight. 
Conclusions: This experiment highlighted that male mice may not be suitable for 
investigating the metabolic effects of antipsychotics and also highlight potential role of 
sedation, in particular in the case of haloperidol.  
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I.1 Introduction 
Early, typical antipsychotics revolutionised the treatment of schizophrenia. However, 
these compounds are dogged by serious extra pyramidal symptoms (EPS) which comprise 
a range of motor disorders such as dyskinesia and Parkinsonism (Dayalu and Chou 2008). 
Subsequent atypical antipsychotics were defined as a group of compounds based on 
reduced EPS liability despite their pharmacological heterogeneity. Importantly, atypical 
antipsychotics can and do cause EPS when administered at high (usually super-
therapeutic) doses (Tarsy et al. 2002). Equally, while EPS understandably was the main 
focus for typical antipsychotics in terms of adverse events, haloperidol and other typical 
drugs have been associated with metabolic dysfunction (Bobes et al. 2003b; Perez-Iglesias 
et al. 2008). 
Hence, it is important to understand the differing propensities and mechanisms 
underlying metabolic dysfunction seen between the major classes of antipsychotic drug. 
Recent evidence suggests that peripheral mechanisms such as increases in fat mass play a 
central role in detrimental metabolic effects of antipsychotics and in obesity in general. It 
is therefore important to understand if the effects of both typical and atypical 
compounds on factors such as accretion of visceral fat mass differ. 
Therefore, we investigated the effects of both a commonly prescribed typical and atypical 
drug on body weight and body composition in mice.  
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I.2 Methods  
Animals 
Male C57Bl/6 mice (Harlan, UK) of approximately six weeks of age were used and were 
singly housed. Animals were maintained on a 12 hour light/dark cycle with lights on at 
7:30 am. Animals had access to standard chow and water ad libitum. All experiments 
were approved by the Animal Experimentation Ethics Committee (AEEC) of University 
College Cork and carried out in accordance with the Cruelty to Animals Act 1876 and 
European Directive 86/609/EEC on the protection of animals used for experimental and 
other scientific purposes. 
Drug preparation 
Olanzapine and haloperidol (Discovery Fine Chemicals, Ireland) solutions were prepared 
fresh daily. Olanzapine and haloperidol were dissolved in a minimal amount of glacial 
acetic acid (approx 0.1 ml) and then made to volume and pH adjusted to approximately 6 
with 1M NaOH. Vehicle consisted of distilled water acidified with glacial acetic acid and 
pH adjusted to 6 with 1M NaOH. 
Drug treatment 
Mice (n=6) received either vehicle, olanzapine (2 mg/kg) or haloperidol (1 mg/kg) daily via 
intra-peritoneal (I.P) injection for 34 days. The injection took place between 9:00 a.m. and 
10:00 a.m. Doses were chosen based on previously published literature (Cooper et al. 
2005; Fell et al. 2005; Hagan and Jones 2005). 
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Body weight 
Body weight was measured daily to the nearest 0.01g using an electronic balance. 
Food intake 
Food intake was measured on two consecutive days each week. Food was weighed using 
an electronic balance to the nearest 0.01g at the same time on each respective day. 
Body composition  
Body composition was analysed in conscious animals using a minispec nuclear magnetic 
resonance body composition analyser (Bruker Optics, MA,U.S.). Briefly, mice were placed 
carefully into a clear plastic tube which was then inserted horizontally into the minispec 
machine. The analysis takes 20-30 seconds before the mouse was removed from the 
tube, the tube cleaned and the next animal placed inside.  
Locomotor activity 
Locomotor activity was monitored for two consecutive days (48 hours) per week using 
home-cage activity monitoring suites (Medscape). Locomotion was monitored by an 
overhead infrared camera. 
Statistical analysis 
Food intake and locomotor activity were analysed using repeated measures ANOVA. Body 
composition and body weight change were analysed using one way ANOVA. LSD post-hoc 
test used for further analysis where appropriate. 
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I.3 Results 
Body weight 
As expected, time had a significant effect on body weight (F(33,495) = 42.116, p < 0.001). 
Drug treatment did not have an overall significant effect (F(2,15) = 2.88, p = 0.087). 
However, there was a significant time x drug interaction, (F(66,495) = 2.124, p < 0.001). No 
significant differences in body weight were observed between treatment groups over the 
course of the experiment (Fig. I.1). 
 
Fig I.1. Effect of haloperidol and olanzapine on body weight gain in C57/Bl/6 mice. Effect 
of vehicle (VEH), haloperidol (HAL) (1 mg/kg) or olanzapine (OLZ) (2 mg/kg) in male 
C57Bl/6 mice following 34 days administration. Data expressed as mean ± SEM. 
Food intake 
Time had a significant effect on food intake (F(3,45) = 12.174, p < 0.001), as did drug 
treatment (F(2,15) = 4.436, p < 0.05). Post-hoc analysis showed that olanzapine treated 
mice had significantly increased food intake compared to haloperidol treated mice on 
days 7-8 and 14-15 (inclusive) (p < 0.05) (Fig. I.2). 
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Fig I.2 Effect of haloperidol and olanzapine on food intake in C57Bl/6 mice. Effect of 
vehicle (VEH), haloperidol (HAL) (1 mg/kg) or olanzapine (OLZ) (2 mg/kg) administration 
on food intake on two consecutive days during each week of treatment over 34 days #p < 
0.05 versus haloperidol treated mice. Data represent mean ± SEM 
Locomotion 
Locomotor activity was significantly affected by time (F(2,30) = 12.244, p < 0.001). Drug 
treatment also had a significant effect (F(2,15) = 3.695 p < 0.05), though there was not a 
significant interaction (F(4,30) = 1.126, p = 0.363). Post-hoc analysis showed that on days 14 
and 15 mice treated with olanzapine or haloperidol had significantly reduced locomotor 
activity compared to mice receiving vehicle (p < 0.05) (Fig. I.3). 
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Fig. I.3 Effect of olanzapine and haloperidol on locomotor activity. Effect of vehicle 
(VEH), haloperidol (HAL) (1 mg/kg) or olanzapine (OLZ) (2 mg/kg) administration on 
locomotor activity on two consecutive days during each week of treatment in C57Bl/6 
mice. Data expressed as mean ± SEM. *p < 0.05 versus vehicle treated mice. 
Body composition 
Drug treatment had a significant effect on body fat percentage (F(2,15) = 6.968, p < 0.01). 
Drug treatment also had a significant effect on body lean percentage (F(2,15) = 4.045, p < 
0.05).  
Post-hoc analysis revealed that mice treated with olanzapine had significantly reduced 
body fat compared to both vehicle treated (p < 0.05) and haloperidol treated mice (p < 
0.01) (Fig. i.4A). The mice receiving olanzapine also had increased lean mass percentage 
compared to the haloperidol treated mice (p < 0.05) (Fig. I.4B). 
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Fig I.4 Effect of haloperidol and olanzapine on body composition in C57Bl/6 mice. Effect 
of vehicle (VEH), haloperidol (HAL) (1 mg/kg) or olanzapine (OLZ) (2 mg/kg) 
administration for 34 days on (A) body fat mass, (B) body lean mass (C) visceral fat and (D) 
subcutaneous fat in male C57Bl/6 mice. Data expressed as mean ± SEM *p < 0.5 versus 
vehicle treated animals,  #p < 0.05 versus haloperidol treated mice.  
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I.4 Discussion 
In this experiment, neither haloperidol nor olanzapine produced increases in body weight 
in male mice. Contrary, to its clinical effects, olanzapine caused a trend for reduced body 
weight over the course of treatment. These findings are in line with other reports 
suggesting mice are resistant to the weight inducing liabilities of antipsychotics (Albaugh 
et al. 2006). 
Olanzapine did however cause subtle increases in food intake further supporting 
increased appetite as a driving force in olanzapine induced weight gain (Davoodi et al. 
2009). 
Sedative effects of antipsychotics are often mooted as a potential explanation for their 
weight gain liabilities, particularly in preclinical studies. To investigate this possibility, and 
to compare a typical with an atypical drug, we used activity-monitoring cages to assess 
locomotion at various stages of the treatment. The mice receiving either haloperidol or 
olanzapine showed reduced locomotor activity which was significant during days 14 and 
15 of treatment. This effect was most pronounced in haloperidol treated mice, which is 
expected given it’s sedative properties at higher doses, a property utilised clinically to 
tackle extreme agitation (MacDonald et al. 2010). However, as mentioned, weight gain 
was not observed during the course of treatment suggesting observed reductions in 
activity in other studies is not a primary cause of weight gain.  
Body composition analysis showed that neither haloperidol nor olanzapine caused 
increases in overall fat mass, but rather, olanzapine treated mice had decreased fat mass 
with a concomitant increase in lean mass.  
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This is somewhat unsurprising given the body weight findings though it is important to 
remember that overall fat mass may not be representative of important changes in fat 
mass in specific regions. Indeed increases in visceral fat have been associated with 
antipsychotic treatment even in the absence of weight gain (Victoriano et al. 2010; 
Albaugh et al. 2011a).  
However, in the present report, no changes in visceral or subcutaneous fat were observed 
suggesting that the protocol employed was insufficient to produce clinically relevant 
changes in metabolic processes. Potential reasons for this include the drug dose selected, 
dosing schedule and/or species. Moreover, use of the home cage activity monitoring suite 
appeared to impact on food intake which was lower than one would expect, and thus this 
likely was a confounding factor in the study. 
Overall, the potential confounding factor of sedation was highlighted and should be an 
important consideration for future investigations, although it is unlikely to be a factor in 
weight gain observed in other murine studies.  
This experiment also highlights the need for careful consideration in carrying 
experimental models in order to ensure any outcomes and conclusions are valid to the 
clinical setting 
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Appendix II 
Assessment of microbiota  
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Fig II.1 Work flow of how the microbiota composition is analysed.   
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